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General introduction and objectives of this thesis 
Cardiovascular disease, in particular coronary artery disease, may lead to 
sudden death, and is responsible for about 4 0 % of total mortality in the 
Netherlands'. Patients with arteriosclerotic vascular disease, surviving their 
cerebral, peripheral or coronary attack, may suffer from precocious disability. In the 
Netherlands in 1993, more than 1,500,000 days of stay in hospital were on 
account of complications of vascular diseases1. Consequently, investigations into 
arteriosclerotic and thrombotic diseases should not only be aimed at preventing the 
mortality but also at decreasing the morbidity. Tobacco smoking, diabetes mellitus, 
elevated blood pressure, and elevated blood cholesterol levels are well known risk 
factors for arteriosclerosis. Immobilization, use of oral contraceptives, pregnancy, 
recent childbirth, protein C, protein S, or antithrombin III deficiencies, and activated 
protein С resistance are established risk factors for venous thrombosis. 
In 1969, a causative connection between arteriosclerotic vascular disease and 
the inborn error of methionine metabolism homocvstinuria. characterized by severe 
accumulation of homocysteine in blood and tissues, was made by McCully2. Later 
on, it was estabished, that if homocysteine-lowering treatment is withheld from 
patients with cystathionine ß-synthase deficiency, the main cause of 
homocystinuria, about 30% will suffer from arterial or venous vascular disease 
before the age of 20 years and about 50% before the age of 30 years3. Since the 
initial observation of Wilcken and Wilcken4 in 1976 that premature arteriosclerosis 
could probably be on the basis of mildly elevated blood homocysteine 
concentrations, the association of such mild hyperhomocysteinemia. with increased 
risk for cardiovascular disease has been scrutinized. During the last 20 years, 
various studies, i.e. case-control, cross-sectional, and prospective epidemiological 
studies have shown an increased prevalence of mild hyperhomocysteinemia among 
patients wi th arterial vascular disease. Nowadays, mild hyperhomocysteinemia is 
a generally accepted risk factor for cardiovascular disease. Furthermore, again in 
line with observations made in homocystinuria, recent studies also prove that 
mildly elevated plasma homocysteine concentrations are a risk factor for venous 
thrombosis as well. 
Objectives of this thesis 
Three main objectives of this thesis are to explore: 
- firstly, what is the origin of mild hyperhomocysteinemia in vascular 
patients, and what are the prevalences of genetic causes? 
- secondly, can vitamin supplementation lower or even normalize 
elevated homocysteine concentrations in such patients? 
- and thirdly, will homocysteine-lowering treatment result in a clinically 
beneficial effect? 
At the time the studies for this thesis were initiated, heterozygosity for 
homocystinuria was reported to account for almost all cases of mild 
hyperhomocysteinemia among vascular patients56. However, another enzyme 
defect eventually leading to hyperhomocysteinemia, i.e. homozygosity for a 
thermolabile mutant variant of methylenetetrahydrofolate reductase (MTHFR), was 
described already in 1991 by Kang et a l . 7 e . 
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Previous studies among family members of arter iosclerot ic 
hyperhomocysteinemic patients, to investigate the possible inheritance of mild 
hyperhomocysteinemia, included family members of coronary patients, but not 
those of patients with peripheral and cerebral arterial occlusive disease 9 1 1 . Apart 
from that, only fasting homocysteine levels have been measured, and not levels 
after standardized methionine loading in order to stress the metabolic pathway, as 
criterion of hyperhomocysteinemia. 
Until 1 9 9 1 , the effect of homocysteine-lowering treatment in vascular 
patients was only reported sporadically. Boers et a l . ' 2 presented data on 
normalization of the homocysteine concentration after methionine loading in 26 out 
of 32 vascular patients with post-load hyperhomocysteinemia by vitamin B6 
treatment. Brattstrom et a l . 1 3 showed a 2 6 % mean post-load increase lowering by 
vitamin B6, and 3 9 % by combined vitamin B6 and folic acid supplementation. In 
contrast to vitamin B6 solely, which showed no lowering of elevated fasting 
homocysteine concentrations, combined vitamin B6 and folic acid led to a 5 3 % 
decrease of the fasting homocysteine level However, in that report the duration 
of treatment, ι e. two weeks, may have been to short to evaluate sufficiently such 
effect. Clinical effects of homocysteine-lowering treatment have not been reported. 
The studies in this thesis are dealing with possible inherited causes of mild 
hyperhomocysteinemia in vascular patients (Part 1, Chapters 4 to 6), and with 
biochemical (Part 2, Chapters 7 to 10) and clinical (Part 3, Chapters 11 to 13) 
effects of homocysteine-lowering treatment in such patients. First an update of 
hyperhomocysteinemia until now is presented in Chapter 2 and a comparison of 
three different laboratory determinations of blood homocysteine is described in 
Chapter 3. 
In Part 1, the prevalence of mild hyperhomocysteinemia among family 
members of hyperhomocysteinemic vascular patients is explored in Chapter 4. We 
studied fasting and post-load homocysteine levels among 96 family members of 21 
post-load hyperhomocysteinemic vascular index patients 
The determination of thermolabile mutant variant of MTHFR and its 
prevalence among hyperhomocysteinemic patients with premature vasculardisease 
is reported in Chapter 5. 
In Chapter 6, a family with two inherited risk factors for vascular disease, ι e 
mild hyperhomocysteinemia and protein С deficiency type 1, is described. 
In Part 2 of this thesis the biochemical effect of homocysteine-lowering 
treatment is demonstrated. 
Chapter 7 gives a review of data on homocysteine-lowering treatment until 
1996 
Biochemical effects of vitamin B6 and combined vitamin B6 and folic acid 
supplementation in post-load hyperhomocysteinemic vascular patients are 
described in Chapter 8 and Chapter 9, respectively. 
In Chapter 10, the results of administration of vitamin B, in nine homozygotes 
for homocystinuna, who persisted to have elevated homocysteine levels in spite 
of conventional homocysteine-lowering treatment, are presented 
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Part 3 of this thesis is focused on the possible clinical effects of 
homocysteine-lowering treatment. 
Chapter 11 presents findings on three markers of endothelial function, i.e. 
von Willebrand factor, thrombomodulin, and tissue-type plasminogen activator, in 
patients with peripheral arterial occlusive disease and mild hyperhomocysteinemia, 
before start and after one year of combined vitamin B6 and folic acid therapy. 
The reliability and accuracy of Magnetic Resonance Imaging and Magnetic 
Resonance Angiography examinations in the detection of mild arteriosclerosis in 
vascular patients with mild hyperhomocysteinemia are described in Chapter 12. 
The results justified the use of these non-invasive techniques in the prospective 
intervention study as described in Chapter 13. In a placebo-controlled prospective 
way of combined vitamin B6 and folic acid therapy during 2 years, a possible 
clinical effect in vascular patients with mild hyperhomocysteinemia was 
investigated as a pilot study. 
Finally, in Chapter 14, the presented studies are discussed, and several 
remarks are made about future perspectives. 
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Hyperhomocysteinemia: an update 
Homocysteine metabolism 
The only source of homocysteine in men is demethylation of methionine, an 
essential amino acid. Via this pathway, up to 20 mmol of homocysteine is formed 
daily1. Homocysteine may either be transsulphurated or remethylated (Figure 2.1). 
The former pathway includes the conversion of homocysteine to cystathionine, 
catalyzed by the enzyme cystathionine ß-synthase. This enzyme requires a biologic 
active form of vitamin B6, ι e pyridoxal 5'-phosphate, as a cofactor The next step 
is the cleavage of cystathionine into homosenne and cysteine by r-cystathionase, 
also a pyridoxal 5'-phosphate dependent enzyme. In the remethylation pathway, 
homocysteine is converted into methionine by either the enzyme betaine-
homocysteme methyltransferase or by the enzyme methionine synthase. The 
former enzyme needs betaine (tnmethylglycine) to donate a methylgroup to 
homocysteine. This enzyme is in human only present in the liver. Methionine 
synthase, active in most body tissues, requires vitamin B12 as a cofactor and 5-
methyltetrahydrofolate (methyl-THF) as a substrate. Methyl-THF is formed from 
5,10-methylenetetrahydrofolate which reaction is catalyzed by the enzyme 5,10-
methylenetetrahydrofolate reductase (MTHFR) Thus, the enzymes involved in the 
metabolism of homocysteine are dependent on vitamin B6, vitamin B1 2 and folate, 
which is also known as vitamin B,, 
Transamination of methionine 
Apart from transmethylation and transsulphuration, methionine can also be 
transaminated into 4-methylthio-2-oxobutyrate (MTOB), followed by oxydative 
decarboxylation of MTOB into 3-methylthiopropionate (3-MTP)2 3 (Figure 2.1 ) The 
branched-chain 2-oxo acid dehydrogenase complex catalyzes this latter reaction 
which is supposedly the rate-limiting step in the transamination of methionine3. 
This complex requires the active form of vitamin B,, thiamine pyrophosphate, as 
a cofactor 3-MTP is converted into methanethiol, dimethylsulphides, and 
methanethiol mixed disulphides Methionine degradation via the transamination 
pathway occurs in humans4, but is probably of minor quantitative importance even 
in cystathionine ß-synthase deficient patients, despite their elevated methionine 
levels in blood5 Only very recently, it has been reported that transamination in 
hypermethionmemic children is increased only if plasma methionine levels exceeded 
300 or 350 / / M 6 7 . 
Homocysteine terminology and methodology 
In blood, about 70% to 80% of homocysteine is bound to protein The 
remaining non-protein bound homocysteine is present as homocystine (disulphide 
of homocysteine), or as homocysteine-cysteine mixed disulphide or as 
homocysteine The term free homocysteine refers in general to the non-protein 
bound homocysteine fractions, whereas total homocysteine refers to the sum of 
both, free plus protein bound forms of homocysteine. 
The determination of the free homocysteine concentration in plasma has been 
described previously89 Three methods for measuring total homocysteine 
concentration in plasma are described and compared with each other in Chapter 
310 Homocysteine levels are often determined in the fasting state, but also during 
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the day ("basal" levels). Methionine-homocysteine metabolism can be stressed by 
oral loading with L-methionine (0.1 g/kg body weight). In such tests, blood 
homocysteine concentrations are preferentially measured at peak post-load 
homocysteine levels, which occurs between 4 to 8 hours after the methionine 
load 1 1 , 1 2 . For practical reasons only one post-load blood sample, mostly that of six 
hours after loading, is drawn. 
2-keto-4-methylthio-
butyrate N,N-<*methyl 
glycine 
S-adenosyt-
S.lO-memyk>ne-THF •""•«J«"·™' 
3-methylthioproponate 
me thane гпюі 
botane 
x-s-s-CH-, 
homocysteine 
ìtNonr 
serine 
choline cystathi ine 
> homosenne 
cyslene 
so; 
Figure 2 . 1 . The methionine metabolism. 1 = cystathionine ^-synthase, 2 = y-
cysthationase, 3 = methionine synthase, 4 = 5,10-methylenetetrahydrofolate 
reductase, 5 = betaine-homocysteine methyltransferase , 6 = transaminase, 7 = 
branched-chain 2-oxo acid dehydrogenase. 
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Causes of severe hyperhomocysteinemia 
The classic and most common form of severe hyperhomocysteinemia, also 
known as homocystinuria, is caused by cystathionine ß-synthase deficiency1. Far 
over 600 patients of such homozygotes for homocystinuria have been described13. 
Deficient activity of the enzymes MTHFR, methionine synthase, or inborn errors of 
methylcobalamin synthesis are other conditions leading to severe 
hyperhomocysteinemia1. These latter three conditions are very rare, with reports 
in the literature of about 50 patients14"20. 
Causes of mild hyperhomocysteinemia 
Heterozygotes for homocystinuria have reduced activity of cystathionine ß-
synthase of about 20% of normal activity1·9,21. These subjects have elevated post-
methionine load plasma homocysteine concentrations, with normal or slightly 
elevated fasting homocysteine levels9,22. The incidence of homozygous 
cystathionine ß-synthase deficiency is estimated to be approximately 1:344,000 
live births worldwide, but may be as high as 1:58,000 in Ireland1. In the 
Netherlands, the exact incidence of homozygotes is unknown because neonatal 
screening of this specific inborn error is not being carried out. Homocystinuria is 
inherited in an autosomal recessive fashion, and so the incidence of the 
heterozygous cystathionine ß-synthase deficiency can be calculated to be about 
1:293 worldwide and as high as 1:125 in the Irish population1,23. Boers et al.24 and 
six years later Clarke et al.25 reported that heterozygosity for homocystinuria, in the 
Netherlands and Ireland, respectively, accounted for the hyperhomocysteinemia in 
almost all their detected vascular patients. However, from a large questionnaire 
study among 203 families with homozygotes for homocystinuria, Mudd et al.26 
estimated that no more than 5% of the heterozygous family members might have 
coronary vascular disease, with a relative risk of the fathers of homocystinuric 
patients of 1.43 (95% confidence interval 0.5 - 3.7), so not statistically 
significantly increased. The frequency of carriers for homocystinuria is by far not 
as large as the frequency of mild hyperhomocysteinemia which is in the normal 
population about 5% to 8%27,28 or to account for the number of vascular patients 
with mild hyperhomocysteinemia23. Therefore, heterozygosity for homocystinuria 
can not be responsible for all cases of mild hyperhomocysteinemia, and the 
observation by Engbersen et al.21 (Chapter 5) is in line with this conclusion. 
Furthermore, Kluijtmans et al.30 reported that heterozygosity for the 833 T-»C 
mutation in cystathionine ß-synthase, which in the homozygous form is found in 
half of the alleles in Dutch homozygous cystathionine ß-synthase deficient patients, 
was found in not any of the 60 studied patients with premature vascular disease, 
and only in one of the 111 control subjects. The same holds true for the Irish 
mutation 919 G-*A, which could not be detected in 100 Irish patients wi th 
premature arteriosclerotic disease29. Kozich et al.31 was not able to identify any 
mutation in the cystathionine ß-synthase cDNA in 4 vascular patients with mild 
hyperhomocysteinemia. 
Other genetic or non-genetic causes must account for the majority of cases 
of mild hyperhomocysteinemia. Blood homocysteine concentrations proved to be 
correlated in healthy twins without vascular disease32,33 and among family 
members of patients with coronary34'36, various vascular arterial occlusive disease37 
or juvenile venous thrombosis38. Therefore, mild hyperhomocysteinemia can be 
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concluded to be genetically determined at least in a part of the cases. Kang et 
a l 14,39,40 r e p 0 r t ed an increased incidence of thermolabile variant of MTHFR 
deficiency among patients with coronary vascular disease. These patients have a 
specific activity of approximately 50% of normal, and a residual activity after heat 
inactivation of less than 3 0 % compared to 50% residual activity in control 
subjects. Such patients may have normal or elevated homocysteine 
concentrations14,39,40. This thermolabile MTHFR deficiency is inherited autosomal 
recessively39. Engbersen et al.21 found thermolabile MTHFR deficiency in 2 8 % of 
the hyperhomocysteinemic patients with premature vascular disease. Very recently, 
homozygous 677 C-»T mutation in the MTHFR gene is shown to cause this 
thermolabile variant of MTHFR41. This mutation in homozygous form could be 
determined three times more frequent in vascular patients than in control 
individuals, 15% and 5.4%, respectively, which constitutes a relative risk of this 
genetic condition for cardiovascular disease of 3.1 (95% confidence interval of 1.0 
to 9.2)30. Compound heterozygotes for MTHFR deficiency with one allele for the 
severe form of MTHFR and one allele for the thermolabile form are mostly 
hyperhomocysteinemic14. Non-genetic causes, such as chronic renal failure, liver 
disease, nutritional or pharmacological induced deficiencies of folate, vitamin B,2, 
or vitamin B6, can also account for increased homocysteine concentrations as 
reviewed extensively by Ueland et al.12,38 and Refsum et al.42. 
Hyperhomocysteinemia and cardiovascular disease 
The Australians Wilcken and Wilcken43 reported in 1976 that 7 out of 25 
patients, with angiographically documented ischemic heart disease at ages younger 
than 50 years, had higher homocysteine levels after methionine load than matched 
control subjects. The association between mild hyperhomocysteinemia and several 
forms of premature arteriosclerosis, i.e. cerebral, peripheral and coronary, have 
been determined by Boers et al.24,44 and Brattstròm et al.45, and many studies 
published since then consolidated these findings. In pooled data from separate 
reports, it is calculated that the prevalence of mild hyperhomocysteinemia in 
patients with peripheral, i.e. 32% to 40%, and cerebral arterial occlusive disease, 
i.e. 2 4 % to 25%, may be higher than in patients with coronary arterial occlusive 
disease, i.e. 15% to 21 % 2 7 · 4 6 · 4 7 . The percentages given in the studies presented 
in Chapters 8 and 9 were well in line with these summarized data11,48. 
Most reports were of retrospective nature, such as case-control or cross-
sectional studies. Six, however, have been conducted prospectively and three of 
those showed results compatible with those of the retrospective studies, so 
supporting the association between hyperhomocysteinemia and cardiovascular 
disease4951. However, three other prospective studies among patients with 
ischemic stroke52,53, myocardial infarction53, and severe angina pectoris64 revealed 
no significant, albeit slightly elevated fasting homocysteine blood levels in patients 
compared to controls. 
Since recent ly, evidence has been accumulated that mild 
hyperhomocysteinemia is also a risk factor for venous thrombosis38,66"58. This 
relationship was found in patients with primary or recurrent venous thrombosis, 
and at all ages. Brattstròm et al.69, and recently also Amundsen et al.60 found no 
significant difference in plasma homocysteine concentration, between small groups 
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of patients and controls. Mild hyperhomocysteinemia has further on been related 
to the occurrence of retinal artery or vein occlusion5561. 
The relationship between the plasma homocysteine concentration and severity 
of the arteriosclerosis, in peripheral6263, cerebral54, and coronary64,65 arteries, is 
more likely to be graded than indicative of a threshold effect. Thus, the higher the 
plasma homocysteine concentration within a patient, the higher the risk of 
arteriosclerosis. Such a graded relationship with homocysteine blood levels was 
also found in asymptomatic subjects as much as carotic stenosis concerns66,67. On 
the other hand, den Heijer et al.68 reported, in patients with venous thrombosis, an 
increased risk only above a certain homocysteine level, which finding suggests a 
threshold relationship between homocysteine concentration and risk for 
thrombosis. 
Pathogenesis of arteriosclerosis 
Although the relationship between hyperhomocysteinemia and arteriosclerosis 
has been extensively reported, the underlying mechanism(s) of mild hyperhomocys-
teinemia in causing vascular damage has not been elucidated until now. Effects of 
homocysteine such as: 
1. damaging endothelial cells and proliferation of smooth muscle cells in arterial 
vessel walls, 
2. activation of blood clotting factors causing fibrin formation, and 
3. increased platelet adhesion and aggregation at the side of the arterial intimai 
damage have been described. 
Effect on endothelium 
Harker et al.68 described, in an animal model, sustained endothelial cell injury 
by homocysteine infusion, leading to desquamation of endothelial cells which 
initiates development of arteriosclerotic lesions. They hypothesized that 
arteriosclerosis in hyperhomocysteinemia is based on this directly damaging effect 
of the highly reactive sulfhydryl-containing amino acid. The concentration of 
homocyst(e)ine used was, however, even higher than that observed in 
homozygotes for homocystinuria. In vitro, the lowest concentration of 
homocysteine in its reduced form resulting in endothelial cell loss was 60pmol/L69 . 
Still, in patients with mild hyperhomocysteinemia with fasting total homocysteine 
levels up to maximally 50//mol/L, the concentration of homocysteine in plasma is 
much lower considering the fact that only about 1 % of the total amount of blood 
homocysteine is present in its reduced non-protein bound state70,71. So, the 
relevance of these studies for the in vivo situation in mild hyperhomocysteinemia 
is questionable. 
Oxidation of thiol-groups of amino acids, such as homocysteine, can generate 
reactive oxygen radicals72,73. In vitro studies showed that homocysteine-induced 
endothelial cell injuries might be on the basis of hydrogen peroxide (H202)72 which 
is generated by oxidation of homocysteine to its disulphides. H202 may also 
increase the level of oxidized low-density lipoproteins72. However, these findings 
could not be reproduced by others74"76. A recent in vitro study provided evidence 
that at physiological concentrations, homocysteine reacts with nitric oxide (NO) to 
form S-nitroso-homocysteine, which potentiates the vasodilatory and antiplatelets 
effect of NO77. Concomitantly, by this reaction the pathogenicity of homocysteine 
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is supposed to be attenuated because of inhibition of its sulphhydryl group's 
oxidation If the concentration of homocysteine exaggerates that of NO, this part 
of homocysteine is not inactivated anymore and may carry out its toxicity to 
endothelial cells. The following resulting endothelial cell loss affects NO synthesis 
itself, by which a cycle is started resulting in arteriosclerosis and thrombosis7 7. 
Besides affecting endothelium, homocysteine can reportedly induce 
proliferation of smooth-muscle cells, a key feature of arteriosclerosis78. 
Effect on coagulation proteins 
Endothelial cells produce various proteins of the coagulation and fibrinolytic 
system, such as thrombomodulin, von Willebrand factor, and tissue-type 
plasminogen activator Elevated levels of these proteins in plasma may indicate 
ongoing endothelial injuries 7 9 8 1 . The cardiovascular prognosis in survivors of 
myocardial infarction with high plasma von Willebrand factor levels has been 
shown to be poorer than in those with normal concentrations7 9. A in vivo study by 
van den Berg et a l . 8 2 8 3 in mildly hyperhomocysteinemic patients with peripheral 
arterial occlusive disease showed indeed elevated levels of plasma von Willebrand 
factor and thrombomodulin. Chapter 11 presents data on amelioration of these 
markers of endothelial dysfunction by homocysteine-lowering treatment8 3 
Thrombomodulin is an anticoagulant protein on the endothelial surface, which 
serves as a cofactor for the activation of protein С by thrombin. Deficiency of the 
anticoagulant protein С is an independent risk factor for venous and arterial 
thrombosis 8 4 8 5 . In vitro studies showed that homocysteine inhibits thrombomodulin 
expression on endothelial cell surface, and thereby hampers protein С 
coact ivat ion 8 6 8 8 . It also inactivates protein С irreversibly8 8 β β , resulting in a 
tendency to venous and arterial thrombosis. This inhibition of thrombomodulin 
expression on cell membrane by homocysteine in in vitro studies seems to be in 
contradiction with the in vivo findings that plasma thrombomodulin concentration 
is elevated in vascular patients with mild hyperhomocysteinemia8 2 8 3. This 
contradiction may be explained by the use of enormously high concentration of 
reduced homocysteine in in vitro studies compared to this homocysteine 
concentration in vivo. Furthermore, apart from inhibition of thrombomodulin 
expression on the endothelial cells, homocysteine is reported to rapidly reduce 
activated protein С generation with a 5 0 % decrease of the activity within half an 
hour after exposure to homocysteine8 6 8 8. This effect is probably due to competitive 
inhibition by homocysteine of the thrombin-thrombomodulin interaction. 
In this respect, it is very interesting that in one family with combined mild 
hyperhomocysteinemia and protein С deficiency, only those family members with 
both inherited risk factors for arterial and venous thrombosis manifested with 
vascular disease8 9. In line with this observation, the report of Mandel et a l . 9 0 is 
remarkable. In seven families with at least one homozygote for homocystinuna, 
venous or arterial thrombosis in these homozygotes exclusively occurred only in the 
presence of factor V Leiden mutation (either in the heterozygous or homozygous 
form), which leads to resistance of activated protein C9 0 These reports suggest 
that hyperhomocysteinemia and deficiency of activated protein С or resistance 
against it, are acting synergistically in inducing arteriosclerosis and/or thrombosis 
In another very recent study by den Heijer et al 6 8, however, it was not possible to 
establish a synergism of mild hyperhomocysteinemia and factor V Leiden mutation 
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¡η excess risk of thrombosis, probably because of insufficient number of included 
cases with both conditions combined. 
In patients with homocystinuria, with severely elevated homocysteine levels, 
reduced antithrombin III activity and factor VII deficiency have been demonstrated 
which normalized during homocysteine-lowering treatment9 1 9 3 . However, another 
study could not confirm reduced antithrombin III levels in patients with hyper-
homocysteinemia due to vitamin B1 2 or folate deficiency
9
*. Rodgers and Kane9 5 
reported that homocysteine increases endothelial cell factor V activity. 
Effect on platelets 
Normally, platelets ignore vascular endothelium, but once the vessel wall is 
damaged, platelet adhesion occurs. Platelet counts were not affected in four 
studied homozygotes for homocystinuria, but their platelet survival was reduced 
by half, which improved and almost normalized after start with vitamin B6 
treatment6 9. On the other hand, other studies reported normal platelet survival in 
such patients 9 6 , 9 7 . 
In conclusion, although abnormalities of endothelial cells, coagulation factors, 
platelets or disorders in the complex interaction of these factors have been held 
responsible for the vascular events in hyperhomocysteinemia, the underlying 
mechanism is far from elucidated at the moment. 
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Introduction 
Over the last decade mild to moderate hyperhomocysteinemia became an 
established risk factor for premature vascular disease (see for reviews1,2), and more 
recently for obstetric complications such as recurrent miscarriage, gross placental 
infarcts and neural tube defects3. In addition, the determination of total 
homocysteine in plasma is applied for the diagnosis and follow-up of folate and 
cobalamin deficiencies as well as the rare inborn errors of cobalamin metabolism, 
cystathionine synthase and methylenetetrahydrofolate reductase deficiency1. 
The increasing interest in the determination of total homocysteine in plasma 
has lead to the development of several different methods. This paper concerns 
three different methods for total homocysteine determination. One method is using 
a classic amino acid analyzer (AAA)4 and the other two are high performance liquid 
chromatography (HPLC) methods5,6. 
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Figure 3 . 1 . (a) Amino acid analyzer chromatogram of ninhydrin derivatives at 570 
nm in pooled plasma. The total homocysteine concentration in plasma is spiked 
with DL-homocysteine to 40.0 //mol/L. Peaks: 1 = cysteine, 2 = homocysteine, 
3 = methionine, 4 = norleucine. (b) HPLC chromatogram of mBrB derivatized 
thiols in a pooled plasma. The total homocysteine concentration is 40.0 //mol/L. 
Peaks: 1 = cysteine, 2 = cysteinylglycine, 3 = homocysteine, 4 = cysteamine. 
(c) HPLC chromatogram of SBD-F derivatized thiols in a pooled plasma. The total 
homocysteine concentration is40.0//mol/L. Peaks: 1 = cysteine, 2 = cysteamine, 
3 = cysteinylglycine, 4 = homocysteine. 
Materials and methods 
The AAA method (Pharmacia/LKB, Alpha-Plus) applied dithiotreitol (DTT) for 
the reduction of the disulphide bounds and postcolumn derivatisation with 
ninhydrin, essentially according to Andersson et al.4. The column was equilibrated 
with 0.6 mol/L lithiumcitrate, pH 3.02 for 45 min. Next a buffer containing 1.0 
mol/L lithiumcitrate, pH 3.45 eluted respectively homocysteine, methionine and 
norleucine (Figure 3.1a) from the ion exchange column (272 mm, I.D. 4.6 mm and 
6 //m particle size) with a f low rate of 0.3 mL/min. To 0.1 5 mL of thawed plasma, 
0.15 mL DTT (40 m M ; pH 9.0) was added, mixed and incubated for 10 min at 
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room temperature. The mixture was deproteinized by adding 0.15 mL of a 
sulphosalicylic acid solution (25% w/v) containing L-norleucine (ЗОбдтоІ/L) as an 
external standard. After vortexing, the mixture was kept on ice for 10 min and 
then centrifuged at 3500xg for 10 min. The supernatant was filtered (0.45 μπ\, 
Millipore) just before analysis. The absorption intensities of ninhydrin derivatives 
were measured at 440 and 570 nm. 
The HPLC NaBH4/mBrB method used NaBH4 for reduction and mBrB for 
derivatization essentially according to Fiskerstrand et al.5 with cysteamine as 
external standard. A programmable sample processor (Gilson model 232 BIO, 
Dilutor 401) was used for automated homocysteine reduction, derivatization and 
sample injection. After equilibration with 30 mmol/L ammoniumnitrate, 40 mmol/L 
ammoniumformate and 4 mmol/L tetrabutylammoniumhydrogensulphate (pH 3.2) 
the thiols derivatives were eluted from the column (Supelcosil LC-18 15 cm, 4.6 
mm, 3 /ym) with a 0 to 10.5% acetonitrile gradient in 11 min with a f low rate of 
1 mL/min (Figure 3.1b). 
HPLC TBP/SBD-F method applied TBP for reduction and SBD-F as 
derivatization agent according to Ubbink et al. 6 with some modifications. For 
derivatization 100 μΐ plasma and 50 μL of internal standard (cysteamine 0.125 
mM) were mixed with 15//L 10% TBP in methylformamide and incubated for 30 
min at 4 °C. The solution was deproteinized with 0.1 5 mL 1 0 % trichloroacetic acid 
containing 1 mmol/L Na4EDTA under vortexing, followed by centrifugation at 10 
min at 4000xg. A 50 μί aliquot of the clear supernatant was mixed with 1 5 //L 
sodiumhydroxide (1.55 mol/L), 125 μί borate buffer (0.125 mol/L), pH 9.5 
containing 4 mmol/L EDTA, and 50/iL SBD-F (1 mg/mL dissolved in borate buffer) 
and incubated for 60 min at 60°C. The sample was diluted with eluent (1:5) and 
20 μ\- of the mixture was injected. The SBD-F derivatives were eluted isocratic 
from the column by 0.1 mM KH2P04/5% acetonitril (pH 2.15) with a f low rate of 
1 mL/min (Figure 3.1c). 
EDTA plasma samples, not spiked, of controls and of vascular patients with 
severe or mild hyperhomocysteinemia were used for correlation studies. 
Results and Discussion 
The detection limits of all these three methods were low (less than 0.5 
//mol/L) and only small amounts (less than 150 μί.) of plasma were required with 
good reproducibility. The inter and intra variation coefficients were less than 6.5%. 
A disadvantage of the amino acid analyzer method is the long injection to 
injection time of 138 min compared to 20 min or less for the HPLC methods. On 
the other hand the amino acid analyzer method measures also other amino acids 
involved in homocysteine metabolism such as methionine, cystathionine and 
cysteine. A disadvantage of both the amino acid analyzer and the HPLC TBP/SBD-F 
method is that they are not fully automated whereas the HPLC NaBH4/mBrB 
method is fully automated for unattended analysis of 105 samples. 
The correlation between the HPLC NaBH4/mBrB method versus the AAA-
method is Y = 0.72 +1.07X, R = 0.985,N = 80. The total homocysteine 
concentrations (free and protein bound) in plasma of controls and patients varied 
from 4 to 156 μπιοΙ/L. The correlation between the HPLC NaBH4/mBrB method 
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versus the HPLC TBP/SBD-F method is Y = 0.14 + 1.04X R = 0 .991 , N = 37, and the 
total homocysteine concentrations in plasma of controls and patients varied for 9 
to 173//mol/L. 
The good correlation coefficients between the different methods show that despite 
the use of different kinds of reducing agents the same amount of total 
homocysteine is recovered from the plasma. 
The HPLC NaBH4/mBrB method was modified and improved by using: 1. 
cysteamine as an external standard whereas Fiskerstrand et al.5 used no standard; 
2. addition of tetrabutylammoniumhydrogensulphate to the mobile phase for 
improvement of separation of the homocysteine peak from the fluorescent side 
products of mBrB; 3. reducing the flow rate from 1.5 mL/min to 1.0 mL/min; 4 . 
increasing the total capacity for unattended analysis from 60 to 105 samples. 
Therefore this method is preferable for measurements of large amounts of samples. 
The HPLC TBP/SBD-F method6 was modified by reducing volumes during 
derivatisation to economize the use of samples and reagents during derivatisation 
and the use of cysteamine as external standard. 
In conclusion, all three studied methods are appropriate for the diagnosis of 
mild and severe hyperhomocysteinemia or cobalamin/folate deficiency in a routine 
laboratory setting. 
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Abstract 
Previous studies have shown that elevated basal homocysteine levels are 
correlated among family members of patients with coronary vascular disease and 
juvenile venous thrombosis. This suggests the possibility of the presence of 
inherited basal mild hyperhomocysteinemia (mHH). We studied homocysteine 
levels, fasting as well as after methionine load, among 96 family members of 21 
post-load hyperhomocysteinemic vascular index patients, i.e. 6 parents, 27 
offspring, 38 siblings, 19 uncles and aunts, and 6 cousins. In 15 out of 21 
screened families post-load mHH was established in at least one family member. 
Fasting and post-load mHH was observed in 19 out of 89 (21%) screened family 
members (fasting homocysteine levels not measured in seven family members), and 
31 out of 96 screened family members (32%), respectively. In 4 0 % of all family 
members, post-load mHH was not accompanied by fasting mHH. We conclude that 
both fasting and post-load mHH seems to be inherited in the majority of 
hyperhomocysteinemic vascular patients. 
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Introduction 
Mild hyperhomocysteinemia (mHH), a risk factor for premature 
arteriosclerosis, is detected in a frequency of 9% to 4 7 % in patients with 
premature cerebral, peripheral, or coronary stenotic arterial disease or with 
thromboembolism' n . In the general population mHH is present in up to 8 % 1 2 . 
MHH can be caused by enzymatic defects such as heterozygosity for cystathionine 
synthase (CS) deficiency, or homozygosity for thermolabile 5,10-
methylenetetrahydrofolate reductase (MTHFR) deficiency, indicating a genetic 
cause in at least a subset of the detected patients3 4 1 2 1 Б . Environmental influences 
such as vitamin B1 2 and folic acid deficiency, and renal or liver disease can also 
induce m H H 1 1 6 1 7 . 
Homocysteine blood concentrations were found to be correlated in 
monozygotic and dizygotic healthy t w i n s 1 8 1 9 and were strongly correlated among 
family members of patients with coronary vascular disease20"22. These studies in 
family members of arterial occlusive diseased patients were performed on the base 
of fasting homocysteine concentration measurements only. Falcon et al. 8 reported 
high plasma homocysteine levels in 5 out of 8 families of patients with juvenile 
venous thrombosis. 
In the present study, we have performed methionine loading tests in 96 
family members of 21 hyperhomocysteinemic vascular patients. In these patients 
as well as their family members vitamin deficiencies or liver or renal failure which 
could lead to secondary mHH had been excluded. The prevalence of mHH, fasting 
as well as after methionine loading, among the family members was assessed to 
examine the possibility of the presence of an inherited cause of mHH in the 
vascular patients. 
Materials and methods 
Methionine Loading Test and Determination of Hyperhomocysteinemia 
In 21 vascular disease patients hyperhomocysteinemia was established on the 
basis of their homocysteine level after methionine loading exceeding the mean + 2 
standard deviations (SD) post-load homocysteine level in 95 controls. Methionine 
loading tests (0.1 g L-methionine/kg body weight) were performed in the family 
members according to a protocol reported previously2 3. Plasma samples in the 
fasting state and 6 hours after methionine load were collected and centrifuged 
instantly. The total homocysteine concentration (free plus protein bound) was 
measured by high-performance liquid chromatography2 4. At the time of screening, 
the index patient of family 10, his parents and sibships, and one cousin (fasting 
and post-load homocysteine levels of 11 and 46 μπΊθΙ/L, respectively) presented 
with decreased vitamin B1 2 levels. Hypercholesterolemia was detected in the 
mother of family 4 (8.3 mmol/L; reference value ^ 6.5 mmol/L), in the index 
patient of family 13 (7.7 mmol/L), hypertriglyceridemia was detected in the index 
patient of family 8 (5.46 mmol/L; reference value á 2.00 mmol/L), and diabetes 
in the index patient of family 3 (fasting glucose: 9.4 mmol/L; reference value ä 
7.8 mmol/L). All other index patients and family members had vitamin Be, vitamin 
B,2, folic acid, glucose, cholesterol, triglycerides levels within the normal ranges, 
were without liver or renal disease, or hypertension of nonrenovascular origin. From 
all patients and the family members information of intake of vitamin supplements 
and medical history was obtained None of the 21 families and the studied parents 
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were related to one other within the second generation. 
Index Vascular Patients 
Of the 21 hyperhomocysteinemic index patients with documented vascular 
disease, 10 patients had suffered from cerebral occlusive arterial disease, 3 from 
peripheral occlusive arterial disease (2 intermittent claudication, and 1 subclavian 
arterial occlusion), 2 from anterior spinal arterial syndrome, 2 from coronary 
occlusive arterial disease, 3 from venous thrombosis (1 deep crural thrombosis and 
2 cerebral thrombosis), and 1 from concomitant coronary occlusive arterial disease 
and deep crural thrombosis. One family (Figure 4 . 1 , family number 13) was also 
known with inherited protein С deficiency2 5. The vascular disease became 
symptomatic in the index patients between their 16 t h and 50 t h year of age (38 ± 
8 years; mean ±SD), the mean age ± S D at their screening was 39 ± 7 years. 
fasting 
post-
load 
FA 
B6 
B,2 
age 
sex 
(m/f) 
vascular 
index 
patient 
(n = 21) 
25 ± 16 
(n = 20)4 
85 ± 28* 
9.3 ± 2.3 
(n = 20) 4 
52 ± 16 
(n = 20) 
280 ± 136 
(n = 20) 
38 ± 10 
4/17 
FM 
(n = 96) 
17 ± 14 
(n = 89) 4 
47 ± 20* 
11.3 ± 
3.4 4 
48 ± 14 
251 ± 
85 
33 ± 12 3 
42/54 
FM with 
elevated 
post-load 
(n = 31) 
27 ± 21 
(n = 29) 4 
69 ± 20 4 
9.3 ± 
2.04 
44 ± 142 
238 ± 
98 
33 ± 141 
17/14 
FM with 
normal 
post-load 
(n = 65) 
12 ± 3 
(n = 60)' 
37 ± 8 
12.3 ± 3.5 
(n = 64)2 
50 ± 14 
(n = 64) 
258 ± 77 
(n = 64) 
33 ± 12 3 
25/40 
Controls 
(n = 95) 
11 ± 3 
37 ± 13 
14.4 ± 
4.6 
52 ± 19 
265 ± 
101 
41 ± 9 
23/72 
Table4.1. Mean ± SD of laboratory characteristics of 21 vascular index patients 
with post-load mild hyperhomocysteinemia, 96 of their family members (FM), and 
95 controls. The family members are divided in 31 family members with post-load 
mild hyperhomocysteinemia, and 65 family members with normal post-load 
homocysteine concentration. FA = plasma folic acid, BR = blood vitamin B«, B,2 
= blood vitamin B l 2 . The age is given in years. M = male, F = female. 1 < 0.05, 2
< 0 . 0 1 , 3 < 0 . 0 0 0 1 , 4 < 0.00001 (Wilcoxon Rank Sum W-test). 
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Family Members 
The methionine loading tests in the studied family members were performed 
on their own request after detection of the index patient, except for 2 families 
(Figure 4 . 1 , family number 10 and 13) which were asked to volunteer in the 
screening of mHH. The index patients of these 2 families were exceptionally 
young, i.e. 16 years of age at the time of their vascular incident. Only those 
families have been included in this study, in whom at least one complete family 
tree, i.e. both parents, or all children, or all brothers and sisters, had been screened 
for hyperhomocysteinemia. The 21 index patients had in total 131 first degree 
family members, i.e. 42 non-consanguineous parents, 30 offspring, and 59 
siblings. Homocysteine concentrations, fasting and post-load, were determined in 
72 out of these 131 family members (29 male and 43 female); i.e. 6 parents, 27 
offspring, and 39 siblings. In family number 10 and 13 (Figure 4.1 ) 10 uncles and 
9 aunts were also tested. These second degree family members were siblings of 
the fathers of both index cases in whom post-load mHH was revealed. In family 
number 10 another 6 third degree relatives (offspring of a post-load 
hyperhomocysteinemic second degree family member) were screened with the 
methionine loading test. At the time of screening the mean age ±SD of the 97 
family members was 33 ± 9 years (range 12 to 68 years). One sister used vitamin 
supplements and was excluded from the study (Figure 4 . 1 , family number 7). Four 
family members suffered from vascular complications at the time of screening 
(Figure 4 . 1 , family number 4, 7, 13, 15). Their age at onset of vascular 
complications ranged from 37 to 59 years of age (mean ±SD 44 ± 8 year). 
Control Subjects 
Because of previously observed differences in mean fasting and post-load 
homocysteine levels between male, premenopausal and postmenopausal female 
control subjects the studied index patients and family members were categorized 
accordingly3 , 2 6. The fasting and post-load homocysteine concentration (2.5 - 97.5 
percentile) respectively was in control men 8 - 1 8 and 25 - 54μηηοΙ/Ι_ (η = 23), in 
control premenopausal women 6 - 1 5 and 1 8 - 5 1 /лтюІ/L ( n = 4 6 ) , and in control 
postmenopausal women 6 - 1 9 and 25 - 69 /miol/L (n = 26) 2 7 . 
Results 
Post-load mild hyperhomocysteinemia (Figure 4.2a, and Table 4.1) 
In 15 out of the 21 screened families post-load mHH was established in at 
least one family member. In 31 out of 96 screened family members post-load mHH 
was observed (32%). Post-load mHH was detected in 5 0 % of the parents (3 out 
of 6 parents), 2 6 % of the offspring (7 out of 27 children), and in 2 9 % of the 
siblings (11 out of 38 siblings among 16 index vascular patients). Seven out of 19 
screened second degree and 3 out of 7 screened third degree family members 
revealed post-load mHH. By definition, the post-load homocysteine concentrations 
of vascular index patients, and post-load hyperhomocysteinemic family members 
were significantly higher than in controls (Table 4.1). Also the total group of 
studied family members showed significantly higher levels than controls. Plasma 
folic acid concentrations of vascular index patients, family members as one group 
and as subgroups with and without post-load hyperhomocysteinemia, were 
statistically significantly lower compared to controls. Plasma vitamin B6 was 
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significantly lower in post-load hyperhomocysteinemic family members (Table 4.1 ). 
There was no evident sex difference among the hyperhomocysteinemic family 
members ( 17 of the 42 male, and 14 of the 54 female family members; chi-square 
p > 0.05). 
Fasting mild hyperhomocysteinemia (Figure 4.2b, and Table 4.1) 
Fasting mHH was present in 19 out of 89 family members (21%), including 
17 among 29 post-load hyperhomocysteinemic family members, and 2 among 60 
post-load normohomocysteinemic family members (fasting homocysteine levels not 
measured in 7 family members). Thus, in the included family members, in 4 0 % 
post-load hyperhomocysteinemia was not accompanied by fasting elevated levels. 
Fasting homocysteine levels were within the normal range in 6 out of 20 
index patients (Figure 4 . 1 , family number 3, 4, 17, 18, 19, 20; fasting 
homocysteine level not measured in 1 index patient). In 5 out of the 6 families of 
these 6 patients, one more post-load hyperhomocysteinemic family member was 
detected, and also in all these 5 family members the fasting homocysteine level 
was within the normal range. In the 14 families, in whom the index case showed 
elevated fasting homocysteine level, only 17 out of 24 post-load 
hyperhomocysteinemic family members showed also elevated fasting homocysteine 
levels (71%). 
The fasting homocysteine levels were statistically significantly higher in 
vascular index patients, in family members as one group, in post-load 
hyperhomocysteinemic family members, but also, albeit less strongly significantly, 
in post-load normohomocysteinemic family members compared to the control group 
(Table 4.1). 
Vascular complications in family members 
Four screened family members were known with vascular manifestations at 
the time of the methionine loading test. Three of them revealed post-load mHH 
(Figure 4 . 1 , family number 4, 7 and 13). The fourth vascular affected family 
member (Figure 4 . 1 , family number 15) showed a high but normal post-load 
homocysteine concentration (fasting homocysteine level was not measured). 
Discussion 
In the present study, 71 % of the families of a patient with various forms of 
arteriosclerosis had at least one other family member with post-load mHH. In 6 out 
of the 21 studied families no other relative had post-load mHH, but only 15 of the 
40 first degree relatives were studied, and therefore, hyperhomocysteinemic family 
members could have been missed. Mildly elevated homocysteine levels were 
present in family members in 21 % on the base of fasting and in 3 2 % on the base 
of post-load homocysteine concentration. Our observations are in line with previous 
reports in which basal homocysteine concentration in healthy twins and in families 
of coronary vascular patients is reported to show a significant correlation18"22. The 
present study demonstrates that both fasting and post-load mHH, in the absence 
of vitamin deficiencies and renal or liver insufficiencies, seems to be inherited in the 
majority of vascular patients. Further enzymatic and molecular studies are needed 
to reveal the involved genetic enzymatic defects and their inheritance patterns. 
Reduced activities in the range of obligate carriers for CS-deficiency have been 
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Figure 4 . 1 . Twenty-one family pedigrees of vascular patients with post-load mild 
hyperhomocysteinemia. At the left side of the symbols, the total homocysteine 
concentration before (above) and after methionine loading (below) are shown. CVD 
indicates cerebral vascular disease; PAD, peripheral arterial disease; Ml, myocardial 
infarction; VT, venous thrombosis; ASAS, anterior spinal artery syndrome; CRAO, 
central retinal artery occlusion; CRVO, central retinal venous occlusion; and Neo, 
neoplasm. 
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Figure 4.2a and 4.2b. Frequency distribution in percentages of post-load (Figure 
4.2a) and fasting (Figure 4.2b) plasma homocysteine concentrations in controls 
(n = 95), index patients (n = 21), and family members of the index patients (n = 96). 
Post-load homocysteine concentrations above 54 //mol/L in men, 51 //mol/L in 
premenopausal women, and 69/ymol/L in postmenopausal women are defined as 
hyperhomocystememia. 
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reported ¡η hyperhomocysteinemic vascular patients3 , 4. This finding was difficult 
to reconcile with the conclusion by Mudd et al. 2 8 of a normal incidence of heart 
attacks or strokes in a large group of obligate heterozygotes for CS-deficiency 
studied by questionnaires. Furthermore, even in populations with the highest 
prevalence of homozygous CS-deficiency, such as in Ireland, the calculated number 
of carriers is too low to account for the number of observed hyperhomocysteinemic 
vascular patients2 9. Indeed, very recently, it was reported that the finding of 
lowered CS-activity was not reproducible in 9 6 % of studied hyperhomocysteinemic 
vascular patients 1 5 , 3 0. Moreover, in the Netherlands where the 833 Τ -» С transition 
is detectable as the mutation in the CS gene on chromosome 21 in 5 0 % of alleles 
of homozygotes for CS-deficiency, in 60 cardiovascular patients this mutation 
could not be identified in any of them 3 0 . The same holds true for the observation 
in Ireland where the 919 G -• A mutation in the CS gene, determined in 7 0 % of 
Irish homocystinuric alleles, could not be detected in a group of 100 Irish patients 
with premature vascular disease31. From all these enzymatic and molecular genetic 
studies summarizing, it can be concluded that there is no evidence, so far, that 
heterozygosity for CS-deficiency plays a role as the basis of mHH in vascular 
patients. In a previous study, we observed an incidence of a thermolabile MTHFR 
enzyme in 2 8 % of hyperhomocysteinemic cardiovascular patients1 5. Such 
thermolability is consistently associated with the 677 С -» Τ mutation in the 
MTHFR gene on chromosome 1 1 2 , and a subject has to be homozygous for such 
mutation to produce hyperhomocysteinemia1 3 , 1 4. Despite a high incidence of this 
thermolabile MTHFR enzyme among hyperhomocysteinemic patients and controls, 
i.e. 2 8 % and 5%, respectively3 0, the frequency of this defect does not seem 
sufficient enough to provide in its own the base of all familial occurrence of mHH 
as observed in the present study. 
It is still questionable whether either fasting or post-load homocysteine 
concentration is the most sensitive indicator of abnormal homocysteine 
metabolism. Both fasting and post-load mHH are considered risk factors for 
cardiovascular disease1 , 6 , 3 2. In case we screened for mHH only on the base of 
fasting homocysteine levels, no more than 14 out of 20 index patients (70%) and 
17 out of 29 family members with post-load mHH (59%) would have been 
considered hyperhomocysteinemic. Even if family members of only the 14 index 
patients with fasting mHH had been screened for fasting homocysteine levels 
alone, 2 9 % (7 out of 24) of the family members who indeed showed post-load 
mHH, would have been classified as normohomocysteinemic. Post-load elevated 
homocysteine levels in the absence of fasting hyperhomocysteinemia is probably 
on the basis of another enzymatic defect than concomitant fasting and post-load 
hyperhomocysteinemia3 3. In our present study, we have screened family members 
of vascular index patients with post-load elevated homocysteine levels. None of the 
21 index patients were known with fasting elevated and post-load normal 
homocysteine concentrations. Therefore, a selection in families has been made on 
the basis of this inclusion criterion. However, studies on fasting homocysteine 
levels in healthy twins and also in families of cardiovascular patients have been 
performed already previously, showing a strong correlat ion 1 8 2 2 . We prefer to 
perform both fasting and post-load homocysteine concentrations in vascular 
patients and family members to investigate their individual homocysteine status 
more completely 1 1 , 2 5 , 3 4 · 3 7 . 
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Plasma folic acid concentrations, were significantly lower in vascular index 
patients, in family members as one group, and in the subgroups of post-load 
normo- and hyperhomocysteinemic family members, compared to controls. This 
finding is in accordance with earlier observations of reduced though not deficient 
folic acid blood levels in cardiovascular patients410 '11. Establishing both in normo-
and hyperhomocysteinemic family members lower folic acid compared to controls, 
could be an indication of a common habit of low folate intake in these families, 
leading to hyperhomocysteinemia in some of the members. However, in family 
members with hyperhomocysteinemia, the decrease in folic acid concentration was 
much more pronounced than in their normohomocysteinemic family members, 
comparable wi th the highly significantly lower levels in the vascular patients in 
these families. This is much more suggestive of the presence of a hereditary defect 
in homocysteine metabolism leading to a higher demand for folate in the 
hyperhomocysteinemic patients and their hyperhomocysteinemic family members. 
Among the 96 investigated family members, 4 had known vascular disease. 
Three of them were hyperhomocysteinemic, and one had high-normal post-load 
homocysteine concentration. Therefore, screening for mHH of family members 
suffering from vascular events among families of a hyperhomocysteinemic patient, 
is recommended. About 90% of the family members with post-load mHH revealed 
no subjective signs of vascular disease, at least so far. Most screened family 
members were younger than their respective index case. This suggests that familial 
mild hyperhomocysteinemia leading to symptomatic vascular disease has a low 
expression, may be age dependent and that homocysteine in mild excess may 
require more triggering factors. 
MHH in vascular patients can be normalized by vitamin B6 and/or folic acid 
treatment11,25-3437. In case homocysteine-lowering intervention in hyperhomo-
cysteinemic vascular patients and their hyperhomocysteinemic family members is 
clinically beneficial in terms of preventing recurrent and first occurrence of arterial 
disease, respectively, such treatment will be of significant importance in general 
health care. 
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THERMOLABILE 5,10-METHYLENE-
TETRAHYDROFOLATE REDUCTASE AS A CAUSE OF 
MILD HYPERHOMOCYSTEINEMIA 
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American Journal of Human Genetics 1995;56:142-150. 
Abstract 
Thermolability of 5,10-methylenetetrahydrofolate reductase (MTHFR) was 
examined as a possible cause of mild hyperhomocysteinemia in patients wi th 
premature vascular disease. Control subjects, vascular patients with mild 
hyperhomocysteinemia and with normohomocystememia were studied. The mean 
( ± SD) specific MTHFR activity in lymphocytes of 22 control subjects was 15.6 
( ± 4.7) nmol CH2G7mg protem/h (range- 9.1 - 26.6) and the residual activity ( ± 
SD) after heat inactivation for 5 mm at 46 °C was 55.3 ( ± 12.0)% (range: 35.9 -
78.3) By measurement of MTHFR activity, two distinct subgroups of 
hyperhomocystememic patients became evident. One group (n = 11) had 
thermolabile MTHFR with a mean ( ± SD) specific activity of 8.7 ( ± 2.1) nmol 
CH20/mg protein/h (range: 5.5-12.7) and a residual activity after heat inactivation 
ranging from 0 to 33%. The other group (n = 28) had normal specific activity ( ± 
SD) of 21 5 ( ± 7.2) nmol CH20/mg protein/h (range: 10.0 - 39.0) and a normal 
residual activity ( ± SD) of 53.8 ( ± 9.2)% (range: 33.1 - 71.5) after heat 
inactivation The mean ( ± SD) specific activity of 29 normohomocysteinemic 
patients was 20.7 ( ± 6.5) nmol CH20/mg protem/h (range: 9.4 - 33 8) and the 
mean ( ± SD) residual activity after heat inactivation was 58.2 ( ± 10.2)% (range: 
43.0 - 82.0). Thus, in 28% of the hyperhomocystememic patients with premature 
vascular disease, abnormal homocysteine metabolism could be attributed to 
thermolabile MTHFR. 
49 
Chapter 5 
Introduction 
Over the last decade, mild hyperhomocysteinemia has become an established 
risk factor for premature vascular disease13 Homocysteine is presumed to damage 
the endothelial cells, although, the mechanism of its toxicity remains obscure4. 
Homocysteine accumulation may be caused by a metabolic block in either the 
degradation of homocysteine to cystathionine or in the remethylation of 
homocysteine to methionine (Figure 5.1). The classic form of severe 
hyperhomocysteinemia is caused by cystathionine ß-synthase deficiency. This 
enzyme catalyzes the formation of cystathionine from homocysteine and serine. 
Another enzymatic cause of severe hyperhomocysteinemia is 5,10-
methylenetetrahydrofolate reductase (MTHFR) deficiency, which affects the 
remethylation of homocysteine to methionine. MTHFR catalyzes the reduction of 
5,10-methylenetetrahydrofolate(MTHF)to5-methyltetrahydrofolate(methyl-THF), 
in which flavin adenine dinucleotide (FAD) serves as cofactor (Figure 5.1). 
Severe hyperhomocysteinemia due to MTHFR deficiency causes neurological 
abnormalities, mental retardation, arteriosclerosis and thrombosis5. The biochemical 
characteristics are hyperhomocystinuna, reduced or low methionine concentrations 
in plasma, low plasma folate levels and very low MTHFR activity in both fibroblasts 
and lymphocytes68 . Low plasma folate levels result from a lack of the MTHFR 
product methyl-THF, which is the main form of circulating folate. The clinical 
severity and the extent of biochemical derangement appears to be correlated with 
the degree of enzyme deficiency5 7. In obligate heterozygotes for severe MTHFR 
deficiency the specific MTHFR activity is about 5 0 % of the normal mean and it is 
unknown whether this condition is associated with an increased risk for vascular 
disease9 
Heterozygotes for cystathionine ß-synthase deficiency have reduced enzyme 
activity in cultured fibroblasts and also mild hyperhomocysteinemia after 
methionine loading10. Reduced cystathionine ß-synthase activity in fibroblasts has 
also been found in the majority of vascular disease patients with mild 
hyperhomocysteinemia in two studies1112 However, this finding could not be 
reconciled with the observations of Mudd et al.13 that in a large series of families 
with a homozygote cystathionine ß-synthase deficient patient the obligate carriers 
did not have an increased risk for vascular disease. While there is evidence of a 
high prevalence of mild hyperhomocysteinemia in patients with vascular disease1 3 
even in populations with the highest prevalence of homozygous cystathionine ß-
synthase deficiency, such as in Ireland, the calculated number of heterozygotes is 
to low to account for the number of observed hyperhomocysteinemic vascular 
patients14 In agreement with this observation, we (Blom, Fowler, Boers and 
Tnjbels, unpublished observations) and others (Kraus, personal communication) 
could not reproduce the finding of lowered cystathionine ß-synthase activity in 
fibroblasts of vascular patients with mild hyperhomocysteinemia. This suggest that 
some aberration other than heterozygosity for cystathionine ß-synthase deficiency 
is causing the hyperhomocysteinemia in vascular patients. 
Recently, a thermolabile variant of MTHFR91517 was shown to be caused by 
a mutation different from that causing the severe form of MTHFR deficiency. 
Homozygotes for thermolabile MTHFR deficiency have a specific activity of 
approximately 50% of normal and a residual activity after heat inactivation of less 
than 30%, compared to 50% residual activity in control subjects. Kang et al 9 
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Figure 5 . 1 . Homocysteine metabolism. CS: cystathionine ß-synthase; MTHFR: 
5,10-methylenetetrahydrofolate reductase; MS: methionine synthase; THF: 
tetrahydrofolate. 
reported an incidence of homozygote thermolabile MTHFR deficiency of 17% in a 
group of 212 patients with coronary artery disease. Obligate heterozygotes for 
thermolabile MTHFR deficiency have a specific enzyme activity of about 75% of 
the normal mean, but probably have thermostable MTHFR17. Compound 
heterozygotes for MTHFR deficiency with one allele for the severe form and one 
allele for the thermolabile form have also been described. These patients have a 
specific enzyme activity of about 25% of the normal mean and their MTHFR is 
probably thermolabile17. 
The present study describes a modified method for measurement of 
thermolabile MTHFR in isolated lymphocytes. Reference values were obtained from 
23 healthy subjects. From our patient group with premature vascular disease18 we 
selected 39 patients with and 29 without mild hyperhomocysteinemia to study the 
relationship between mild hyperhomocysteinemia and thermolabile MTHFR. 
Patients and controls 
Patients with arteriosclerosis or venous thrombosis under 55 years of age 
were screened for mild hyperhomocysteinemia by the methionine loading test (0.1 
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g L-methionine/kg body weight) in the Univeristy Hospital Nijmegen11. Patients wi th 
hyperlipoproteinemia, hypertension and diabetes mellitus were excluded. There 
were no other selection criteria. 
Reference values for homocysteine concentrations, before and after 
methionine loading, were obtained from 88 control subjects, 65 premenopausal 
women and 23 men. Reference values for folic acid and vitamin B12 levels were 
obtained from 68 control subjects, 45 premenopausal women and 23 men. Mild 
hyperhomocysteinemia was defined as total homocysteine blood levels after 
methionine loading higher than the mean + 2SD of the reference group. The mean 
± 2SD range of the reference group for total homocysteine concentration was 4 -
16/ymol/L (skewness: 0.9, kurtosis: 1.0) after fasting and 15 - 49/ /mol /L after 
methionine loading (skewness: 0.7, kurtosis: -0.3). Mean ± 2SD range for plasma 
folic acid was 5.3 - 22.5 nmol/L (skewness: 1.1, kurtosis: 1.1) and for vitamin B12 
84 - 487 pmol/L (skewness: 0.9, kurtosis: 1.0). Four patients (number 8, 1 1 , 16 
and 23) were folate deficient ( < 5.3 nmol/L) and one patient (number 14) had 
reduced vitamin B12 (79 pmol/L). However, these patients showed no classical 
clinical symptoms of folate or vitamin B12 deficiency. 
As a reference, MTHFR activity was measured in a group of 23 healthy 
subjects consisting of hospital personnel without any clinical evidence for vascular 
disease. Their mean ( ± SD) age was 32.7 ( ± 7.4) years. One subject clearly 
showed thermolabile MTHFR and was excluded from the control group. The 
presence of thermolabile MTHFR was studied in several groups of vascular patients 
after their homocysteine status was established by methionine loading. One group 
with mild hyperhomocysteinemia consisted of 39 patients, 28 premenopausal 
women and 11 men, with proven vascular disease (17 patients with cerebral, 9 
patients with peripheral and 5 patients with coronary arterial occlusive disease and 
8 patients with venous thrombosis). The mean ( ± SD) age of these patients at the 
time of study was 40.3 ( ± 8.9) years. The mean ( ± SD) age of clinical onset of 
the vascular abnormalities in this group was 35.6 ( ± 10.1) years. 
Another group consisted of 29 normohomocysteinemic patients, 14 female 
and 15 male, with premature vascular disease (21 patients with cerebral, 6 
patients with peripheral and one patient with coronary arterial occlusive disease 
and one patient with venous thrombosis). Their mean ( ± SD) age at the time of 
study was 43.8 ( ± 12.5) years. The mean ( ± SD) age of clinical onset of vascular 
disease in this group was 40.3 ( ± 11.4) years. 
Materials and methods 
Potassium phosphate, L-( + )-ascorbic acid, 35% formaldehyde, toluene and 
acetic acid were obtained from Merck (Darmstadt, Germany). FAD (disodium salt), 
menadione sodium bisulfite, dimedone and methyl-THF (barium salt) were obtained 
from Sigma Chemical Co (St.Louis, USA). Ethylenediamine-tetraacetate (EDTA) 
was obtained from Fluka BioChemika (Buchs, Switzerland) and [Me-14C] methyl-
THF (50 mCi/mmol, barium salt) was obtained from Amersham International pic 
(Amersham, UK). An Eppendorf 5436 thermomixer (Hamburg, Germany) was used 
for preincubating the enzyme extract and for incubating the incubation mixture. 
Lymphocytes were isolated from 20 ml heparinized blood using Lymphoprep 
(Nycomed Pharma AS, Oslo, Norway)19 and were washed twice with Hank's buffer 
(ICN Biomedicals Ine, Costa Mesa, UK). The cell pellet was stored at - 80°C until 
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enzyme assay. 
The MTHFR activity was determined radiochemically in lymphocytes, in its 
physiological reverse direction (Figure 5.1). [Me-1 4C] Methyl-THF served as the 
substrate in the presence of menadione as electron acceptor. Activities were 
measured using a modified method of Kang et al.9. The cells were resuspended in 
50 mM potassium phosphate buffer pH 7.2, frozen and thawed three times, and 
centrifuged 40 min at 15.8 χ 10 3 g. A part of the supernatant was preincubated 
for 5 min at 46°C to determine the heat stability. FAD was omitted during this 
heat inactivation2 0. The incubation mixture, with a final volume of 600 //I, 
consisted of 0.18 M potassium phosphate buffer pH 6.8, 1.15 mM EDTA pH 7.0, 
11.5 mM ascorbic acid, 54μΜ FAD, 2 0 μ Μ [Me-1 4C] methyl-THF (5.0 χ 10 s dpm), 
3.5 mM menadione and a maximum of 250 μ\ enzyme extract (preincubated 
supernatant or normal supernatant). The incubation was started by addition of 
menadione and lasted for 20 min in the dark at 37°C. The blank contained all the 
components of the incubation mixture, except enzyme extract. The incubation was 
terminated by the addition of 10 //I of 1.0 M carrier formaldehyde, 50 //moles 
dimedone in 200//I ethanohwater (1:1) and 100//I 3.0 M potassium acetate, pH 
4.5. The reaction mixture was heated at 95°С for 15 min, after which it was 
cooled on ice for about 10 min. The reaction mixture was added to 3.0 ml toluene 
and stirred vigorously for 15 sec. After low speed centrifugation, 2.0 ml of the 
toluene phase was taken for measurement of radioactivity. Protein was determined 
by the method of2 1. Enzyme activity is expressed as nmoles of formaldehyde 
formed/mg protein/h. 
Cystathionine ß-synthase activity was measured as described elsewhere10,22 
without addition of pyridoxal phosphate to the assay-mixture in cultured fibroblasts 
of eight vascular hyperhomocysteinemic patients. For comparison cystathionine ß-
synthase activities were also measured in fibroblasts of 13 obligate heterozygotes 
for cystathionine ß-synthase and 12 control subjects. 
Total (free plus protein bound) homocysteine concentrations, fasting and after 
methionine loading, were measured in EDTA plasma by means of high performance 
liquid chromatography using fluorescence detection23. Folic acid and vitamin B12 
levels were determined in heparinized plasma and vitamin Be levels in whole blood 
by routine hospital assays. 
Statistics 
Rank-sum-two sample test and the Fisher's exact test (2-tail) were applied. 
Normal distribution was supposed to be present in case the skewness and kurtosis 
tests ranged from -1 to + 1 . Spearman rank test was used for determining 
correlations. 
Results 
Patients and controls 
Twenty-three healthy subjects were studied to obtain reference values. One 
subject was excluded from the control group because of thermolabile MTHFR 
deficiency, with a specific activity of 7.7 nmol CH20/mg protein/h and a residual 
activity after heat inactivation of 15.6%. In the other 22 control subjects a mean 
( ± SD) specific MTHFR activity of 15.6 ( ± 4.7) nmol CH20/mg protein/h (range: 
9.1 - 26.6) and a mean (± SD) residual activity after heat inactivation of 55.3 ( ± 
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12.0)% (range: 35.9 - 78.3) was observed. In concordance with Kang et al.9 1 6 1 β , 
thermolabile MTHFR was defined as a specific activity of 5 0 % of the normal mean 
and a residual activity after heat inactivation of less than 3 6 . 0 % of the initial 
activity The hyperhomocysteinemic vascular patients (n = 39) could be divided into 
t w o distinct subgroups (Table 5.1). One group (n = 11) with thermolabile MTHFR, 
showed a mean ( ± SD) specific activity of approximately 5 0 % of the normal 
mean: 8 7 ( ± 2.1) nmol CH20/mg protein/h (range: 5.5 - 12.7) and a residual 
activity after heat inactivation ranging from 0 to 3 3 . 0 % . The specific MTHFR 
activity of the thermolabile group showed a small overlap with the control group, 
so heat inactivation was employed to discriminate between control subjects and 
patients with thermolabile MTHFR (Figure 5.2). The other group of 
hyperhomocysteinemic vascular patients (n = 28) had a normal specific activity ( ± 
SD) of 21 5 ( ± 7.2) nmol CH20/mg protein/h (range: 10 0 - 39.0) and a residual 
activity after heat inactivation of 53.8 ( ± 9.2)% (range: 33.1 - 71.5). The mean 
( ± SD) specific activity of the 29 normohomocysteinemic vascular patients was 
20.7 ( ± 6.5) nmol CH20/mg protein/h (range: 9.4 - 33.8) and their mean ( ± SD) 
residual activity after heat inactivation was 58.2 ( ± 10.2)% (range: 4 3 . 0 - 82.0) 
Therefore, among the 29 normohomocysteinemic patients no thermolabile MTHFR 
activity was observed (Table 5.1), which was significantly different ( p < 0.002) 
from the incidence of 11 cases of thermolabile MTHFR among the 39 
hyperhomocysteinemic patients. 
Cystathionine ß-synthase activity was measured in available fibroblasts of ten 
patients with mild hyperhomocysteinemia (patients number 3, 10, 13, 16, 18, 20, 
23, 25, 27, 33). Their enzyme activities were, respectively, 5.0, 6.5, 9.5, 7.9, 
1.6, 5.8, 3.3, 8.0, 6.4 and 6.0 nmol cystathionine/mg protein/h. (normal range 2.3 
- 18.2 nmol cystathionine/mg protein/h, N = 12). So, only patient number 18 had 
activity within the range of obligate heterozygotes for cystathionine ß-synthase 
deficiency (0.25 - 2.4 nmol cystathionine/mg protein/h, N = 13) Only two studied 
patients (number 3 and 10) had thermolabile MTHFR and their cystathionine ß-
synthase activities were normal. 
The 11 patients with thermolabile MTHFR had diverse clinical abnormalities. 
4 patients suffered from cerebral, 2 from peripheral and one from coronary artery 
disease and 4 patients had venous thrombosis. Among the patients with 
thermolabile MTHFR no correlation was observed between specific MTHFR activity 
and fasting total homocysteine or total homocysteine after methionine loading. 
Among all patients with normal MTHFR activity, age did not correlate with specific 
MTHFR activity or residual MTHFR activity after heat inactivation. The mean ( ± 
SD) plasma folic acid level of the patients with thermolabile MTHFR (7.9 ± 2.9 
nmol/L) was significantly lower (p< 0.0002) than of the reference group (13.6 ± 
3 8 nmol/L). However, the plasma folic acid levels of the total group of 
hyperhomocysteinemic patients (9.2 ± 3.4) was also significantly lower (p< 
0 0001 ) than for the reference group The mean ( ± SD) vitamin B12 concentration 
of the thermolabile MTHFR deficient patients (222 ± 75 pmol/L) was significantly 
different (p = 0 052) from that of the reference group (290 ± 1 1 5 pmol/L) but the 
vitamin B12 levels of the total group of hyperhomocysteinemic patients (227 ± 84) 
was also significantly lower (p< 0.02) than for the reference group. 
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Figure 5.2. Residual MTHFR activity after heat inactivation, versus the specific 
activity in lymphocytes of hyperhomocysteinemic patients and control subjects. 
The dashed square contains the patients with thermolabile MTHFR. * = control 
subjects. • = hyperhomocysteinemic vascular patients. 
Assay 
After incubation at 37°C, the formaldehyde produced was derivatized by 
dimedone and the resulting product, formaldemethone, was extracted with toluene. 
Addition of carrier formaldehyde increased the amount of labeled formaldemethone 
and therefore the specific MTHFR activity (Figure 5.3). Dimedone and 
formaldehyde react at a ratio of 2 : 1 2 4 . This means that the amount of dimedone 
must always exceed twice the amount of formaldehyde present. We investigated 
the derivatization method by optimizing the carrier formaldehyde concentration at 
a constant dimedone concentration, and optimizing the dimedone concentration at 
a constant carrier formaldehyde concentration. Optimal derivatization and 
extraction was achieved by addition of 10//moles of carrier formaldehyde and 50 
//moles of dimedone. 
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Table 5 . 1 . Sex, age, homocysteine concentrations fasting and after loading, 
specific and residual MTHFR activity after heat inactiviation in patients wi th 
premature vascular disease, nd: not determined. ' Age at the time of this study; b 
Total fasting homocysteine; c Total post-load homocysteine. 
Patient Sex Age' Heys" 
O h 
Hcysc 
6 h 
Specific 
MTHFR activity 
(nmol CH20/mg 
protein/h) 
Hyperhomocysteinemic patients with thermolabile MTHFR: 
1 F 28 20 57 9.5 
2 
3 
4 
5 
6 
7 
8 
9 
10 
11 
F 
F 
F 
F 
M 
F 
M 
F 
F 
F 
mean 
± SD 
52 
26 
46 
49 
21 
35 
49 
37 
40 
29 
37.5 
± 1 0 . 6 
13 
19 
13 
17 
31 
18 
32 
27 
17 
38 
22.3 
± 8 . 4 
94 
51 
54 
57 
76 
67 
68 
52 
88 
92 
68.7 
± 1 6 . 4 
5.5 
8.4 
9.0 
6.5 
12.7 
7.3 
8.2 
11.9 
8.6 
8.2 
8.7 
±2 .1 
Hyperhomocysteinemic patients with normal MTHFR activity: 
12 F 46 10 77 23.1 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
25 
26 
27 
28 
29 
30 
31 
32 
33 
34 
35 
36 
37 
38 
39 
M 
M 
M 
M 
M 
M 
M 
M 
M 
mean 
± SD 
51 
31 
50 
50 
51 
53 
43 
39 
46 
28 
43 
29 
40 
33 
42 
20 
19 
35 
44 
41 
40 
63 
48 
46 
48 
42 
46 
41.7 
± 9.9 
11 
27 
20 
21 
14 
nd 
34 
19 
14 
10 
nd 
144 
13 
12 
nd 
30 
16 
26 
15 
13 
nd 
12 
23 
7 
22 
61 
11 
24.4 
± 27.9 
75 
116 
54 
68 
56 
75 
71 
50 
63 
54 
115 
148 
60 
75 
69 
57 
52 
50 
61 
62 
84 
61 
52 
59 
74 
145 
67 
73.2 
± 26.3 
22.6 
11.6 
12.5 
25.9 
14.7 
23.2 
13.5 
17.8 
30.4 
22.2 
18.7 
10.0 
26.8 
30.1 
28.1 
10.3 
18.6 
21.7 
39.0 
19.6 
23.2 
16.5 
18.4 
16.5 
28.9 
25.6 
33.1 
21.5 
± 7.2 
Residu. 
MTHFF 
activity(0 
19.4 
0 
5.4 
5.5 
29.8 
26.5 
19.5 
31.5 
33.0 
11.1 
29.2 
19.2 
± 1 1 . 9 
52.7 
35.5 
49.7 
52.0 
71.5 
54.1 
67.7 
47.7 
48.3 
55.1 
59.3 
52.2 
62.0 
63.4 
54.6 
61.1 
43.0 
56.8 
46.4 
67.7 
59.8 
47.4 
49.5 
63.1 
57.5 
42.4 
52.9 
33.1 
53.8 
± 9.2 
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Normohomocysteinemic patients: 
40 
41 
42 
43 
44 
45 
46 
47 
48 
49 
50 
51 
52 
53 
54 
55 
56 
57 
58 
59 
60 
61 
62 
63 
64 
65 
66 
67 
68 
F 
M 
M 
M 
F 
F 
M 
M 
F 
M 
M 
M 
F 
M 
F 
F 
F 
M 
F 
M 
F 
F 
F 
M 
M 
F 
F 
M 
M 
mean 
± SD 
47 
48 
25 
41 
47 
27 
55 
56 
37 
53 
41 
40 
22 
55 
22 
35 
52 
46 
48 
39 
46 
39 
31 
42 
47 
51 
34 
56 
57 
43.8 
± 12.5 
13 
15 
14 
11 
13 
11 
12 
14 
10 
8.7 
7.5 
13 
10 
13 
11 
7.8 
17 
15 
13 
13 
8.7 
13 
11 
11 
10 
17 
15 
12 
14 
12.2 
ì ± 2.5 
40 
44 
31 
31 
49 
28 
43 
34 
32 
25 
22 
37 
27 
38 
28 
27 
42 
46 
40 
39 
21 
33 
32 
31 
32 
42 
41 
43 
34 
34.9 
± 7.3 
23.7 
31.3 
22.1 
24.6 
30.5 
14.8 
19.6 
14.0 
11.4 
33.8 
18.1 
16.0 
25.8 
18.9 
14.8 
20.5 
13.0 
20.0 
23.7 
9.4 
29.4 
17.0 
21.3 
24.6 
28.6 
13.0 
26.9 
19.6 
14.0 
20.7 
± 6.5 
52.7 
71.6 
58.8 
50.8 
82.0 
64.9 
61.2 
47.1 
43.0 
76.2 
49.7 
61.9 
60.9 
64.0 
65.0 
55.0 
50.0 
68.7 
52.7 
49.2 
67.7 
43.2 
69.2 
50.8 
46.3 
50.0 
66.2 
61.2 
47.1 
58.2 
± 10.2 
Three different blanks were tested (1) the reaction mixture including the 
enzyme extract and no incubation at 37°C; (2) the reaction mixture incubated at 
37°C without the enzyme extract; (3) the reaction mixture and addition of the 
enzyme extract after the incubation at 37°C. Blank 1 was inadequate because it 
resulted in recovery of much less radioactivity than either blank 2 or 3. No 
difference between blank В and С was observed (data not shown). Blank 2 was 
used in this study, because it required no enzyme extract. 
MTHFR activity depends on the concentration of the cofactor FAD. A maxi­
mum activity was observed at 50 μΜ FAD. In all assays 54 μΜ FAD was used. 
Formaldehyde production was linear with incubation time up to 40 min and with 
amount of enzyme between 10 and 250 μς protein. The incubation time used was 
20 min and the amount of enzyme extract added varied from 22 to 150μο, protein. 
A Km for methyl-THF of 1 9 μ Μ was observed. Overall, the modifications resulted 
in higher specific MTHFR activities in lymphocytes than reported elsewhere9 , 1 6 '1 7. 
The thermolability of MTHFR in the enzyme extract of pooled lymphocytes of 
controls was examined by preincubating for 5 min at 37, 40, 46 and 49°C. 
Incubation at 49°C resulted in a 7 0 % loss, at 46°C in a 5 3 % loss and at 40°C in 
a 17% loss of activity. Preincubation at 46°C resulted in a 7 7 % loss of enzyme 
activity at 20 min, 5 3 % loss at 10 min, 4 3 % loss at 5 min and 1 8 % loss of enzy­
me activity at 2 min (Figure 5.3). Heat inactivation was performed by incubating 
the enzyme extract for 5 min at 46°C, thus allowing a reliable distinction between 
thermolabile and thermostable MTHFR in patients and control subjects. 
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specific MTHFR activity (nmol CH20/mgr protein.h) 
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Figure 5.3. Effect of variation of the amount of carrier formaldehyde on the 
derivatization of labelled formaldehyde with dimedone at two different 
concentrations. • = 6//mol dimedone, • = 50//mol dimedone. 
Discussion 
In this study the thermolabile form of MTHFR was observed in 11 of 39 
premature vascular disease patients with mild hyperhomocysteinemia after 
methionine loading. Nine out of these 11 patients were hyperhomocysteinemic in 
the fasting state. No thermolabile MTHFR was observed among 29 
normohomocysteinemic patients with premature vascular disease and in 23 healthy 
subjects one case had thermolabile MTHFR. These findings indicate that 
thermolabile MTHFR is one of the causes leading to mild hyperhomocysteinemia, 
established by methionine loading in patients with vascular disease. 
S-adenosylmethionine is a major regulating compound in homocysteine 
metabolism because it activates cystathionine ß-synthase and inhibits MTHFR25. 
Plasma homocysteine concentration is supposed to reflect the capacity of 
homocysteine remethylation in the fasting state because of the low S-
adenosylmethionine levels. Whereas, the homocysteine concentration after oral 
loading with unphysiologic amounts of methionine is believed to evaluate the 
cystathionine ß-synthase status2,3. However, in the present study all vascular 
patients with the thermolabile form of MTHFR had elevated homocysteine levels 
after loading and not always in the fasting state. Probably, the folate dependent 
homocysteine remethylation contributes to homocysteine conversion not only in 
58 
Chapter 5 
25 
preincubation time (min) preincubation temperature ( C) 
55 
20 r 
15 
10 
0% 20% 40% 60% 
residual MTHFR activity 
80% 100% 
Figure 5.4. Effect of preincubation for 5 min at different temperatures on the 
residual MTHFR activity ( • ) . Effect of variation of preincubation time at 46°C on 
the residual MTHFR activity (• ) . 
the fasting state but also after methionine loading. 
Cystathionine ß-synthase activity was assayed in 10 of the 21 vascular 
patients with mild hyperhomocysteinemia, including two patients (number 3 and 
10) with thermolabile MTHFR. All except one (number 18) had normal 
cystathionine ß-synthase activity. This indicates that decreased cystathionine ß-
synthase activity is not the major cause of hyperhomocysteinemia in patients wi th 
premature vascular disease. 
Kang et al.9 observed an incidence of 17% of thermolabile MTHFR in a group 
of 212 patients with coronary arterial disease. Their homocysteine metabolism was 
not examined by means of a methionine loading test. In a previous study18 we 
observed in a large group of patients with diverse forms of vascular disease a 
prevalence of hyperhomocysteinemia of 24% by using methionine loading tests. 
The present paper showed that approximately 28% of such hyperhomocysteinemic 
patients have the thermolabile form of MTHFR. Thus, an incidence of thermolabile 
MTHFR of 7% among our total group of vascular patients can be calculated which 
is lower than Kang et al.9 observed among coronary patients. 
The hyperhomocysteinemic patient group consisted of more female than male 
patients, compared to the normohomocysteinemic patient group. 
Hyperhomocysteinemic women may be more susceptible to developing vascular 
disease than hyperhomocysteinemic men18. The age of onset of vascular disease 
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among the thermolabile MTHFR deficient patients varied from 18 to 50 years. The 
clinical expression of vascular disease among the 11 patients with thermolabile 
MTHFR was very diverse, including cerebral, peripheral and coronary arterial 
disease and venous thrombosis. Therefore, thermolabile MTHFR is a risk factor not 
only for coronary arterial disease, as reported by Kang et al.9-15 but probably for 
vascular disease in general. 
An incidence of the homozygous form of thermolabile MTHFR of 5% in the 
normal population is reported915. This is consistent with our finding of one 
thermolabile MTHFR deficient subject among 23 healthy subjects. Thus, the 
heterozygous form must have an incidence of approximately 22% in the normal 
population. Such a high frequency of this thermolabile MTHFR mutation might be 
explained by a concomitant beneficial effect of the mutation. Perhaps in times of 
starvation a reduced MTHFR activity decreases homocysteine remethylation and 
preserves the available one-carbon moieties of the THF derivatives for the vital 
synthesis of purines and thymidine. 
Severe MTHFR deficiency is very resistant to many homocysteme-lowenng 
and methionme-elevating forms of therapy, including folates, methionine, 
pyndoxine, vitamin B,2 and carnitine57. Betaine appears the best choice of 
therapy5 26 2e. It enhances the remethylation of homocysteine to methionine via an 
alternative pathway (Figure 5.1) and methionine levels increase at the expense of 
homocysteine. Logical choices of therapy for thermolabile MTHFR deficient patients 
seem to be folic acid and betaine. Riboflavin could also be an appropriate option 
since FAD is the cofactor of MTHFR and may stabilize the mutant MTHFR. Two 
patients with thermolabile MTHFR and mild hyperhomocysteinemia showed a 
dramatic decrease of total homocysteine concentration after folic acid therapy16. 
Folic acid administration may increase the concentrations of MTHF which is the 
substrate of MTHFR. 
On the relationship between vasculardisease and mild hyperhomocysteinemia 
due to a 50% reduction in MTHFR activity the following considerations can be 
made: ( 1 ) in the vascular wall THF dependent remethylation constitutes the primary 
mechanism for homocysteine conversion. The betaine-homocysteine 
methyltransferase is present only in the liver and maybe in the kidney and the Km 
of cystathionine ß-synthase is at least ten times higher than that of the enzymes 
involved in THF dependent homocysteine remethylation25; (2) mild 
hyperhomocysteinemia is likely caused by a combination of genetic and 
environmental factors, including methionine, betaine, choline, folate, vitamin B6 and 
B12; (3) in addition, although thermolabile MTHFR and hyperhomocysteinemia are 
correlated, and hyperhomocysteinemia is a risk factor for vascular disease, some 
other effect of thermolabile MTHFR besides its resultant hyperhomocysteinemia 
may put patients at risk for vascular disease. 
In conclusion, thermolabile MTHFR is the most likely cause of abnormal 
homocysteine metabolism in approximately 28% of the vascular patients with mild 
hyperhomocysteinemia. 
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FAMILIAL CEREBROVASCULAR ACCIDENTS DUE TO 
CONCOMITANT HYPERHOMOCYSTEINEMIA AND 
PROTEIN С DEFICIENCY TYPE 1. 
D.G. Franken, A. Vreugdenhil, G.H.J. Boers, 
A. Verrips, H.J. Blom, I.R.O. Novakova 
Stroke 1993;24:1599-1600. 
Abstract 
Background and purpose: Hyperhomocysteinemia as well as protein С 
deficiency are risk factors for thromboembolism. Hyperhomocysteinemia have been 
reported to inhibit the expression of thrombomodulin and to inactivate both 
thrombomodulin and protein С irreversibly, leading to a decreased protein С 
activity. 
Case: In a 16-year-old girl, who developed a sinus sagittalis thrombosis, and 
in her father, who experienced a transient ischemic attack, both 
hyperhomocysteinemia and protein С deficiency type 1 were present. Protein С 
deficiency alone was found in one of the two sisters who was without any clinical 
vascular history. 
Conclus ions: In th is fami ly w i t h independent ly inher i ted 
hyperhomocysteinemia and protein С deficiency, clinical cerebrovascular disease 
occurred only in those members with a combination of both risk factors, 
suggesting a synergistic interaction between these thrombogenic risk factors. 
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Introduction 
Mild hyperhomocysteinemia has come to be recognized as an independent risk 
factor for thromboembolic and premature arteriosclerotic complications1'5. Although 
the mode of inheritance is not established, there is evidence that mild 
hyperhomocysteinemia is influenced by genetic factors6. 
Protein С deficiency type 1 is a disorder with autosomal dominant inheritance 
with variable penetrance, in which protein С activity as well as protein С antigen 
is decreased 7 8 . The conversion of protein С into activated protein С is enhanced 
by the cofactor thrombomodulin. A deficiency of the anticoagulant protein C, both 
in its hereditary and acquired forms, is also recognized as an independent risk 
factor for venous and arterial thrombosis 9 1 0 . 
Homocysteine has been reported in in vitro studies to inhibit thrombomodulin 
expression on endothelial cell surface and to inactivate both thrombomodulin and 
protein С irreversibly1 1 - 1 2. Thus, hyperhomocysteinemia as well as protein С 
deficiency are not only both independent risk factors for thrombotic and 
thromboembolic complications, but furthermore, hyperhomocysteinemia may 
exaggerate the decrease of the protein С activity in case of protein С deficiency. 
In this report, we present as the history of a teenage girl from a family with 
inherited hyperhomocysteinemia as well as protein С deficiency type 1. 
Case report 
A 16-year-old girl born to non-consanguineous parents was admitted to our 
hospital with vomiting, fever, and nuchal rigidity. Penicillin was administrated 
because bronchitis was suspected. After 3 days she developed headache, 
dysphasia, dysarthria, and a right-sided hemiparesis. Venous and arterial digital 
subtraction angiography revealed thrombosis of the superior and inferior sagittal 
sinus and straight sinus. Additionally, a moderate hypercholesterolemia (7,7 
mmol/L; reference value ¿ 6,0 mmol/L) was detected. She had been smoking 
about 2 to 5 cigarettes daily for 3 years, and used sub-50 oral contraceptives, 
containing 35 micrograms ethinylestradiol and 2 milligrams Cyproteronacetate 
(Diane-35H) for 5 months. 
The diagnosis hyperhomocysteinemia in the index case and family members 
was made by means of a standardized methionine loading test as reported 
previously13. The plasma total homocysteine concentration immediately before and 
6 hours after the methionine loading was analyzed by high performance liquid 
chromatography14. Protein С activity and antigen screening in these persons was 
performed and analyzed by a previously described method 1 6 . 
Both hyperhomocysteinemia (19 before and 60//mol/L after load; reference 
mean ± 2 SD for premenopausal women is 5 to 15 //mol/L and 15 to 49 //mol/L, 
respectively) and protein С deficiency type 1 (protein С activity of 3 3 % , protein С 
antigen of 4 5 % ; reference values are > 6 0 % and > 7 0 % , respectively) were 
present in the index patient. 
The patient's 43-years-old father had smoked 20 cigarettes daily since the 
age of 14 years, and had a history of a transient ischemic attack at the age of 4 0 . 
In addition, both hyperhomocysteinemia (34 //mol/L before and 71 //mol/L after 
load; reference mean ± 2 SD for men 7 to 17 //mol/L and 20 to 51 //mol/L, 
respectively) and protein С deficiency type 1 (protein С activity of 6 0 % , protein С 
antigen of 58%) were established. The patient's 39-years-old mother, who had 
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smoked from age 14 to 33, and two younger sisters (15 and 13 years of age, 
respectively), both without smoking habits, were without history of vascular 
complications, and did not show hyperhomocysteinemia after methionine loading 
(13, 13 and 12/ymol/L before load, respectively, and 35, 23 and 24//mol/L after 
load, respectively). The protein С activity and protein С antigen in her mother ( 9 5 % 
and not measured, respectively) and in one of the t w o sisters (68% and 7 4 % , 
respectively) appeared to be normal. However, protein С deficiency type 1 was 
present in the other sister (protein С activity of 4 1 % , protein С antigen of 4 7 % ) . 
With the exception of the use of tobacco in both parents, there were no 
further predisposing factors for vascular disease present in the parents and sisters. 
In particular, no hyperlipoproteinemia, diabetes or high blood pressure was noted. 
Discussion 
Cerebral venous thrombosis is often associated with sepsis, dehydration, 
polycythemia, malignancies, post partum state, use of oral contraceptives, 
antithrombm III deficiency, systemic lupus erythematodes, head injury and Behcet's 
syndrome1 6. Both hyperhomocysteinemia and protein С deficiency type 1 also are 
risk factors for thrombosis4 5 8. In the studied family both states were independently 
inherited, and clinical thrombosis occurred only in those family members with 
hyperhomocysteinemia as well as protein С deficiency type 1. In these cases the 
elevated homocysteine concentration may have decreased the deficient protein С 
activity even more, resulting in a very high risk for thrombosis. 
Hyperhomocysteinemia was treated with vitamin B6, 250 mg daily, and the 
homocysteine concentration decreased to 1 5 and 37 /лтюІ/L in the index patient 
and to 24 and 57 //mol/L in her father before and after load, respectively. The 
thrombotic tendency caused by the protein С deficiency was attenuated by 
anticoagulant therapy in the 16-year-old girl and by salicylate administration in her 
father While on this treatment, no further complications as a result of their 
proneness to thrombotic events have occurred during the last 2 years. 
The basis of the hyperhomocysteinemia in this family is unclear. Before the 
performance of the methionine loading test, secondary causes of mild 
hyperhomocysteinemia had been excluded such as vitamin B6, B1 2 and folic acid 
deficiencies, and failure of liver and renal functions. Possible genetic defects in 
methionine metabolism leading to mild hyperhomocysteinemia are heterozygosity 
for cystathionine synthase deficiency or homozygosity for thermolabile 5,10-
methylenetetrahydrofolate reductase 1 2 1 7 . The determination of these enzymes 
activities was not performed on a routine base and are not available in these 
hyperhomocysteinemic family members The beneficial effect of homocysteine-
lowering treatment with vitamin B6 might suggest the presence of the 
heterozygosity for cystathionine synthase deficiency in this particular family. 
We conclude that screening for hyperhomocysteinemia as well as for protein 
С deficiency in patients presenting with thromboembolic events of unknown origin 
is recommendable because both factors may lead independently to thrombosis. 
Moreover, both factors may have specifically a possible synergistic interaction as 
is indicated in previous in vitro studies1 1 12 
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Abstract 
A review of studies is presented on the effect of homocysteine-lowering 
therapy in mildly hyperhomocysteinemic vascular patients. Pooled data showed 
that it is possible to decrease elevated fasting plasma homocysteine levels as much 
as a mean of 4 0 % by the use of a low dose of 0.65 mg folic acid daily. A higher 
dose, i.e. 5 mg daily, resulted in a slightly larger reduction of about 50%; 10 mg 
folic acid daily had no extra effect. Vitamin B12 in a low oral dose of 0.400 mg 
daily is advisable to add because of its modest homocysteine-lowering effect but 
more to avoid folic acid-refractoriness in cases of vitamin B12 deficiency and to 
prohibit the development of neuropathy due to unrecognized perniciosa. Vitamin 
B6 does not affect fasting hyperhomocysteinemia. 
Elevated post-load homocysteine levels as established by means of 
methionine loading, can be normalized in more than 90% of the patients by 
treatment with 100 mg vitamin B6 plus 5 mg folic acid daily. This combination 
showed a mean reduction of post-load concentrations of about 50%, somewhat 
higher than the 4 0 % obtained by vitamin B6 as single agent. The efficacy of lower 
doses of vitamins has not been studied. 
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Introduction 
In line with the first report by Sardharwalla et al.1 of mildly elevated 
homocysteine levels after an oral methionine load in obligate heterozygotes for 
cystathionine synthase deficiency, it has been proposed that the comparably mild 
hyperhomocysteinemia detected in about 25% of vascular patients also originates 
from heterozygosity for this specific enzyme defect2. In the 2 reports presenting 
determinations of cystathionine synthase activity in cultured fibroblasts from 
hyperhomocysteinemic vascular patients, an intermediate enzyme deficiency, 
indeed, has been confirmed in the majority of these patients34. In recent years, 
however, it has become increasingly clear that identification of 
hyperhomocysteinemic patients with vascular disease as heterozygotes for 
cystathionine synthase deficiency has not been convincing so far6. More recent 
determinations of enzyme assays in such patients show that cystathionine 
synthase activity is defective only in sporadic cases57 and that thermolability of 
5,10-methylenetetrahydrolate reductase is a far more common genetic defect 
among these patients5 8. Notwithstanding its occurrence up to 25% in some groups 
of hyperhomocysteinemic vascular patients5, this prevalence still does not seem 
high enough to predict a predominant role of this defect among possible causes of 
mild hyperhomocysteinemia in vascular patients. The total range of these possible 
causes either genetical or environmental is not at all completely explored and, as 
a consequence, the design of homocysteine-lowering treatment with maximal 
efficacy may be at the moment illusory for the whole group of 
hyperhomocysteinemic patients. 
The earlier assumption - albeit incorrect in retrospective - of heterozygous 
cystathionine synthase deficiency as the major cause of mild hyperhomo-
cysteinemia in vascular patients, has had created the comfortable situation in 
which it was justified to deduce the guidelines for homocysteine-lowering 
intervention in these 'heterozygotes' from the extended experience in the 
homozygous condition. In homozygotes for cystathionine synthase deficiency the 
severely elevated homocysteine levels in the blood can be lowered or even 
normalized by treatment with high doses of vitamin B6 which as pyndoxine 
phosphate is cofactor in the specific enzymatic reaction. The majority of the adult 
patients responds beneficially to such treatment and in case of absent or 
insufficient effect additional supplementation of cofactors or cosubstrates for the 
remethylation of homocysteine into methionine such as folic acid, vitamin B12, and 
betaine ( = trimethylglycine) will be favourable9. The ultimate therapeutical option 
of dietary methionine restriction is therefore seldom required. Analogously to this 
established therapeutical regimen in severely hyperhomocysteinemic patients, 
homocysteine-lowering intervention has also been carried out in mildly 
hyperhomocysteinemic vascular patients. 
Review of previous reports 
The effect of vitamin B6 and folic acid 
The first data on biochemical responsiveness of vascular patients with mild 
hyperhomocysteinemia to potentially homocysteine-lowering treatment were 
presented by Boers in 198810. Out of 32 of suchlike patients 26 (81 %) normalized 
their pathological hyperhomocysteinemia after methionine loading on treatment 
with vitamin B6, 250 mg daily for 6 weeks, supplemented with folic acid, 5 mg 
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daily, only in cases in which folate deficiency was present. The remaining 6 
patients, unresponsive to vitamin Be, showed a normalization of the post-load 
hyperhomocystememia after the start with betaine, 6 gram daily. In these patients 
fasting homocysteine levels and their response upon treatment were not presented 
because the concentrations measured as free homocysteine and not as total 
homocysteine what became possible in later years, were indiscriminately low11. 
The dosages of the prescribed substances had been deduced arbitrarily from the 
established regimen in homozygotes for cystathionine synthase deficiency. It was 
considered that in these 'heterozygotes' with less severe hyperhomocystememia, 
a lower dose of vitamin B6 should be sufficiently potent. Furthermore, the risk of 
sensory peripheral neuropathy which had been reported as a sporadical adverse 
effect in non-hyperhomocysteinemic users of high doses up to 6 gram daily, had 
to be minimahzed11 '2 . The dosages of folic acid and betaine had not been adjusted 
because no side effects of these substances are known11. 
Brattstròm et al.13 in 1990 reported in 20 hyperhomocysteinemic vascular 
patients the homocysteine-lowering effect of treatment with 240 mg vitamin B6 
daily followed by a period of 2 weeks with 10 mg folic acid daily in addition. After 
vitamin B6 alone the mean basal concentration remained unchanged but the mean 
increase of the levels after methionine loading decreased by 26%. The combined 
treatment, however, resulted in a mean reduction of the basal levels by 5 3 % and 
of the post-load increase by 39%. In how many patients the 
hyperhomocystememia had been normalized while on treatment is not indicated. 
Dudman and coworkers in 1993 showed about similar results with a lower 
supplement of 100 mg vitamin B6 daily which induced a decrease of the post-load 
homocysteine levels of 35% in hyperhomocysteinemic patients with vascular 
disease14. Folic acid as the sole therapy, 5 mg daily, resulted in a reduction of 45% 
and the combination of vitamin B6 and folic acid, 100 mg respectively 5 mg daily, 
in a decrease of 51 % of the post-load levels. The numbers of treated patients in 
each group were small, however, i.e. 5, 6, and 12 respectively, but it could be 
calculated that these effects did not differ statistically significantly from each 
other. In this study free homocysteine has been determined in the blood. The 
effects of the various treatments on the fasting levels are not available. 
Franken et a l . " presented in 1994 retrospective data on homocysteine-lowe-
ring treatment in a large group of hyperhomocysteinemic vascular patients. During 
the period 1980 to 1990 a total of 421 young arteriosclerotic patients had been 
screened for mild hyperhomocystememia by means of a methionine loading test 
Fasting homocysteine levels were not considered because the determination of the 
concentration of free instead of total homocysteine left the basal levels 
unmanageably low. Out of the 421 patients 100 proved to be 
hyperhomocysteinemic and 82 of these had been treated with 250 mg vitamin Be 
daily. After 6 weeks of treatment post-load homocysteine levels again were 
assessed and 56% of the treated patients showed a normalization of their 
hyperhomocystememia, 20% had an intermediate response at least 60% reduction 
of the pathological elevation of the post-load levels and 24% a poor response of 
less than 6 0 % reduction or no response at all. The mean reduction of the post-load 
levels was 39%, higher than the 26% reduction observed by Brattstròm et al.13 
after not more than 2 weeks of treatment with nearly the same dose of vitamin B6 
but about equal as obtained by Dudman et al u in long-term treatment with a lower 
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dose of 100 mg vitamin Β
β
 daily. The non-normalized patients after 6 weeks of 
therapy with vitamin Be were further treated with folic acid, 5 mg daily, and/or 
betaine which resulted in 9 5 % in a normalization as yet, whereas vitamin B6 was 
continued only if it had had at least some intermediate response. 
Also in 1994 van den Berg et a l . ' 5 published the results of screening of mild 
hyperhomocysteinemia in 309 young vascular patients of whom 2 3 % showed 
abnormal homocysteine levels after methionine loading while only half of these 
detected patients presented concomitantly fasting hyperhomocysteinemia. In all 
hyperhomocysteinemic patients the prescribed treatment was identical, i.e. 250 mg 
vitamin B6 plus 5 mg folic acid daily for 6 weeks. Post-load hyperhomocysteinemia 
normalized in 9 2 % of the treated patients and fasting hyperhomocysteinemia, if 
concomitantly present, in 91 %. The mean reduction of the post-load homocysteine 
concentrations was 4 8 % , remarkably similar as the decrease which Dudman1 4 
observed in his 12 treated patients after the use of only 100 mg of vitamin Be in 
combination with the same dose of 5 mg folic acid daily. However, the decrease 
of the post-load levels was higher than the 3 9 % as obtained by Franken et al. 1 1 
after an equal period of therapy with the same dose of vitamin Be alone, and also 
higher than the 3 9 % reduction as achieved by Brattstrom et a l . 1 3 with the same 
combination but only for 2 weeks. The mean decrease of the fasting levels, i.e. 
5 1 % , equalled that from Brattstrom's study. 
Ubbink and coworkers presented in 1994 the results of a placebo-controlled 
intervention to lower fasting homocysteine levels16. From a group of 2788 
ambulatory men, aged between 20 and 73 years, who were referred for routine 
medical investigations for life insurance purposes, they recruited 100 participants 
with a fasting homocysteine level exceeding the normal reference range, i.e. above 
16.3 //mol/L These persons were randomly assigned to one of 5 groups, 20 for 
each. Group A received placebo tablets, group В folic acid tablets (0.65 mg), group 
С vitamin B6 tablets (10 mg), group D cyanocobalamm tablets (0.4 mg) and group 
E a tablet containing all these vitamins in the above-indicated doses as a 
combination. After the use of these tablets in a dose of 1 daily for 6 weeks, the 
fasting blood levels of homocysteine showed no change in group A, a reduction of 
4 2 % ( p < 0.001) in group B, 5% (not significant) in group C, 15% ( p < 0.01) in 
group D, and 5 0 % ( p < 0.001) in group E. The largest reduction caused by the 
supplement containing all 3 vitamins (group E) differed not statistically significantly 
from that obtained by folate supplementation alone (group B). Therefore, the 
conclusion of the authors is that the homocysteme-lowering effect of the 
multivitamin combination is mainly originating from its folic acid component. 
Notwithstanding that, it was remarkable that only in the group with combined 
vitamin supplementation 100% of the participants responded with a reduction of 
their circulating homocysteine concentration whereas in the group with folic acid 
as a single agent therapy 10% of the persons failed to respond. 
Only very recently in 1995, Landgren et al. 1 7 studied the effect of the use of 
various doses of folic acid on the fasting homocysteine level in 53 patients after 
a myocardial infarction. Sixteen, i.e 3 0 % , showed moderate fasting 
hyperhomocysteinemia with levels above 17.3/лпоІ/L. The patients were randomly 
allocated in an open study either to no treatment (n = 20), to treatment with 2.5 
mg (η = 1 7), or 10 mg (n = 16) of folic acid daily. After 6 weeks the no-treatment 
group even showed a subtile still significant increase ( + 4%) of the plasma 
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homocysteine levels, whereas the groups which took 2.5 mg as well as the group 
which used 10 mg folic acid daily presented a mean reduction in their fasting 
homocysteine level of 27%. In the 12 included patients wi th 
hyperhomocystememia the mean reduction was more marked than in the 
normohomocysteinemic ones, i.e. about 37%, but this effect was not superior to 
that obtained by Ubbink16 with a dose of folic acid as low as 0.65 mg daily. 
The effect of vitamin B12 
Both in healthy subjects1819 and in hyperhomocysteinemic vascular 
patients1317 there are indications that vitamin B12 supplementation is only effective 
as a homocysteine-lowenng treatment in cases with low or low-normal vitamin B12 
blood levels, which condition leads to elevated fasting homocysteine concentration 
but not to exaggerated rises after methionine loading. Nevertheless, Ubbink et al.16 
obtained by oral supplementation of 0.4 mg cyanocobalamm daily a modest, still 
significant decline of the mean fasting homocysteine level of 15% in 20 
hyperhomocysteinemic subjects. Some of their participants, however, could have 
had low vitamin B12 blood levels because the pretreatment vitamin nutritional 
status was unknown. 
Apart from this - albeit moderate - ability to lower fasting homocysteine 
levels, additional arguments to include vitamin B12 in a homocysteine-lowenng 
regimen are the fact that folate supplementation alone will not correct 
hyperhomocystememia if it is the result of low vitamin B12 status20, and that the 
use of folic acid as a sole treatment will deteriorate a silent neuropathy due to 
unrecognized pernicious anaemia. A daily oral dose of at least 0.4 mg 
cyanocobalamm should be sufficient to guarantee adequate resorption of vitamin 
B12 from the gastrointestinal tract even in perniciosa patients'6. 
The effect of betaine 
So far, the effect of the use of betaine on the homocysteine levels in hy-
perhomocysteinemic vascular patients, has been reported only in sporadic cases. 
When it has been prescribed because of an insufficient response of the post-load 
hyperhomocystememia to first choice treatments like vitamin B6 and/or folic acid, 
it could always normalize the excess rise of homocysteine in a dose of 6 g 
daily10 " 15. Dudman et al.11 showed that out of 9 hyperhomocysteinemic vascular 
patients 7 yielded a mean decrease of their post-load homocysteine levels of 3 8 % 
after the use of 1.68 g betaine daily for one week, which response was about 
similar to that obtained by vitamin B6 or folic acid in these patients. The 2 non-
responders to betaine did not react to any homocysteine-lowenng treatment. 
Effects of betaine treatment upon fasting hyperhomocystememia have not been 
mentioned in the various reports. 
Despite these promising, although very scattered reports of betaine therapy 
as homocysteine-lowenng agent, the prescription of this substance on a large scale 
in hyperhomocysteinemic vascular patients will meet difficulties in many countries 
because it is a non-registered drug. Long-term treatment in many homozygotes for 
cystathionine synthase deficiency did not reveal any adverse effect of the 
substance, however9. 
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What to treat: fasting or post-load hyperhomocysteinemia? 
It is beyond the scope of this paper to decide at this stage if detection of mild 
hyperhomocysteinemia in an individual vascular patient requires the performance 
of a methionine loading test or that the determination of a fasting plasma level 
should be sufficiently sensitive. In our experience, in as much as 30 to 5 0 % of 
post-load hyperhomocysteinemic vascular patients there is no concomitant fasting 
hyperhomocysteinemia15,21. From pooled data on about 500 patients wi th 
arteriosclerotic vascular disease under the age of 60 years and in about 300 
control subjects, an odds ratio of 13.0 (95% confidence interval 5.9 - 28.1) can 
be calculated as the estimate of the relative cardiovascular risk in subjects wi th an 
abnormal response to methionine loading compared to normal responders22. On the 
other hand, two recent studies assessed prospectively the risk of coronary disease 
in 21,000 persons from the general population23 and in about 15,000 physicians 
who participated in the US-Physicians' Health Study24. In the former study, a 
relative risk was shown of 1.32 (95% confidence interval 1.05-1.65) and in the 
latter one of 1.18 (95% confidence interval 1.03-1.36) for each one-standard 
deviation increase of homocysteine above the mean. Therefore, the relative risk of 
cardiovascular disease constituted by abnormal post-load homocysteine seems to 
be higher than that associated with moderately elevated fasting levels. However, 
more insights are expected in the next future from the publication of the results of 
a large case-control study performed in more than 800 prematurely arteriosclerotic 
patients and as much matched control subjects recruited from several European 
countries25. 
It could be argued that loading with an excess of methionine to screen for 
hyperhomocysteinemia in vascular patients is reflecting an unphysiological state 
because the thereby induced increase of S-adenosylmethionine concentration is 
directing the homocysteine metabolism disproportionally towards the 
transsulphuration pathway due to stimulation of activity of cystathionine synthase 
and inhibition of methylenetetrahydrofolate reductase activity by this 
intermediate29. Such mechanism has also been held responsible for the finding that 
vitamin B6, cofactor in the cystathionine synthase reaction, is effective in lowering 
a post-load hyperhomocysteinemia but does not affect a fasting elevated 
homocysteine level. 
On the other hand, the intraindividual day-to-day variation in fasting homo-
cysteine levels is disturbingly wide, up to 25%, which should represent also a day-
to-day variation in risk of developing myocardial infarction of about 25%2 7 ! One of 
the reasons for this variation could be dietary changes during the day preceding the 
fasting venous samplings because it has been proven that a protein-rich meal may 
affect plasma homocysteine for at least 8 hours27. A post-load homocysteine 
determination, 4 or 6 hours after the methionine intake in the fasting state in the 
morning, will have a distance in time from the last protein-containing meal of at 
least 16 hours and during the test itself the protocol prohibits protein intake. 
Therefore, less intraindividual variation in post-load homocysteine levels is probable 
although not proven so far. 
A very serious argument against the use of the post-load homocysteine level 
as criterion of hyperhomocysteinemia will be the fact that the methionine loading 
test is too laborious and expensive to include in the design of epidemiological 
studies with large numbers of participants. But already in diagnostic procedures in 
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individual vascular patients, the practical concerns and high costs of establishing 
post-load homocysteine levels will make most probably the determination of fasting 
levels the only accessible when in the future screening for this risk factor will 
become a routine procedure on a large scale. If so, more studies have to be done 
to standardize the sampling of fasting levels as much as possible and great 
attention should be paid to the relation with food intake the day preceding the 
blood sampling. 
Conclusions 
Pooled data from the above reviewed reports on the effect of homocysteine-
lowering treatment in hyperhomocysteinemic vascular patients justify several 
conclusions. It should be possible to induce a reduction of about 4 0 % of mildly 
elevated fasting homocysteine levels by the use of folic acid in a dose as low as 
0.65 mg daily. A dose of 2.5 mg daily had the same effect, 5 mg daily resulted in 
a slightly larger decrease of about 50%, increasing the dose up to 10 mg daily had 
no extra effect. Supplementation of vitamin Be did not affect fasting 
hyperhomocysteinemia significantly. Vitamin B12 in an oral dose of 0.400 mg 
cyanocobalamin daily will have an only modest effect but it is advisable to add 
such dose to folic acid therapy more to avoid folic acid-refractoriness in case of 
vitamin B12 deficiency and to prohibit the development of neuropathy due to 
unrecognized perniciosa. 
So, in summary, at present knowledge, the prescription of 0.65 mq folic acid 
plus 0.400 mq cyanocobalamin daily is required and sufficient to lower a mild 
fasting hyperhomocysteinemia for about 50%. The efficacy of even a lower dose 
of folic acid has not been explored so far. Indeed, a dose of folic acid of 0.65 mg 
is only 3 times higher than the recommended daily allowance (RDA 0.2 mg in most 
countries). However, to substitute vitamin suppletion in such low dose by dietary 
guidelines to increase folate intake from food, might be illusory because it would 
require a substantial change in ingrained dietary habits. Furthermore, it has been 
shown that dietary adjustment to guarantee the intake of at least 0.200 mg folic 
acid daily from the food was not able to maintain an acceptable folic acid blood 
level in subjects who tended to have low-normal concentrations28. 
Pooling the available data on the effect of various homocysteine-lowering 
regimen upon mildly elevated post-load homocysteine levels, learns that the use of 
100 mg vitamin Be plus 5 mg folic acid daily after at least 6 weeks of treatment 
caused a decrease of these levels of about 50%. Vitamin B6 as a single agent in 
doses from 100 to 250 mg daily resulted in a slightly lower reduction of about 
40%. Folic acid as the sole therapy, however, has been studied only in 6 patients 
so far, but showed in these patients a 45% decrease. The efficacy of lower doses 
of vitamin B6 and/or folic acid as single treatment or combined therapy has not 
been explored. Remarkably, only the combination of vitamin B6 plus folic acid 
resulted in 9 0 % or more of the treated patients in a complete normalization of the 
pathological post-load homocysteine levels, whereas the respective single 
treatments did much less, i.e. in about 50%. In the exceptional 
hyperhomocysteinemic patients who did not normalize after the use of vitamin B6 
plus folic acid, betaine in a dose of 6 g daily did always. In summary, at this state, 
in the treatment of post-load hyperhomocysteinemia it seems most preferable to 
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prescribe 100 mo vitamin B f plus 5 ma folic acid daily in view of the greatest 
efficacy of this combination and the highest rate of normalization of pathological 
homocysteine levels. 
The above indicated recommendations for the treatment of fasting hyper-
homocysteinemia are well in line with the design of a soon to start concerted 
action of several European countries in a placebo-controlled randomized dose-
finding study29. The effect of treatment with folic acid in respective doses of 0.200 
mg, 1 mg, and 5 mg, each in combination with 0.400 mg vitamin B12 will be 
compared with that of 0.400 mg vitamin B,2 alone and with that of a placebo. In 
this design the apparently crucial role of folic acid as the universal homocysteine-
lowering agent is well reflected. The still not completely clarified complexity of the 
aetiology of mild hyperhomocysteinemia either genetically or environmentally 
based, is much greater than originally thought. Notwithstanding that, the 
supplementation of folic acid seems to be the panacea in nearly all cases to lower 
the pathological homocysteine levels. 
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TREATMENT OF MILD HYPERHOMOCYSTEINEMIA 
IN VASCULAR DISEASE PATIENTS 
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Frans J .M. Trijbels, and Peter W.C. Kloppenborg. 
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Abstract 
Mild hyperhomocysteinemia is recognized as a risk factor for premature 
arteriosclerotic disease. A few vitamins and other substances have been reported 
to reduce blood homocysteine levels, although, normalization of elevated blood 
homocysteine concentrations with any of these substances has hitherto not been 
reported. Therefore, we screened 421 patients suffering from premature peripheral 
or cerebral occlusive arterial disease by oral methionine loading tests for the 
presence of mild hyperhomocysteinemia. Thirty-three percent of patients with 
peripheral, and 20% of patients with cerebral occlusive arterial disease were 
identified with mild hyperhomocysteinemia, i.e. in 14% of the men, 3 4 % of 
premenopausal and 26% of postmenopausal women. Mildly hyperhomocysteinemic 
patients were administered vitamin Be, 250 mg daily. After six weeks, methionine 
loading tests were again assessed to evaluate the effect of treatment. Patients 
with non-normalized homocysteine concentrations were further treated with 
vitamin B6, 250 mg daily, and/or folic acid, 5 mg daily, and/or betaine, 6 g daily, 
solely or in any combination. Vitamin B6 treatment normalized the afterload 
homocysteine concentration in 56% of the treated patients, i.e. 71 % in men, 4 5 % 
in premenopausal, and 88% in postmenopausal women. Further treatment resulted 
in a normalization of homocysteine levels in 95% of the remaining cases. Thus, 
mild hyperhomocysteinemia, which is frequently encountered in patients with 
premature arteriosclerotic disease, can be reduced to normal in virtually all cases 
by safe and simple treatment with vitamin B6, folic acid and betaine, substances 
each involved in methionine metabolism. 
81 
Chapter 8 
Introduction 
Classic homocystinuna, due to homozygosity for cystathionine synthase (CS) 
deficiency, is characterized by severe accumulation of homocysteine in blood and 
tissues. The incidence of this hereditary dysfunction varies geographically and is 
estimated 1 200,000 worldwide1. Homocystinuna is generally considered to cause 
premature arteriosclerosis and thromboembolism. It is treated with high-dose 
administration of vitamin Be, the active form, of which pyridoxal phosphate, 
functions as cofactor in the conversion of homocysteine into cystathionine (Figure 
8.1). The marked homocysteine-lowering effect of vitamin B6 is attributable to its 
stimulation of the residual activity of the cystathionine synthase enzyme1 4. 
Additionally, folic acid and betaine, both involved in the remethylation of 
homocysteine into methionine, can lower or even normalize the elevated 
homocysteine level in patients who respond poorly or not at all to vitamin B6 
treatment1 3. The incidence of vascular accidents is significantly reduced after 
initiating homocysteine-lowering treatment, revealing the clinically beneficial effect 
of such intervention in homozygous patients4. 
Mild hyperhomocysteinemia, with homocysteine concentrations equivalent to 
those as found in heterozygotes for CS deficiency, is characterized by mildly 
elevated blood homocysteine concentrations in the fasting state or after 
standardized methionine loading. However, intermediate CS deficiency is not the 
only possible genetic determinant of mild hyperhomocysteinemia. The occurrence 
of a mutant variant of methylenetetrahydrofolate reductase, characterized by 50% 
of normal activity and thermolability of the enzyme, has also been described 
recently in vascular patients with mild hyperhomocysteinemia5. Overall, in 9% to 
4 2 % of the patients under 50 years of age suffering from peripheral or cerebral 
occlusive arterial disease, myocardial infarction or thromboembolism, mild 
hyperhomocysteinemia has been observed and has come to be recognized as an 
independent risk factor for premature arteriosclerotic disease624. 
Routine screening for mild hyperhomocysteinemia among patients with signs 
of premature arteriosclerosis or thromboembolism at young age is recommendable 
if elevated homocysteine levels can be reduced by a safe and simple regimen that 
will produce a beneficial clinical effect. The homocysteine-lowering effect of 
vitamin B6, folic acid or betaine has been observed in small groups of patients 
suffering from arteriosclerotic disease1225. However, normalization of elevated 
homocysteine concentrations after methionine loading in large groups of 
hyperhomocysteinemic arteriosclerotic patients treated with high-dose 
administration of one or more of these compounds has not been reported. The 
present study not only included a large number of hyperhomocysteinemic patients, 
all suffering from premature peripheral or cerebral occlusive arterial disease, but, 
more importantly, also considered the homocysteine-normalizing effect of high-
dose administration of vitamin B6, folic acid, and betaine. 
At the time of these studies the determination of the free homocysteine 
concentrations was routinely performed, which left the fasting levels 
unmanageably low. Therefore, only peak levels of homocysteine after methionine 
loading could be included. The introduction of the technique to measure total 
homocysteine, i.e. free plus protein bound, in our laboratory in 1991, after 
completion of this study, allowed a more sensitive determination of homocysteine 
blood levels in the fasting state. However, future studies will have to prove the 
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adequacy of sensitively and specificity of fasting total homocysteine levels for the 
establishment of a mildly hyperhomocysteinemic state in the individual vascular 
patient. 
Materials and methods 
Study population 
During the period January 1980 through December 1990, 421 patients under 
55 years of age with documented premature peripheral or cerebral occlusive arterial 
disease were screened for mild hyperhomocystememia by means of an oral 
methionine loading test. The diagnosis cerebral infarction was documented by 
cerebral computerized tomography scanning in all these patients. Patients with 
known risk factors such as diabetes (fasting plasma levels more than 7.3 mmol/L), 
hyperlipoproteinemia (fasting serum levels of cholesterol more than 6.5 mmol/L and 
triglycerides more than 2.00 mmol/L), and hypertension (systolic and diastolic 
blood pressure more than 150 mmHg and 95 mmHg, respectively) of non-
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Figure 8.1 The metabolism of methionine. The transsulfuration of homocysteine 
into cystathionine (1,2) and remethylation of homocysteine into methionine (3, 4, 
5) 
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renovascular origin were excluded from the study. In all patients the blood levels 
of vitamin B6 (normal range 2 8 - 1 0 7 nmol/L),Bi2 И 60 -750 pmol/L), folic acid (5.5 
- 40.0 nmol/L), creatinine, the liver enzymes (aspartate amino-transaminase and 
alanine amino-transaminase) were within the normal ranges. 
Of the included patients, 131 (58 men and 73 women) had peripheral 
occlusive arterial disease, that had led to intermittent claudication or renovascular 
hypertension, and 290 (145 men and 145 women) had cerebral occlusive arterial 
disease, with a variety of persistent or transient neurologic signs (such as 
hemiplegia and aphasia). All patients originated from different kindreds. 
The effect of homocysteine-lowering treatment could be evaluated 
retrospectively in 82 hyperhomocysteinemic patients, i.e. 21 men, 53 
premenopausal, and 8 postmenopausal women with a mean age ± 1SD 
respectively 42 ± 8 years (range 16 - 55), 39 ± 6 years (range 24 - 50), and 50 
± 3 years (range 46 - 55). 
In 63 controls a methionine loading test was performed to establish the 
normal range of post-load homocysteine levels. All control subjects were without 
vascular complications or any medication, and in all control subjects the vitamin 
B6, B1 2 and folic acid concentrations were within the normal ranges. The control 
men (n = 20), premenopausal (n = 33) and postmenopausal (n = 10) women had a 
mean age ± 1SD of respectively 42 ± 11 years (range 22 - 55), 32 ± 10 years 
(range 16 -54), and 53 ± 3 years (range 45 - 55). Postmenopausality was 
questionairy been established by questionaaire (no menses for more than one year) 
and clinically ascertained by oestrogen level. 
Methionine loading test and mild hyperhomocysteinemia 
The methionine loading test was performed after an overnight fast. L-
Methionine at a dose of 0.1g/kg body weight was administered orally in orange 
juice. During the next 8 hours the patient received a meal containing 14 mg of 
methionine. Four, six and eight hours after methionine loading blood samples were 
drawn. The blood samples were immediately centrifuged, the serum was 
deproteinized and stored at -20 °C until analysis. Free homocysteine concentrations 
were determined in all blood samples as homocystine and homocysteine-cysteine 
mixed disulphide concentrations by ion-exchange chromatography (Biotronik LC 
2000 amino acid analyzer)6 , 2 6 , 2 7. Patients were considered to be 
hyperhomocysteinemic if their homocysteine peak level after methionine loading 
exceeded the mean peak level plus 2 standard deviations (SD) in the group of 
control subjects. Because of observed differences in mean homocysteine peak 
levels after methionine loading between control men, pre-, and postmenopausal 
women, the studied patients were categorized accordingly6 , 2 6 , 2 7. The peak in post-
load homocysteine levels occurred in 8 7 % of all performed tests at 6 hours, in 6 % 
at 4 hours and in 7 % at 8 hours after loading. 
Protocol of homocysteine-lowering treatment 
Patients identified as hyperhomocysteinemic received orally vitamin B6 
(pyridoxine hydrochloride), 250 mg daily. Six weeks later, with treatment 
continuing, a second methionine loading test was performed to assess the 
homocysteine-lowering effect. Because the aim of treatment was to normalize the 
elevated homocysteine level, we defined the reduction R by the formula: 
84 
Chapter 8 
where L1 ¡s homocysteine peak level after methionine loading before treatment, L2 
is homocysteine peak level after methionine loading while on treatment, Lc is mean 
homocysteine peak level after methionine loading plus 2SD in control subjects. 
We defined a reduction of L2 to Lc (or to a lower value) as 'normalization', 
a reduction of less than 60% as a 'poor or nonresponse' and a reduction of 
between 60% and 99% as an 'intermediate response'. This classification of the 
patient's response determined the mode of further treatment. In 
hyperhomocysteinemic patients in whom vitamin Be therapy failed to achieve 
normalization of the homocysteine peak level after methionine loading, the 
treatment was changed. In case of an intermediate response, vitamin Be therapy 
was continued, reinforced with folic acid, 5 mg daily, and in case of a poor or 
nonresponse vitamin B6 was substituted by folic acid, 5 mg daily. If normalization 
of the hyperhomocysteinemia was shown by the methionine loading test performed 
6 weeks after beginning the folic acid, no further change of treatment fol lowed. 
In cases in which hyperhomocysteinemia persisted (intermediate or poor or 
nonresponse), betaine anhydrous (Sigma 2629), 6 g daily, was prescribed whereas 
folic acid was continued only if it achieved a 60% or greater reduction. The effect 
of betaine was also determined by a repeated methionine loading test 6 weeks 
after its start. In this regimen it was thus possible for the hyperhomocysteinemic 
patients to have a monotherapy of either vitamin B6, folic acid or betaine, some 
combination of two of these, or even with the triple combination. 
Statistics 
The prevalence of mild hyperhomocysteinemia in the specified categories of 
patients and the respective effects of treatment were analyzed by a chi-square 
independence test. A probability value of 0.05 or less was considered statistically 
significant. 
Results 
Prevalence 
Mild hyperhomocysteinemia was detected in 100 out of 421 vascular patients 
(24%), i.e. 29 out of 203 men (14%), 62 out of 183 premenopausal (34%) and 
9 out of 35 postmenopausal women (26%) (Figure 8.2). The prevalence of mild 
hyperhomocysteinemia in premenopausal female patients was significantly higher 
than that in male patients (p< 0.0001), both in the peripheral subgroup (p< 
0.002) and in the cerebral occlusive arterial disease subgroup (p< 0.002). The 
prevalence of mild hyperhomocysteinemia in all patients with peripheral occlusive 
arterial disease (33%) was significantly higher than that in patients with cerebral 
occlusive arterial disease (20%) (p< 0.03). 
Effect of homocysteine-lowering treatment 
After vitamin B6 treatment for 6 weeks, in which the blood vitamin B6 
concentration in all 82 treated patients increased at least five fold compared to the 
pretreatment concentration, the homocysteine peak level after methionine loading 
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had normalized in 46 patients (56%), an intermediate response was found in 16 
patients (20%), and in 20 patients (24%) the response was poor or absent (Figures 
8.3 and 8.4). No significant difference in terms of normalization was detected 
between the subgroups of patients with peripheral and cerebral occlusive arterial 
disease (58% and 5 5 % , respectively; p > 0.8). Vitamin Be treatment normalized 
the hyperhomocysteinemia in men significantly more frequently than in 
premenopausal women ( 7 1 % versus 4 5 % ; p < 0.05). In terms of absolute 
reduction, the mean peak homocysteine concentration decreased after treatment 
from 30.5 ± 8.5//mol/Lto 17.7 ± 7.0//mol/L (mean ± 1 SD) in male, from 28.5 
± 14.2/miol/L 
I r · · hofnocytl«ln«~conc«ntrallon (umol/l)
 e o 
Ν - ζω 
ola 
л 
Figure 8.2. Individual free homocysteine levels after methionine loading (//mol/L) 
in 421 vascular male, premenopausal and postmenopausal female patients; the 
mean ± 2SD in control subjects and the range of obligate heterozygotes for 
cystathionine synthase deficient homocystinuria are indicated. 
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to 17.0 ± 7.2 //mol/L in premenopausal, and from 43.7 ± 5.5//mol/L to 31.1 ± 
22.7/vmol/L in postmenopausal patients. 
Nine patients presenting an intermediate response and thirteen patients 
presenting a poor or nonresponse entered further the therapy as described in the 
section "Methods" (4 men, 17 premenopausal and 1 postmenopausal woman). All 
these patients yet normalized except one, who after continued treatment wi th 
vitamin B6 and folic acid persisted in an intermediate response. 
In conclusion, treatment of mild hyperhomocysteinemic patients suffering 
from peripheral or cerebral occlusive arterial disease resulted in 8 2 % of treated 
patients in normalization of the homocysteine levels. Statistical analysis showed 
that if all patients in whom homocysteine levels after six weeks of vitamin B6 
treatment had not normalized and had received further treatment, normalization of 
the elevated homocysteine levels would have occurred in 98% of the patients. 
free homocysteine-concentration (umol/l) 
80 + \ 
0 — 
premenopausal 
women 
postmenopausal 
women 
Figure 8.3. Response of the free homocysteine levels after methionine loading with 
6 weeks of vitamin B6 treatment, 250 mg daily, in 82 hyperhomocysteinemic 
vascular patients. 
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Discussion 
The emphasis on hyperhomocystememia as a risk factor for premature 
arteriosclerosis and thromboembolism is based upon observations in patients 
suffering from classic homocystmuria1 3. From a collaborative study on more than 
600 homozygotes for homocystmuria Mudd et al.4 concluded that there was a 
chance of 50% for untreated patients to have a vascular accident before the age 
of 30 years. Homocysteine, a sulfhydryl amino acid formed by demethylation of 
methionine, is generally considered to be an atherogenic and thrombotic agent, 
although the pathogenic mechanism has not been clarified128 34. 
Mild hyperhomocystememia, with levels comparable to those in heterozygotes 
for homocystmuria, was detected by us previously in 28% of patients with 
premature peripheral or cerebral occlusive arterial disease without known risk 
factors such as diabetes, hyperlipoproteinemia, or non-renovascular hypertension6 
However, the number of patients, 25 in each group, was rather small. Since then, 
screening by a standardized methionine loading test of 421 such patients disclosed 
mild hyperhomocystememia in 33% of those with peripheral and in 20% of those 
with cerebral occlusive arterial disease. This is well in line both with our own earlier 
finding and with subsequent f indings6213S Clarke et al.17 using a methionine 
Normalization 
56% 
Poor or non 
response 
24% 
intermediate 
response 
20% 
pyridoxine response in 82 patients 
Figure 8 4 Individual free homocysteine levels after methionine loading before and 
after 6 weeks of vitamin B6 treatment, 250 mg daily (n = 82). 
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loading test similar to ours, found mild hyperhomocysteinemia in up to 2 8 % of 21 
patients with peripheral and up to 4 2 % of 38 patients with cerebral occlusive 
arterial disease. Patients with classic risk factors were not excluded in that study, 
but statistical analysis showed that mild hyperhomocysteinemia was an 
independent risk factor in addition to hypercholesterolemia, hypertension and 
smoking. 
Remarkably, mild hyperhomocysteinemia was found to be significantly more 
prevalent among premenopausal female compared with male vascular patients. This 
finding confirms our earlier observation6, and was reconfirmed by Brattstrom et 
al. 1 2 after screening in 72 patients. We do not have a well-founded explanation for 
this sex difference in prevalence of mild hyperhomocysteinemia. We have 
speculated that lower levels of serum free homocysteine in premenopausal women 
compared with those in men may be a sign of more efficacious methionine 
handling, pointing to a defense mechanism that protects women during their 
reproductive years against vascular disease27. Failing such protection, as in case 
of mild hyperhomocysteinemia, young women seem more susceptible developing 
vascular disease than men The hormonal background also may act also 
protectively with respect to young women's conventional risk factors. To develop 
arteriosclerotic events they simply may need some extra and unconventional 
interference like hyperhomocysteinemia. 
Now that mild hyperhomocysteinemia is generally recognized as one of the 
risk factors for the development of vascular disease, research into homocysteine-
lowenng treatment is needed. Homozygotes for homocystinuna, in whom serum 
free homocysteine levels in the fasting state may range as high as 200 to 300 
μπηοΙ/L, respond in about 5 0 % of cases to vitamin Be treatment in very high doses 
(up to 1 g daily)4. Although such treatment has been found to normalize the 
elevated homocysteine levels in the fasting state, it does not enhance the patient's 
capacity to efficiently handle a major methionine load2 Treatment with folic acid, 
betaine or dietary methionine restriction results in a reduction of homocysteine 
levels in the majority of the patients who respond poorly or not at all to vitamin B6 
t reatment 3 3 6 A significantly reduced number of initial vascular events following 
reduction of pathologically high homocysteine levels has been shown 
retrospectively in a large group of homozygotes for homocystinuna4. 
Present study retrospectively reviewed normalization of mildly elevated 
homocysteine levels after methionine intake in a large group of vascular patients 
with vitamin B6, folic acid and betaine treatment. Brattstrom et al
 1 2
 report a 2 6 % 
reduction of mildly elevated homocysteine levels after methionine loading in 20 
vascular patients after two weeks of vitamin Be treatment, 240 mg daily. After t w o 
more weeks of treatment with vitamin B6, 240 mg daily, plus folic acid, 10 mg 
daily, a total reduction of elevated homocysteine levels of 3 9 % was achieved. 
However, normalization of methionine handling by such treatment was not 
mentioned. In the present study, vitamin B6 was treatment of first choice, and 
normalization of the homocysteine peak level after methionine loading was 
achieved in 5 6 % of the patients. Normalization was observed considerably less 
frequently in premenopausal patients than in male and postmenopausal patients, 
4 5 , % 7 1 % and 8 8 % , respectively. From this observation one might hypothesize 
that a different mechanism for hyperhomocysteinemia is responsible in young 
females Vitamin B6, folic acid and betaine solely or in any combination led in 
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virtually all treated patients to normalization of their overresponse by homocysteine 
to methionine loading. In view of these findings we have recently treated 21 newly 
detected hyperhomocysteinemic patients with vitamin B6, 250 mg daily, combined 
with folic acid, 5 mg daily, and have found all of them to present normal responses 
to methionine loading within 6 weeks (data not shown). 
In 18 patients from the present study in whom normalization of the 
homocysteine levels had been achieved with vitamin B6, folic acid or betaine solely 
or in any combination, a methionine loading test performed after one year of 
continued treatment showed persistence of the normalized homocysteine levels 
(data not shown). 
Enzyme activity determinations were not been performed on a routine base 
in the studied patients with mild hyperhomocysteinemia. In about half of them the 
vitamin B6 treatment corrected the homocysteine peak level, which suggests that 
these patients are heterozygotes for CS deficiency. The remaining patients in 
whom homocysteine handling was not normalized by vitamin B6 might be affected 
by either a vitamin B6-nonresponding CS mutant in heterozygous form or by a 
defect in homocysteine remethylation. The latter may be the thermolabile form of 
5,10-methylenetetrahydrofolate reductase (Figure 8.1), reported by Kang et al.5. 
This defect occurred in 17% of patients with coronary artery disease, although it 
did not automatically lead to mild hyperhomocysteinemia in the fasting state in the 
patients. 
Vitamin B6 at doses from 200 mg up to 6 g has sporadically been considered 
as a cause of sensory neuropathy37,38. Remarkably, these side effects were not 
observed in patients with homocystinuria who received long-term treatment (up to 
24 years) with doses up to 750 mg3,39. Folic acid and betaine at the dosages 
prescribed by us being 5 mg and 6 g daily, respectively, are not reported to 
produce side effects36'40'41. 
The present study proved that normalization of mild hyperhomocysteinemia 
is attainable in virtually all patients by safe and simple treatment with vitamin B6, 
folic acid and betaine. Further dose-response studies will disclose the lowest 
required dosage of these substances. 
A decreased number of vascular events in arteriosclerotic patients with mild 
hyperhomocysteinemia due to homocysteine-lowering treatment has not been 
demonstrated so far. We are presently conducting a placebo-controlled intervention 
study that may provide a clinical justification for screening in prematurely 
arteriosclerotic patients. 
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Abstract 
Hyperhomocysteinemia is associated with arteriosclerotic and thromboembolic 
events. The homocysteine-lowering effect of combined treatment with vitamin B6 
plus folic acid has never been explored in a large group of vascular patients. 
Therefore, we studied the effects of at least 6 weeks treatment with these 
vitamins in 72 patients with cardiovasculardisease and mild hyperhomocysteinemia 
(defined as an increase of the plasma homocysteine level after methionine loading 
>97 .5 percentile of age-matched controls but < 200//mol/L). 
The existence of mild hyperhomocysteinemia was investigated in 309 
consecutive patients under 50 years of age suffering from peripheral arterial 
occlusive disease, cerebral arterial occlusive disease, or coronary artery occlusive 
disease. All patients with an abnormal loading test were treated with vitamin B6, 
250 mg daily, plus folic acid, 5 mg daily. After 6 weeks of treatment a second 
methionine loading test was performed to assess the homocysteine-lowering 
effect. 
Mild hyperhomocysteinemia was detected in 72 patients (23%), 33 (46%) 
of whom also had hyperhomocysteinemia when fasting. Treatment with vitamin 
B6 plus folic acid normalized the post-load plasma homocysteine concentration in 
66 of the 72 patients (92%), whereas fasting hyperhomocysteinemia was 
normalized in 30 of 33 (91%) patients. In 6 patients therapy failed to achieve 
normalization of the post-load homocysteine levels. In 3 of these patients, the 
same treatment was continued for a further 6 weeks and in the remaining 3 
patients betaine was added to the treatment regimen. After 6 weeks of additional 
treatment all these 6 patients had normal post-load plasma homocysteine 
concentrations. 
The prevalence of mild hyperhomocysteinemia in young patients with arterial 
occlusive disease is high. Simple and inexpensive therapy with vitamin B6 plus folic 
acid will normalize homocysteine metabolism, as assessed by the homocysteine 
plasma level after methionine loading, in virtually all these patients. 
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Introduction 
Homocystinuria in its classic form is an autosomally inherited disease 
characterized by very high plasma levels (>200/ymol/L) of the thiol-containing 
amino acid homocysteine. Patients may have ectopia lentis, skeletal abnormalities, 
mental retardation, Marfanoid features, thrombosis and premature arteriosclerosis1. 
These patients with severe hyperhomocysteinemia can be successfully treated by 
administration of high doses of vitamin B6, which lowers plasma concentrations of 
homocysteine by stimulating the residual cystathionine synthase (CS) activity, 
which converts homocysteine to cystathionine (Figure 9.1)1,2. In case of a poor 
response to vitamin Be therapy, addition of folic acid or betaine may result in a 
dramatic decrease of the homocysteine levels because of enhanced remethylation 
of homocysteine to methionine3,4. Therapy with these cofactors or cosubstrates of 
homocysteine metabolism reduces the risk of cardiovascular events in patients with 
classic homocystinuria4. 
Recent studies indicate a relationship between mild hyperhomocysteinemia 
(mHH) and arterial occlusive disease5'8. The impairment of homocysteine 
metabolism in cases of mHH may be caused by deficient activity of cystathionine 
synthase (CS), methylenetetrahydrofolate reductase (MTHFR) or other still 
unknown enzyme deficiencies (Figure 9.1),7·9,10 or by environmental factors such 
as deficiencies of the vitamins B6, B12 and folic acid5,6. In patients under 50 years 
of age diagnosed with peripheral arterial occlusive disease, cerebral arterial 
occlusive disease or coronary artery occlusive disease, an excessive homocysteine 
concentration after oral methionine loading has been observed with a prevalence 
varying from 8% to 42%5 '7,e·11. As in classic, severe homocystinuria, treatment 
with cofactors or cosubstrates of homocysteine metabolism may lower the plasma 
homocysteine concentration in patients with arteriosclerosis and mHH7,12. In a 
group of 20 vascular patients with mHH Brattström et al.12 reported a mean 
reduction of the post-load homocysteine concentration after treatment with vitamin 
B6 of 26%, whereas the mean fasting level was unchanged. When vitamin Be was 
combined with folic acid, the mean reduction was 39% for post-load levels and 
53% for fasting levels12. However, the relatively small number of patients studied 
by Brattström et al.12 precluded a precise assessment of the efficacy of treatment 
with vitamin B6 plus folic acid, both in terms of the reduction of plasma 
homocysteine levels after methionine loading and in terms of the percentage of 
patients in whom the methionine loading test result normalized. 
We, therefore, investigated the prevalence of mHH (as defined by 
homocysteine levels after methionine loading) in 309 consecutive patients younger 
than 50 years of age with symptomatic arterial occlusive disease. Seventy-two 
patients had pathological tests (23%). In these patients, we studied the effects of 
treatment with vitamin B6 plus folic acid on both fasting and post-load 
homocysteine concentrations. 
Patients and methods 
Patients 
From March 1991, until February 1993, we studied 309 patients with 
symptomatic vascular disease (198 men and 111 women under 50 years of age) 
consecutively admitted to a large secondary referral center. All these patients had 
symptomatic peripheral arterial occlusive disease, cerebral arterial occlusive 
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Figure 9 . 1 . Methionine/homocysteine metabolism. CS (cystathionine synthase), 
MTHFR (5,10-methylenetetrahydrofolate reductase), MS (methionine synthase), 
THF (tetrahydrofolate). 
disease, or coronary artery occlusive disease. Peripheral arterial occlusive disease 
was defined by the presence of intermittent claudication confirmed by ankle/arm 
indexes < 0.9 or a decrease of > 0.15 of the index on treadmill testing, or ischemic 
rest pain, gangrenous ulcers, or amputation for ischemia. Cerebral arterial occlusive 
disease was defined by the presence of symptomatic cerebral vascular disease 
(ischemic stroke or transient ischemic attack, World Health Organization [WHO] 
clinical definitions) and, in the case of stroke, was confirmed by computed 
tomography. Coronary artery occlusive disease was defined as the presence of 
myocardial infarction (WHO clinical definition plus new Q waves on 
electrocardiography or diagnostic enzyme changes). This restrictive definition of 
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coronary artery disease was used because we wanted to avoid the possibility of 
misclassification in view of the somewhat uncertain relation between 
hyperhomocysteinemia and coronary artery disease5'8. All these patients had 
normal levels of vitamin B6 ( > 1 7 nmol/L; fluorescence high performance liquid 
chromatography = HPLC), vitamin B12 ( > 1 2 0 pmol/L; radioassay, Becton 
Dickinson, Erembodegem-Aalst, Belgium) and folic acid ( > 3.4 nmol/L; radioassay, 
Becton Dickinson) and no signs of renal failure (serum creatinine < 120//mol/L) or 
liver dysfunct ion (serum aspartate aminotransaminase and alanine 
aminotransaminase < 3 0 U/L and absence of physical signs). Of these patients, 
143 (46%) had peripheral disease, 86 (28%) had cerebral disease and 80 (26%) 
had a myocardial infarction. We recorded risk factors for occlusive arterial disease 
(diabetes mellitus [WHO criteria], hyperlipoproteinemia [total cholesterol > 6 . 2 
mmol/L or triglycerides > 2 mmol/L], current smoking habits and hypertension 
[diastolic blood pressure > 9 0 mmHg or systolic blood pressure > 1 4 0 mmHg 
(measured after 15 minutes of rest in the supine position without altering 
antihypertensive regimens) or taking antihypertensive drugs]). 
Methods 
After an overnight fast, blood was drawn for measurement of serum total 
cholesterol and triglycerides (measured enzymatically), creatinine (modified Jaffé 
reaction), and glucose (glucose oxidase method). For technical reasons we did not 
measure high-density lipoprotein cholesterol. The presence of mHH was studied by 
an oral methionine loading test. An ethylenediamine tetraacetic acid (EDTA) plasma 
sample for determination of the fasting homocysteine concentration was drawn at 
8 AM. After it was centrifuged for 10 minutes at 1800 G, plasma was stored at -
30 °C until analysis. Next, an oral dose of L-methionine (0.1 gram/kg body weight) 
was administered in orange juice. During the test the patients ate a standardized 
methionine-poor breakfast and lunch (containing 14 mg methionine/gram protein). 
Six hours after the methionine load a second EDTA-plasma sample was drawn for 
determination of the post-load homocysteine concentration. All measurements 
were performed within one week. 
Total (free plus protein bound) homocysteine concentrations (disulphide 
homocysteine plus mixed disulphides) were measured by use of tri-n-
butylphosphine as the reducing agent and ammonium 7-fluorobenzo-2-oxa-1,3-
diazole-4-sulfonate as the fluorochromophore, followed by HPLC with fluorescence 
detection13. Intraassay and interassay coefficient of variation for total 
homocysteine were 2 . 1 % and 5 . 1 % , respectively. 
Patients were considered to have mHH if homocysteine concentrations 
measured 6 hours after methionine loading exceeded the 97.5 percentile in healthy 
volunteers and were lower than (arbitrarily) 200//mol/L. Healthy volunteers (mean 
age (SD) for men and women, 36.9 (5.7) and 42.3 (9.5), respectively) were 
recruited from the hospital staff and had vitamin B6, B12, and folic acid 
concentrations within the normal ranges. In healthy men (n = 23), the mean post-
load homocysteine concentration (2.5-97.5 percentile) was 37 (25-54) //mol/L, in 
healthy premenopausal women (n=41) it was 31 (18-51) //mol/L, and in healthy 
postmenopausal women (n = 27) it was 43 (25-69) /ymol/L. Mean fasting 
homocysteine levels in these control groups were 12 (8-18), 10(6-15), and 11 (6-
19) //mol/L, respectively. 
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Therapy 
Patients with mHH were treated with vitamin Be (pyridoxine), 250 mg daily, 
in combination with folic acid, 5 mg daily. After 6 weeks of treatment, a second 
methionine loading test was performed to assess the homocysteine-lowering 
effect. In those patients in whom normalization of the post-load homocysteine 
concentration was not achieved, a third methionine loading test was performed 
after another 6 weeks of further treatment. 
Data are given as mean (95%-confidence interval [CI]), or as mean (SD), 
unless otherwise indicated. Significance was tested by the two-tailed Student t-
test and the Chi-square independence test. Correlations were studied with 
Pearson's or Spearman's tests, as appropriate. The ρ values < 0 . 0 5 were 
considered significant. 
Results 
We observed a normal post-load homocysteine level in 237 of the 309 
patients with arteriosclerotic arterial occlusive disease (77%), whereas fasting 
levels were normal in 266 patients (86%). In patients with normal post-load levels 
(n = 237), the mean homocysteine concentrations were 35.5 (8.3), 33.9 (11.1) and 
39 (9.5) μιηοΙ/L for men, premenopausal women and postmenopausal women, 
respectively. In patients with normal fasting levels (n = 266), the mean fasting 
homocysteine levels were 10.8 (2.9), 9.3 (2.7), and 10.1 (3.0) //mol/L " 
Prevalence 
Mild post-load hyperhomocysteinemia was present in 72 of the 309 patients 
(23%; 95%-confidence interval [CI], 19-28), i.e., 36 of 143 patients with 
peripheral disease (25%; CI 18-32), 24 of 86 patients with cerebral disease ( 2 8 % ; 
CI 19-39) and 12 of 80 patients with coronary disease (15%; CI 8-25). The 
prevalence of other risk factors (hyperlipoproteinemia, smoking habits, diabetes 
mellitus and hypertension) was similar in the patients with and without mHH (Table 
9.1). However, in patients with hyperhomocysteinemia, the percentage of men 
was significantly lower than in patients without hyperhomocysteinemia (43% 
versus 6 4 % , p < 0.05). Fasting hyperhomocysteinemia was observed in 33 of the 
72 patients with post-load hyperhomocysteinemia (46%). Of these 33 patients, 17 
patients had peripheral vascular disease, 10 patients had cerebral artery disease, 
and 6 patients had coronary artery disease, a distribution that was not significantly 
different from the distribution observed in the 72 patients with post-load 
hyperhomocysteinemia. Patients with (n = 33) and without (n = 39) fasting 
hyperhomocysteinemia were not significantly different with regard to the 
prevalence of other risk factors (hyperlipoproteinemia, 3 0 % versus 2 8 % ; 
hypertension, 2 4 % vs 2 1 % ; smokers, 7 5 % vs 8 2 % ; diabetes, 3% vs 3%). The 
sex ratio was also similar (47% vs 3 6 % men). 
Effects of therapy. 
Treatment with vitamin B6 plus folic acid had no effect on the fasting glucose, 
cholesterol, triglyceride and creatinine levels (Table 9.2). After 6 weeks of 
treatment, the mean blood concentrations of both vitamin B6 and folic acid had 
increased at least fivefold compared to the pretreatment concentration. After 6 
weeks of treatment 66 of the 72 patients (92%; CI 83-97) showed normal plasma 
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Table 9 1. Prevalence of risk factor in patients with and without 
hyperhomocysteinemia. 
Hyperhomocysteinemia 
Risk factor 
Mean age(yr) 
Male sex (%) 
Hyperlipoproteinemia (%) 
Smoking (%) 
Diabetes (%) 
Hypertension (%) 
NS = Not significant; *Chi-square analysis; " I n the total group the ratio 
male:female was 198:111. Numbers in parenthese indicate 9 5 % CI. 
Table 9.2. Effect on serum levels of glucose, cholesterol, triglycerides, and 
creatinine of 6 weeks of treatment with vitamin Be plus folic acid in patients with 
mild hyperhomocysteinemia. 
present 
43.8(3.2) 
42 (30-54) 
30 (19-41) 
79 (68-88) 
3 (0-10) 
23 (13-34) 
absent 
44.6(2.1) 
64 (58-70) 
24 (19-30) 
83 (78-88) 
4 (2-7) 
19 (14-24) 
Ρ Value* 
NS 
< 0.05 ' 
NS 
NS 
NS 
NS 
Value" 
Before treatment After treatment 
(n = 72) (n = 72) 
Glucose 5.0(0.4) 5.0(1.2) NS 
Cholesterol 6.0(1.1) 6.1(1.1) NS 
Triglycerides 1.8(0.9) 1.8(1.4) NS 
Creatinine 8 3 ( 1 4 ) 8 4 ( 1 5 ) NS 
NS = Not significant ( p > 0.05); 'Student t-test; Values expressed as mean (SD). 
homocysteine concentrations after methionine loading, whereas fasting 
homocysteine levels normalized in 30 of the 33 patients ( 9 1 % ; CI 76-98). In 6 
patients (1 man, 5 premenopausal women) the post-load homocysteine 
concentration had not normalized after 6 weeks of therapy. Three patients (1 man, 
2 premenopausal women) continued their therapy for an additional 6 weeks, which 
resulted in a normalization of the post-load plasma homocysteine concentration. 
In the 3 remaining patients (3 premenopausal women) betaine anhydrous (Sigma 
2629; Sigma Chemical Co., St. Louis, Mo), 6 g daily, was added to the treatment 
regimen for 6 weeks. In these 3 patients the post-load homocysteine levels also 
normalized. 
Treatment resulted in a mean reduction of the post-load plasma homocysteine 
concentration of 4 8 % (CI 35-57) in all patients after 6 to 12 weeks. The mean 
reduction of the fasting homocysteine concentration was 5 1 % (CI 32-64) after 6 
weeks. The mean decrease in the post-load homocysteine concentration after 6 to 
12 weeks of therapy was similar in men (46%; CI 25-86), premenopausal women 
(48%, CI 35-58) and postmenopausal women (55%; CI 39-74; Table 9 3, Figure 
9.2). The mean decrease in fasting homocysteine concentrations was 5 6 % (CI 40-
69) in men, 4 6 % (CI 31-59) in premenopausal women, and 5 1 % (CI 1-94) in 
postmenopausal women, respectively. The responses to therapy were not 
significantly different among the groups of men and premenopausal or 
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rectangles indicate normal ranges (2.5 to 97.5 percentile). 
Table 9.3. Mean post-load homocysteine concentrations in 72 patients with 
hyperhomocysteinemia before and after treatment with vitamin B6 plus folic acid. 
Group Number of 
patients 
All patients 72 
Men 29 
Premenopausal women 35 
Postmenopausal women 8 
Before treatment After treatment? 
fasting post-load tasting post-load 
19 (13) 71 (21) 9 (3) 37 (12)§ 
23 (15) 69 (21) 10(3) 37 (10)§ 
15 (4) 64(15) 8 (4) 33 (12)§ 
20 (12) 109 (14) 10 (2) 49 (15)t 
In all groups, there were significant differences between fasting homocysteine 
concentrations (before versus after treatment) and between post-load 
concentrations (before versus after). S = p < 0 . 0 0 1 , and t = p < 0.02 (Student's 
t-test). Values expressed as mean (SD) /лтіоІ/L 
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postmenopausal women, or between the fasting and post-load levels Similarly, the 
response to treatment did not differ significantly according to the location of 
vascular disease. Thus, the mean decreases in fasting and post-load homocysteine 
concentrations were 5 3 % (CI 23-84) and 4 6 % (CI 30-62) in patients with 
peripheral occlusive disease, 48%(CI 17-78) and 4 9 % (CI 30-65) in patients with 
cerebral occlusive disease, and 4 9 % (CI 11-86) and 5 2 % (CI 33-69) in patients 
with myocardial infarction, respectively. Fasting homocysteine levels, either before 
or after treatment, were not related to serum creatinine (r = 0.19, ρ = 0.21 and r = -
0 0 0 1 , ρ = 0 . 9 , respectively). Post-load homocysteine levels were related to serum 
creatinine before (r = 0.36, p = 0.02) but not after treatment (r = -0 04, p = 0.6) 
Discussion 
Pathogenesis 
Increased levels of plasma homocysteine are generally accepted as one of 
the causes leading to arteriosclerosis and thromboembolism1. In vitro, 
homocysteine induces endothelial cell injury and affects endothelial cell function 1 4 
16
 Homocysteine is belived to damage endothelial cells by several mechanisms, 
such as generation of hydrogen peroxide and depletion of nitric oxide-mediated 
detoxification of homocysteine 1 7 1 8 . In patients with classic homocystmuria, the 
high homocysteine concentrations are most commonly caused by a deficiency of 
CS act iv i ty 1 2 In contrast, mHH may have both environmental and genetic causes. 
First, elevated homocysteine levels have been observed in patients with kidney 
failure (through unknown mechanisms) and in patients with deficiencies of 
cofactors or cosubstrates of methionine metabolism (folic acid, vitamin B1 2, or 
vitamin B6 [Figure 9 1]) s. Second, mildly elevated homocysteine levels may be 
genetically determined5, although the primary defect in such patients has not been 
elucidated Apart from CS deficiency, a decreased activity of 5,10-methylenete-
trahydrofolate reductase or other unknown enzyme deficiencies have been 
suggested 7 1 0 
Clinical expression 
Fifty percent of untreated patients with classic homocystmuria will have a 
cardiovascular event before the age of 30 4 . Taylor et al. 1 9 reported that patients 
with vascular disease with elevated plasma homocysteine levels in the fasting state 
were more likely to have clinical progression of lower extremity and coronary 
disease, but not of cerebral vascular disease. In addition, the rate of progression 
was more rapid in these patients than in patients with normal fasting homocysteine 
levels. Stampfer et al. 2 0 reported, in healthy men, an 18 2% increase in relative risk 
of myocardial infarction for each 1SD increase in fasting homocysteine 
concentration. Other studies, however, suggest that the homocysteine level after 
methionine loading, as compared to the fasting level, discriminates more efficiently 
between patients with or without vascular disease7 B. The relative predictive value 
of fasting versus post-load concentrations can only be determined in a prospective, 
direct comparison, but such data are not available. 
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Prevalence 
We observed mHH after methionine loading in 25% of patients with 
peripheral occlusive arterial disease and in 28% of patients with cerebral occlusive 
disease. In concordance with previous reports we observed a lower prevalence of 
hyperhomocysteinemia (15%) in the subgroup of patients with a myocardial 
infarction6,21. In the two groups with and without mHH, the distribution of other 
potential risk factors such as hyperlipoproteinemia, smoking habits, diabetes 
mellitus and hypertension was not significantly different. There were relatively 
more women than men among the patients with mHH, however. Possibly the 
endothelial cells of women are more vulnerable to high homocysteine levels7. 
Although hyperhomocysteinemia is believed to be an independent risk factor8·22, 
the interaction of hyperhomocysteinemia with other risk factors needs further 
investigation. 
Therapy 
Homocysteine can be either catabolized to cysteine in the transsulfuration 
pathway by the cystathionine synthase enzyme, with the use of vitamin Be as an 
essential cofactor, or be remethylated to methionine, a reaction that requires folate 
and vitamin B12, as cosubstrate and cofactor, respectively (Figure 9.1). In addition, 
homocysteine can be remethylated through the demethylation of betaine (Figure 
9.1). In vascular patients with mHH Brattström et a l . '2 observed a mean reduction 
of 39% in plasma total homocysteine concentrations after a methionine load within 
four weeks of treatment with vitamin Be plus folic acid, whereas fasting levels 
were reduced by 53%. We found similar reductions in post-load (49%; CI 35-57) 
and fasting (51 %; CI 32-64) homocysteine concentrations after 6 to 12 weeks of 
therapy. In addition, we observed normal post-load and fasting homocysteine levels 
in 92% and 91 % of the patients after 6 weeks of treatment with vitamin B6 plus 
folic acid. Six hyperhomocysteinemic patients showed no normalization of the post-
load homocysteine levels within 6 weeks. Three patients normalized their post-load 
homocysteine level after addition with betaine, but 3 other patients also normalized 
their post-load homocysteine concentrations without reinforcement with betaine. 
Therefore, the effect of vitamin therapy is probably not maximal after 6 weeks of 
treatment. 
Side effects such as progressive sensory ataxia have been described in 
patients receiving large doses (up to 6 g) of vitamin B6 daily23. However, no 
symptoms of neuropathy were found in patients with classic homocystinuria during 
long-term vitamin Be treatment24. No serious side effects of treatment with 5 mg 
folic acid or betaine 6 g daily have yet been reported25,26. 
Limitations 
Several limitations of our study should be considered. First, we did not 
analyze plasma vitamin concentrations (which were within the normal range) as 
determinants of homocysteine levels either before or after treatment. It is unlikely, 
however, that such an analysis would affect the main conclusion from this study -
that treatment with vitamin B6 plus folic acid effectively reduces homocysteine 
concentrations. Second, we did not perform dose-response studies, and the doses 
of vitamin B6 and folic acid, although effective and apparently safe, are not 
necessarily optimal. Third, we did not assess the efficacy of the proposed 
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treatment in terms of improvement of vascular prognosis. Therefore, long-term 
intervention studies are needed to investigate whether chronic treatment with 
vitamin B6 plus folic acid will reduce the progress of the arteriosclerotic process in 
vascular patients with mHH. 
Lowering of plasma homocysteine in patients with mHH appears to be 
simple and inexpensive. Our study shows normal responses to methionine loading 
after 12 weeks of treatment with vitamin Be plus folic acid in virtually all patients 
with mild hyperhomocysteinemia. Therefore, in patients with mHH normalization 
of homocysteine metabolism is possible within 12 weeks, and, in practice, there 
seems no need to investigate the effects of therapy before these 12 weeks. 
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THIAMINE (VITAMIN B,) SUPPLEMENTATION DOES 
NOT REDUCES FASTING BLOOD HOMOCYSTEINE 
CONCENTRATION IN MOST 
HOMOZYGOTES FOR HOMOCYSTINURIA 
Diana G. Franken, Henk J . Blom, Godfried H.J. Boers, Albert Tangerman, 
Chris M.G. Thomas, Frans J.M. Trijbels. 
Biochimica Biophysica Acta 1996; In Press. 
Abstract 
Homozygotes for homocystinuna due to cystathionine synthase (CS) 
deficiency accumulate homocysteine and methionine in their blood and tissues. 
High-dose pyridoxin, folic acid, vitamin B12, or betaine are therapeutical options to 
lower the elevated homocysteine concentration. These compounds stimulate the 
transsulphuration or remethylation of homocysteine. Despite such treatment, 
elevated blood homocysteine concentrations may persist in many homocystinuncs. 
Therefore, it is warranted to study alternative regimen to reduce the blood 
homocysteine concentration in homocystinuncs. Apart from entering the 
transsulphuration pathway, methionine can be catabolized via the transamination 
pathway, by conversion into 4-methylthio-2-oxobutyrate (MTOB), followed by 
oxydative decarboxylation of MTOB to 3-methylthiopropionate. Thiamine 
pyrophosphate, the active form of thiamine, is a cofactor of the supposed rate-
limitmg oxidative decarboxylation in the transamination of methionine. The effect 
of thiamine administered in 2 or 3 daily doses of 25 mg orally, was studied in nine 
homozygote CS deficient patients. Methionine levels decreased in 6 out of 9 
patients In 8 out of 9 patients, however, the levels of plasma homocysteine 
remained virtually unchanged, as did the serum transamination metabolites in all 
patients. We conclude that vitamin B, cannot be used as an additional homocystei-
ne-lowering treatment in most homozygotes for homocystinuna. 
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Introduction 
Patients with classic homocystinuria due to cystathionine synthase (CS) 
deficiency accumulate homocysteine and methionine in their blood and tissues. The 
disease is clinically characterized by arteriosclerosis, thromboembolism, eye-lens 
luxation, marfanoid features, osteoporosis, and mental retardation. Therapy is 
based on reduction of the hyperhomocysteinemia by stimulation of residual CS 
activity by high levels of the cofactor pyridoxal-5'-phosphate1. About 6 0 % of these 
patients respond to pyridoxine. In poor or non-pyridoxine responsive patients, 
treatment can be extended with folic acid, vitamin B12 or betaine supplementation, 
which enhances the homocysteine remethylation (Figure 10.1)1. As an ultimative 
option, dietary methionine restriction may be mandatory to reduce the blood 
homocysteine concentration. Despite this variety of therapeutical options, severely 
elevated homocysteine concentrations may persist in homozygotes for 
homocystinuria2 , 3. It is therefore warranted to study additional possibilities to 
reduce the blood homocysteine concentration in homocystinurics. 
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Figure 1 0 . 1 . Metabolism of methionine. 
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Apart from entering the transsulphuration pathway, methionine can also be 
degraded via the transamination pathway by conversion into 4-methylthio-2-
oxobutyrate (MTOB), followed by oxydative decarboxylation of MTOB to 3-
methylthiopropionate (Figure 10.1 )4. In the latter reaction thiamine pyrophosphate, 
the active form of thiamine, is a cofactor. 
We previously demonstrated in an in vitro study that thiamine pyrophosphate 
stimulates the degradation of methionine via the transamination pathway in rat liver 
homogenates5. The same result was obtained in human liver homogenates (Blom; 
unpublished results). In this study, the methionine and homocysteine-lowering 
effect of thiamine (vitamin B,) was tested in nine homozygote CS deficient 
patients. 
Materials and methods 
Homozygotes for homocystinuria due to CS deficiency 
The criteria for selection of homozygotes for homocystinuria to enter this 
study were: regulary visiting our hospital, known with good compliance to their 
homocysteine-lowering treatment, prolonged elevated fasting homocysteine levels 
in blood despite homocysteine-lowering treatment for at least 2 years, and at least 
14 years of age. Homozygosity for homocystinuria in nine patients was proven by 
hypermethioninemia, severe hyperhomocysteinemia as well as a near to absent CS 
activity in cultured skin fibroblasts3. None of them were on a regimen of 
methionine restriction, except one (patient number 9; Table 10.1). In addition to 
their conventional homocysteine-lowering treatment, 6 patients received 25 mg of 
thiamine hydrochloride for 6 weeks three times daily and 3 patients twice daily 
(Table 10.1 : patient number 2, 6 and 7). The latter 3 patients received only in total 
50 mg thiamine hydrochloride conforming with their conventional homocysteine-
lowering treatment which was also twice daily. Patients 3 and 4 are brothers, as 
well as patients 6 and 7 (Table 10.1). 
Methionine and homocysteine assay techniques 
Fasting EDTA venous blood samples were centrifuged immediately after 
puncture and stored at -20 °C until analysis. Methionine concentrations were 
determined on a LC 2000 amino acid analyzer (Biotronik Wissenschaftliche Geräte, 
Munich, Germany)6. The total homocysteine concentrations (free plus protein 
bound) were measured by a technique based on high-performance liquid 
chromatography (HPLC) and fluorescent detection7. 
Transamination metabolites assay techniques 
The degradation of methionine via the transamination pathway before and 
after treatment was studied by quantification in serum by the sum of the 
transamination metabolites 4-methylthio-2-oxobutyrate and the mixed disulphides 
of methanethiol (R-S-S-CH3). The blood concentrations of these metabolites are 
low and near the detection limit, and because of reasons of accuracy, we prefer 
to measure the total sum of these transamination metabolites. This technique is 
based on gas chromatography (Packard type 429; Packard-Becker, Delft, the 
Netherlands), supplied with a sulphur-specific flame-photometric detector (Packard, 
model 906) в , э . Details of the transamination metabolites measurement have been 
reported previously1 0. 
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Vitamin В, measurements 
Total thiamine concentrations were determined by a modified procedure of 
the reversed-phase ion-pair HPLC technique described by Wielders and Mink 1 1 . 
Whole blood specimens are deproteinized with perchloric acid, followed by acid 
phosphatase hydrolysis of thiamine tri-, di- and monophosphate to thiamine, and 
post-column derivatisation of total thiamine with K3Fe(CN)6 to thiochrome which 
is quantified fluorimetrically at excitation and emission wave lenghts of 364 nm 
and 462 nm, respectively. Due to preparation steps prior to HPLC, total analysis 
time of a blood specimen takes approximately 20 hours while the HPLC run itself, 
requires less than 10 minutes. The lower limit of detection of the technique is 2.3 
nmol thiamine per liter and excellent linear standard dose-responses is obtained up 
to 400 nmol/l. At mean concentrations of 123 nmol/L, the precision of the 
technique revealed intra-assay and inter-assay coefficients of variation of 4 . 8 % (9 
assay runs) and 6.8% (100 consecutive assay runs), respectively. 
Statistical analysis 
Results are given as mean ± SD. The two tailed Wilcoxon rank sum test 
was used in assessing statistical significance. 
Results 
The mean age ± SD of all 9 homozygotes for homocystinuria was 24.4 ± 
6.2 year (range 14 to 34 year); the mean ± SD duration of homocysteine-lowering 
treatment was 9.0 ± 2.4 year (range 5 to 17 year). The mean ± SD body weight 
was 72.3 ± 10.6 kg (range 52.5 to 88.0 kg) and the mean ± SD mg thiamine 
dosage per kg body weight for the patients was 0.90 ± 0.25 mg thiamine 
supplementation per kg body weight (range 0.48 to 1.43). 
The vitamin B, plasma concentration in the homozygotes for homocystinuria 
increased from 123 ± 30 (mean ± SD) nmoles/L (n = 7) before thiamine treatment 
to 207 ± 38 nmoles/L (n = 7) after 6 weeks of thiamine treatment (Table 10.1). 
The fasting blood methionine concentration decreased from 194 ± 127//moles/L 
(mean ± SD) before thiamine treatment to 128 ± 94 |/moles/L after thiamine 
treatment (n = 9) ( p < 0.06). The mean fasting plasma homocysteine 
concentrations did not differ significantly before and after thiamine therapy, i.e. 91 
± 25 //mmoles/L versus 83 ± 22 //moles/L. Only one out of the nine thiamine 
treated patients showed a considerable lowering of the homocysteine 
concentration simultaneously with a major decrease of the methionine level (Table 
1 0 . 1 : patient number 1). Currently, this patient continues the vitamin B, 
supplementation for 3 years, and the basal total homocysteine concentration at the 
most recent determination is now as low as 34 //moles/L. The level of the 
transamination metabolites after thiamine did not increase in the patients. In fact, 
these levels remained low or undetectable in 6 patients and even decreased slightly 
in 3 other patients (Table 10.1). Even in the single patient with a decrease of the 
homocysteine concentration since the start with thiamine supplementation, the 
level of the transamination metabolites remained unchanged. 
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Discussion 
Methionine degradation via the transamination pathway occurs in human but 
is probably of minor quantitative importance10. However, patients with 
hypermethioninemia due to methionine adenosyltransferase (MAT) deficiency do 
degrade quantitative amounts of methionine via the transamination pathway12,16, 
whereas patients with hypermethioninemia due to cystathionine synthase (CS) 
deficiency do not, despite elevated methionine levels6. The functional impairment 
of methionine transamination may be due to the different biochemical level of the 
blockade in the methionine metabolism or due to the treatment of CS deficient 
patients by pharmacological amounts of vitamins, in particularly pyridoxine6. The 
present study was performed because of the theoretical possibility to lower 
homocysteine concentrations by enhancement of methionine degradation via the 
transamination pathway in CS deficient patients. Previous in vitro studies with 
rats5 and human homogenates [Blom H, unpublished data] have shown that 
thiamine pyrophosphate stimulated the methionine degradation via the 
transamination pathway 2.5 fold. This active form of thiamine is a cofactor of the 
branched-chain 2-oxo-acid dehydrogenase complex which catalyses the oxydative 
decarboxylation of 4-methylthio-2-oxobutyrate into 3-methylthiopropionate13'14. 
This decarboxylation is supposed to be the rate-limiting reaction in the transamina-
tion of methionine4. 
Thiamine was administered in 9 homozygotes for homocystinuria in addition 
to their conventional homocysteine-lowering treatment. All these patients except 
one, demonstrated virtually unchanged levels of plasma homocysteine and serum 
transamination metabolites, despite the observed reduction of their methionine 
concentrations. Very recently, it has been reported that transamination in 
hypermethioninemic children is abnormally elevated only when plasma methionine 
levels exceeded 300 or 350//M1 5 , 1 6 ] . In the present study, only patient number 9 
(Table 10.1) has a methionine level above this methionine level, and indeed, his 
transamination metabolites were higher than in the other 8 investigated 
homozygotes for homocystinuria, but still much lower than those of MAT deficient 
patients wi th comparable methionine levels6'16. But even his serum transamination 
metabolites concentration did not increase after the supplementation of thiamine. 
We have no straightforward explanation for the reduction of the methionine 
concentration in most of the homocystinuric patients due to thiamine 
supplementation. The flux of methionine degradation through the transamination 
pathway can be decreased by glutamine, glutamic acid, alanine or leucine in the 
presence of 4-methylthio-2-oxobutyrate17. Thiamine is involved as a cofactor in the 
oxydative decarboxylation in the degradation of many amino acids, including the 
four mentioned above. Theoretically, thiamine administration may decrease the 
levels of glutamine, glutamic acid, alanine and leucine, and indirectly stimulate 
methionine degradation via its transamination pathway. However, the serum 
transamination metabolites of methionine were not elevated during thiamine 
administration. But, the levels of these metabolites may have remained unchanged 
despite an increased methionine degradation through the transamination pathway. 
Studies using stable isotopes of methionine could clarify this matter. 
In conclusion, orally administered thiamine lowered the homocysteine level 
in only one out of the nine homocystinuric patients studied despite the reduction 
of the methionine concentration in most patients. Therefore, vitamin B, appears to 
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be only a minor alternative option for homocvsteine-lowering treatment next to 
vitamin B6, B,2, folic acid, and betaine in homozygotes for homocystinuria. 
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Abstract 
Hyperhomocysteinaemia, defined as an abnormally high plasma homocysteine 
concentration after an oral methionine load, is common in young ( < 50 yr) patients 
with peripheral arterial occlusive disease. It is thought to predispose to 
atherosclerosis by injuring the vascular endothelium. Treatment with pyndoxine 
and/or folic acid may lower plasma homocysteine levels. In mildly 
hyperhomocysteinaemic patients with peripheral arterial occlusive disease, we 
studied the effect of daily treatment with pyndoxine (250 mg) plus folic acid (5 
mg) on homocysteine metabolism (i.e., plasma concentrations in the fasting state 
and after methionine loading; in 48 patients) and on endothelial function (in 18 
patients). Endothelial function was estimated as the plasma concentrations of the 
endothelium-denved proteins, von Willebrand factor (vWF), thrombomodulin (TM), 
and tissue-type plasminogen activator (tPA). At baseline, fasting homocysteine 
levels were above normal in 24 of the 48 patients (50%); post-load levels, by 
definition, in 100%. After 12 weeks of treatment, fasting and post-load levels 
were normal in 98 and 100%, respectively. 
Endothelial function was assessed in 18 patients who completed one year of 
treatment At baseline, median vWF (235%) and TM (57.1 ng/ml) levels were 
above normal At follow-up, vWF levels had decreased to 1 7 0 % (pO.01) and TM 
levels to 49 ng/ml (p = 0.04) tPA levels were normal at baseline and did not 
change. 
Endothelial dysfunction is present in young patients with peripheral arterial 
occlusive disease and hyperhomocysteinaemia. Pyndoxine plus folic acid treatment 
normalises homocysteine metabolism in virtually all patients, and appears to 
ameliorate endothelial dysfunction. 
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Introduction 
Mild hyperhomocysteinaemia (mHH) is an independent risk factor for 
peripheral arterial occlusive disease1 4. Studies in animals and in vitro indicate that 
high plasma concentrations of homocysteine, derived from demethylation of dietary 
methionine, may predispose to atherosclerosis by injuring the vascular endothelium, 
which results in endothelial dysfunct ion 5 9 . Pyridoxme and/or folic acid 
supplementation have been shown to reduce plasma homocysteine concentrations 
in mildly hyperhomocysteinaemic patients with peripheral occlusive disease10, but 
it is not known to what extent such treatment normalises homocysteine 
metabolism as estimated by plasma homocysteine concentrations in the fasting 
state and after an oral methionine load. It is also unknown whether endothelial 
dysfunction is present in these patients, and, if so, whether treatment aimed at 
normalising homocysteine metabolism improves endothelial function. 
We assessed endothelial function in young patients with peripheral arterial 
occlusive disease and hyperhomocysteinaemia as defined by an abnormal plasma 
concentration after methionine loading1. A gold standard for endothelial 
dysfunction is not available; we, therefore, measured plasma levels of 3 
endothehum-denved proteins involved in the regulation of haemostasis, i.e., von 
Willebrand factor (vWF), thrombomodulin (TM) and tissue-type plasminogen 
activator (tPA), because in vitro and in vivo data suggest that endothelial injury is 
associated with increased plasma levels of these proteins 1 1 1 β . In addition, we 
investigated the effects of treatment with pyridoxme plus folic acid on 
homocysteine metabolism and endothelial function. 
Patients and methods 
Patients 
From November, 1 9 9 1 , to April, 1993, 205 consecutive patients presenting 
with peripheral arterial occlusive disease at age 50 or younger were recruited from 
the Department of Vascular Surgery at the Free University Hospital, Amsterdam. 
Symptomatic peripheral arterial occlusive disease was defined as intermittent 
claudication and/or ischaemic ulceration, rest pain and gangrene, and/or amputation 
for ischaemia, and was confirmed by Doppler and/or angiographic studies. After 
obtaining informed consent, clinical and laboratory data were collected. 
Blood pressure was measured after 1 5 mm of supine rest without altering 
antihypertensive regimens. Diabetes was defined according to WHO criteria, and 
known diabetes duration was recorded. Patients were classified as non-smokers 
(those who did not smoke cigarettes, cigars, or pipe) or smokers (all others). Drug 
use was also recorded. After an overnight fast, blood was drawn for measurement 
of serum total cholesterol (measured enzymatically), creatinine (modified Jaffé 
reaction), glucose (glucose oxidase method), and endothelial function parameters 
(specified below), and an oral methionine loading test was performed to detect 
hyperhomocysteinaemia. The clinical data were collected and laboratory assays 
performed by personnel "blinded" to the presence of treatment with pyridoxme plus 
folic acid. 
Methionine loading test 
Plasma levels of homocysteine were determined in the fasting state and 6 
hours after an oral methionine load (0.1 g/kg). Plasma homocysteine levels were 
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measured as total homocysteine by using HPLC with fluorescence detection19. 
Normal fasting and post-load values measured in our laboratory are < 18 and < 51 
/ymol/L in men (n = 23), < 15 and < 4 9 //mol/L in premenopausal women (n = 56), 
and < 1 9 and < 6 9 //mol/L in postmenopausal women (n = 20). Deficiencies of 
vitamin B12, pyndoxine and folic acid were excluded by measuring serum levels. 
Normal values are > 1 2 0 pmol/L for vitamin B12, > 1 9 nmol/L for pyndoxine, and 
>3 .4 nmol/L for folic acid. 
Two hundred and five patients were so tested; 48 (23%) had 
hyperhomocysteinaemia as defined by an abnormal post-load plasma 
concentration1. Table 11.1 shows the clinical features of these patients. All had 
normal renal and hepatic function. 
Main outcome measures 
The 48 hyperhomocysteinaemic patients were all treated with pyndoxine (250 
mg daily) plus folic acid (5 mg daily). The effect on fasting and post-load 
homocysteine levels was studied after 6 weeks, and, in patients in whom the post-
load plasma concentration at 6 weeks was not in the normal range, again 6 weeks 
later. Parameters of endothelial function, and the effect of treatment on these 
parameters, were investigated in all patients who, in June, 1993, had completed 
at least one year of treatment (n = 18), a period chosen to allow a reasonable 
amount of time for the effect of treatment on endothelial function to become 
manifest. 
Endothelial function: The plasma concentrations of von Willebrand factor 
antigen (vWF)20, thrombomodulin (TM; Asseraduron Trombomoduhne, Diagnostica 
Stago, France)18, and tissue-type plasminogen activator antigen (tPA; Imulyse tPA, 
Biopool, Sweden)21, were measured by enzyme-linked immunosorbent assays. The 
plasma vWF level is expressed as a percentage of normal pooled plasma, the 
antigen level of which is defined as 100% (normal range, 50-150%'3) . For TM and 
tPA, normal ranges are 16.5-47.5 ng/ml and 1.84-9.80 ng/ml, respectively, as 
obtained in a control group (n = 21) matched for age with the 18 
hyperhomocysteinaemic patients in whom TM and tPA were measured. All blood 
samples were taken between 8 and 9 a.m., after an overnight fast. We were 
careful to avoid acute increases in the concentrations of these proteins associated 
with exercise, smoking, prolonged venous occlusion, hypoglycaemia, and acute 
illness. The intra- and interassay variation of the vWF, TM and tPA assays is less 
than 10%; the within person day-to-day variability of vWF is about 10%; that of 
tPA, about 15% (unpublished). 
Statistical analysis 
Data are given as mean (SD) or as median (range), unless indicated otherwise. 
Parametric and non-parametric tests were used as appropriate. Paired tests were 
used for comparing baseline with post-treatment data. We used univariate analysis 
to study the relation between endothelial function and possible determinants 
thereof: fasting and post-load homocysteine levels as well as 'classic' risk factors 
for atherosclerotic vascular disease (age, sex, smoking habits, systolic and diastolic 
blood pressure, and serum cholesterol; diabetes was not included in the analysis 
because there was only one diabetic among the 18 patients in the endothelial 
function study). The relationship of these 'classic' risk factors with endothelial 
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function parameters was assessed both at baseline and at follow-up (ie, at one 
year). In addition, we studied the relationship between homocysteine levels (fasting 
and post-load) and endothelial function parameters at baseline, and between 
homocysteine levels after treatment (ie, at 6 weeks) and endothelial function 
parameters at follow-up (ie, at one year). All testing was two-tailed with 0.05 as 
the level of significance. 
Results 
The patients reported no adverse effects of the pyridoxine plus folic acid 
treatment. No new vascular events occurred during follow-up, either in the 48 
patients followed for 6 to 12 weeks or in the subgroup of 18 patients followed for 
> one year. Mean (SD) fasting and post-load plasma homocysteine levels were 
20.7(14.7) and 73.8 (22.3) //mol/L before treatment, and 9.6 (3.6) and 36.8(9.1) 
//mol/L after treatment ( p < 0.001 for both comparisons; Figure 11.1). By 
definition, post-load homocysteine concentrations before treatment were abnormal 
in all patients; in contrast, fasting concentrations were within the normal range in 
24 of the 48 patients (50%). After 6 weeks of treatment, the fasting and post-load 
homocysteine concentrations were within the normal range in 47 (98%) and 45 
(94%) of 48 patients, respectively. After 12 weeks, these figures were 47 (98%) 
and 48 (100%). 
Table 11.2 shows the clinical characteristics of the 18 patients who 
completed at least one year of treatment (in whom endothelial function was 
assessed). At baseline, vWF and TM levels were above normal, but tPA levels were 
in the normal range. At follow-up, plasma vWF concentrations had decreased from 
median 235 to 170% (p = 0.01) and plasma TM concentrations from 57.1 to 49.0 
ng/ml (p = 0.04). Plasma tPA levels had not changed (6.9 ng/ml at baseline versus 
6.5 ng/ml at follow-up [p = 0.91]; Table 11.2, Figure 11.2). 
With regard to the classic risk factors, significant relationships were observed 
at baseline (but not at follow-up) between age and tPA (r = 0.57, ρ =0.01), serum 
cholesterol and vWF (r = 0.48, ρ = 0.04), and smoking habits and TM (smokers had 
lower TM levels than non-smokers (49 [29-72] versus 70 [48-113] ng/ml; 
ρ = 0.03). The fasting homocysteine plasma levels at baseline and after 6 weeks 
of treatment were not related to endothelial function parameters at baseline and 
follow-up, respectively, except for the homocysteine level at 6 weeks and the tPA 
level at follow-up (r = 0.44, ρ = 0.06). In contrast, the post-load homocysteine 
plasma levels at baseline and after 6 weeks of treatment showed trends towards 
significant relationships with the endothelial function parameters at baseline and 
follow-up, respectively: vWF (baseline: r = 0.36, ρ = 0.14; follow-up: r = 0.69, 
p = 0 . 0 0 1 , Figure 11.3), TM (baseline: r = 0.73, p = 0 . 0 0 1 ; follow-up: r = 0.35, 
p = 0.15), and tPA (baseline: r = 0.06, p = 0.8 ; follow-up: r = 0.38, p = 0.12). 
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Table 1 1 . 1 . Clinical characteristics of patients with peripheral arterial occlusive 
disease and hyperhomocysteinaemia. Data are mean (SD) unless otherwise 
indicated. 
N (M/F) 48(17/31) 
Age(yr) 4 3 . 9 ( 1 . 1 ) 
Blood pressure (mmHg) 138/87 (20/20) 
Smokers 32 (68%) 
Serum cholesterol (mmol/L) 6.3 (1.2) 
Diabetes mellitus 2 (4%) 
Serum creatinine (//mol/L) 85 (21) 
Table 11.2. Characteristics of the hyperhomocysteinaemic patients who completed 
one year of treatment. Data are mean (SD) unless otherwise indicated. § ρ = 0 . 0 1 , 
1 ρ = 0.04. 
Baseline Follow-up 
N (M/F) 18(6/12) 
Age (yr) 43.6(1.2) 4 4 . 6 ( 1 . 2 ) 
Follow-up duration (mo) 12.1 (12-13) 
Blood pressure (mmHg) 142/91(18/26) 141/86(18/10) 
Serum cholesterol (mmol/L) 6.3 (0.2) 6.0 (0.4) 
Smoking (Y/N) 13/5 11/7 
Diabetes mellitus 1 (5.6%) 1 (5.6%) 
von Willebrand factor (%) 235 170 § 
Thrombomodulin (ng/ml) 57.1 49 1 
Tissue-type plasminogen 
activator(ng/ml) 6.9 6.5 
Discussion 
In keeping with earlier reports' 4, our results indicate a high prevalence of 
mHH among young patients with peripheral arterial occlusive disease. Such 
patients show evidence of endothelial dysfunction as estimated by vWF and TM 
plasma concentrations. Endothelial dysfunction is thought to play an important role 
in atherogenesis. Treatment with pyridoxine plus folic acid normalises 
homocysteine metabolism in virtually all patients, both in terms of the fasting 
homocysteine plasma level and the level after an oral methionine load. 
Treatment with pyridoxine and folic acid is based on their involvement in 
homocysteine metabolism. Furthermore, either agent has been shown to lower the 
grossly elevated homocysteine plasma levels observed in classic homocystinuria, 
an inborn error of metabolism characterised by premature atherosclerosis and 
venous and arterial thromboembolism4. Classic homocystinuria is usually caused 
by homozygous deficiency of cystathionine synthase, an enzyme involved in 
theconversion of homocysteine to cystathionine. The active form of pyridoxine, 
pyridoxal phosphate, is a cofactor in this reaction. Its homocysteine-lowering effect 
is thought to be due to stimulation of cystathionine synthase activity. In contrast, 
folic acid reduces the plasma homocysteine concentration by enhancing its 
remethylation to methionine4. Therefore, the effects of these treatment modalities 
can theoretically be expected to be additive. 
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Figure 11 .1 . Plasma homocysteine concentrations (fasting and after methionine 
loading) before and on treatment (6 weeks in 45 patients and 12 weeks in 3 
patients) with pyridoxine plus folic acid, o, men; Δ , premenopausal women; •, 
postmenopausal women. 
Our patients were selected for having mHH, which may be due to 
heterozygous cystathionine synthase deficiency1, or to other metabolic defects 4 , 2 2 . 
Reliable and convenient methods to directly measure such deficiencies are not 
available at present. Instead, methionine loading, which stresses the pathways 
involved in homocysteine metabolism, can be used as a diagnostic test to uncover 
abnormalities of homocysteine handling. It is not clear which estimate of 
homocysteine metabolism, fasting3 ·2 3 or post-load1 - 2 level, should be chosen to 
guide treatment, because it is unknown which is the better predictor of 
atherosclerotic disease. We, therefore, measured both and observed no major 
differences in the metabolic efficacy of pyridoxine plus folic acid treatment whether 
expressed as fasting or as post-load homocysteine concentrations. 
Importantly, we found such treatment to be associated with improvement, 
although not normalisation, of endothelial function, suggesting that 
hyperhomocysteinaemia-associated endothelial dysfunction might be reversible. 
Homocysteine, a highly reactive sulphur-containing amino acid, is thought to 
damage endothelial cells by several mechanisms, eg, generation of hydrogen 
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Figure 11.2. Endothelial function parameters before and after one year of treatment 
with pyridoxine plus folic acid. vWF = von Willebrand factor; TM = 
thrombomodulin; tPA = tissue-type plasminogen activator. §,t = values not to 
scale, of + 716 and + 727 (§), and + 454 (1). The black rectangles indicate the 
normal ranges. 
peroxide7 and depletion of nitric oxide-mediated detoxification of homocysteine9. 
In addition, as hyperhomocysteinaemia is often due to genetic defects in the 
enzymes that regulate homocysteine metabolism1 , 2 , 4 , 2 2, and because these defects 
are also present in endothelial cells8, the endothelium of these persons may be 
especially vulnerable to homocysteine toxicity6. Endothelial dysfunction is a central 
feature of current models of atherogenesis2 4. Increased vWF and TM plasma 
concentrations probably reflect ongoing endothelial injury1 1"1 8. Furthermore, high 
plasma vWF levels have been shown to predict a poor cardiovascular prognosis in 
survivors of myocardial infarction1 2 and in patients with non-insulin-dependent 
diabetes mellitus1 3 The nature of the link between atherosclerosis and vWF and TM 
is not known with certainty. High vWF and TM probably are markers of the 
presence of endothelial injury and the process of atherogenesis. In addition, high 
plasma vWF levels may have functional significance because vWF enhances 
platelet adhesion and coagulation, the latter by stabilising factor VIII. TM, a 
membrane-bound protein, contributes to the inhibition of thrombin generation, 
thereby establishing an important local control of the coagulation cascade. Elevated 
TM plasma levels may reflect decreased binding to the cell membrane1 5, thus 
125 
Chapter 11 
Post-load homocysteine level on treatment ψτηοΐ L~') 
Figure 11.3. von Willebrand factor after one year of treatment with pyridoxine plus 
folic acid as a function of the post-methionine load plasma homocysteine 
concentration. r = o.69; p < 0 . 0 0 1 . 
allowing enhanced thrombin activity, or, alternatively, may result from 
homocysteine-induced increased synthesis and turnover2 5. The precise mechanism 
by which hyperhomocysteinaemia increases vWF and TM plasma concentration is 
unknown. In vitro studies have suggested that homocysteine might decrease vWF 
secretion2 6 and TM expression2 7, findings that indicate major differences between 
the in vitro and in vivo situation. 
The normal plasma level of tPA, an important regulator of fibrinolysis, 
suggests that endothelial function was not altered in this respect. Interpretation is 
limited, however, by the fact that we studied a relatively small group of patients. 
In addition, we did not measure tPA's inhibitor, PAI-1, which together with tPA is 
thought to determine fibrinolytic capacity. 
Other limitations of our study should also be considered. First, the treatment 
was neither randomised nor controlled. It appears unlikely, however, that the 
substantial effect of treatment on homocysteine levels was a chance finding, as 
such levels are known to be quite stable over time, whereas other conditions 
known to affect homocysteine metabolism were excluded4. In addition, although 
a placebo-controlled trial would obviously be the most preferable study design, our 
experience with symptomatic hyperhomocysteinaemic patients suggests that many 
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would not consent to such a trial in view of the perceived safety and efficacy of 
vitamin therapy4. Second, we cannot be certain that the changes in endothelial 
function parameters were induced by the pyridoxine plus folic acid treatment, 
although this interpretation is supported by the strong correlation between post-
treatment homocysteine and vWF levels (Figure 11.3). Nevertheless, the 
correlations observed between homocysteine levels and endothelial function 
parameters, although theoretically plausible, should be considered preliminary until 
confirmed in a larger group. As other cardiovascular risk factors did not change 
significantly during follow-up, changes in factors such as smoking habits are an 
unlikely explanation for the decreases in vWF and TM observed. Furthermore, vWF 
levels are relatively stable over periods of up to 3 years in (diabetic) patients 
remaining free of cardiovascular disease13, suggesting that regression to the mean 
is also unlikely to explain the changes in vWF. Third, notwithstanding the 
promising effects of pyridoxine plus folic acid supplementation on endothelial 
function parameters, the clinical efficacy of the proposed treatment needs to be 
investigated in terms of prevention of new vascular events. 
In conclusion, endothelial dysfunction is present in young patients with 
peripheral arterial occlusive disease and mHH. Pyridoxine plus folic acid treatment 
normalises homocysteine metabolism in the majority of patients, and appears to 
ameliorate endothelial dysfunction. 
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Abstract 
Mild hyperhomocysteinemia (mHH) is an independent risk factor for premature 
arteriosclerosis. We investigated the accuracy in the detection of early arterios­
clerotic lesions in such patients. The left and right wall of the abdominal aorta, the 
aortic bifurcation and both common iliac arteries were evaluated with gated Τ Ί -
weighted magnetic resonance imaging (gT1 MRI) and gated 2D-time of flight 
magnetic resonance angiography (g2D-TOF MRA) and were compared with intra­
arterial digital subtraction angiography (iaDSA) in 11 patients with arteriosclerosis 
and mHH. 
Six patients showed arteriosclerosis in one or more of the total number of 55 
studied arterial segments with iaDSA. Thirty-two out of 37 normal and 12 out of 
18 stenotic segments with gT1 MRI, and 29 normal and 6 stenotic segments with 
g2D-TOF MRA were correctly classified. Sensitivity of gT1 MRI and g2D-TOF MRA 
versus iaDSA was 6 7 % and 3 3 % , the specificity was 8 6 % and 7 8 % , and the 
accuracy was 8 0 % and 6 4 % , respectively. 
We conclude that arteriosclerosis in patients with mHH is a regular finding, 
and gT1 MRI in such patients is an acceptable technique. 
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Introduction 
Mild hyperhomocysteinemia (mHH) is an established risk factor for premature 
arteriosclerotic disease such as cerebral, peripheral and coronary arterial occlusive 
disease. Prevalence of mHH in vascular patients under 55 years of age is reported 
varying from 9% to 4 7 % [1-3]. A recent multicenter study including more than 
750 patients with arteriosclerosis and as much matched control subjects showed 
a relative risk of homocysteine levels in the upper decile of the distribution of 
control levels of about 4 to develop arterial occlusive disease [4]. The degree of 
peripheral arteriosclerosis might be related to the homocysteine concentration in 
blood [5] Very recently, the neuroradiological aspects of hyperhomocysteinemia 
has been extensively reported by van den Berg et al. [6]. 
Intraarterial digital subtraction angiography (laDSA) has been accepted as the 
gold standard to detect the presence and to indicate the severity of arteriosclerosis 
in the vascular system. The main disadvantages of this technique are its invasive 
character and the involvement of ionizing radiation. The use of magnetic resonance 
imaging (MRI) and magnetic resonance angiography (MRA) has grown interest 
because these methods overcome these disadvantages. Furthermore, MRA can 
provide additional functional flow information. Several studies on MRI and MRA of 
the abdominal aorta and iliac arteries show a good correlation of the results of 
those techniques with those of conventional laDSA [7-12]. In most of these studies 
the arteriosclerotic lesions were classified into mild stenosis (1 to 50% of arterial 
diameter), moderate stenosis ( 5 1 % to 75%), or severe stenosis (76% to 100%). 
However, the accuracy and reliability of MRI and MRA examinations in the 
detection of mild arteriosclerotic occlusive disease has only poorly been evaluated. 
Proof of validity of these techniques is warranted before using these in the 
determination of early signs of generalized arterial disease in patients prone to 
arteriosclerosis A model of such generalized arteriosclerotic state is presented in 
subjects with elevated homocysteine levels in their blood, albeit mildly to 
moderately elevated concentrations compared to those in classical homocystinuna. 
Moreover, MRI and MRA studies in patients with mild hyperhomocysteinemia have 
not been reported until now [6]. 
Therefore, in this study we compared data obtained by means of MRI and 
MRA techniques with those provided by laDSA in patients with proven arterial 
occlusive disease in the presence of mHH. 
Methods 
Patient Selection 
In patients wi th premature arterial occlusive disease, mild 
hyperhomocysteinemia was established by means of a standardized methionine 
loading test measuring total homocysteine concentration in plasma [13-14] 
Combined supplementation of vitamin B6 and folic acid has proven to decrease and 
even to normalize pathological homocysteine blood levels in the majority of patients 
with arteriosclerosis and with mHH [15-16]. Clinically beneficial effect of such 
homocysteme-lowering intervention, in terms of decreasing number of vascular 
events, has not been demonstrated so far. Eleven detected hyperhomocysteinemic 
patients presenting post-load homocysteine levels above the 97.5 percentile in 
controls [16], seven men and four women, consecutively selected for participation 
in a running prospective placebo-controlled intervention study on the effect of 
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homocysteine-lowering treatment, were recruited for the present study. The eleven 
patients had suffered from arteriosclerotic disease as shown in Table 12 .1 . 
Cerebral arterial occlusive disease was confirmed by computer tomography. 
Coronary arterial occlusive disease was established by means of new Q waves on 
electrocardiography and/or diagnostic enzyme changes. Anterior spinal arterial 
syndrome was established by means of clinical presentation. This patient showed 
no infarction by means of computer tomography of the brain. Peripheral arterial 
occlusive disease was confirmed by an ankle-brachial blood pressure index less 
than 0.9. In one of these 2 patients, the ankle-brachial blood pressure 
measurements revealed arteriosclerotic changes in the superficial femoral artery at 
the right side and popliteal artery at the left side. In the other patient with 
peripheral arterial occlusive disease, the ankle-brachial blood pressure 
measurements revealed aortoiliac vascular changes. None of the patients revealed 
vitamin B6, B,2 or folic acid deficient blood levels, liver or renal disease, which 
conditions can also induce mHH [17). Other risk factors for vascular disease such 
as diabetes, hyperlipoproteinemia and hypertension of non-renovascular origin were 
excluded. Not any of these patients was known to have a cardiac pace maker or 
surgical clips or was pregnant. The mean age ± 1 SD of the patients was 41.6 ± 
8.5 years (range 21 to 51 years) at the time of the examinations, and 38.9 ± 7.9 
years at the time the vascular events had occurred (range 21 to 51 years). The 
protocol for this study had been approved by the Hospital Ethical Committee, and 
all included patients had signed an informed consent. 
Table 12.1 . The established vascular disease of which the patient suffered from 
is given with "cerebral" = cerebral arterial occlusive disease, "asas" = anterior 
spinal artery syndrome, "coronary" = coronary arterial occlusive disease, 
"peripheral" = peripheral arterial occlusive disease, age' ± SD = age at the time 
the first vascular events had occurred, and age ± SD = age at the time of the 
examinations. 
patient 
number 
1 
2 
3 
4 
5 
6 
7 
8 
9 
10 
11 
age' 
± SD 
37 
51 
41 
33 
41 
34 
45 
45 
41 
21 
39 
38.9 ± 
7.9 
age2 
± SD 
40 
51 
45 
41 
51 
34 
46 
46 
42 
21 
40 
41.6 
± 8.5 
arteriosclerosis 
cerebral 
asas 
cerebral 
cerebral/coronary 
cerebral/coronarv 
peripheral 
cerebral/peripheral 
coronarv 
cerebral 
cerebral 
cerebral 
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Intraarterial Digital Subtraction Angiography Technique 
In this study, laDSA was used as gold standard, to assess the reliability of 
MRI and MRA. laDSA studies were performed with a Polytron 1000 VR (Siemens-
Elema, Sweden) with a high resolution 1024x1024 pixel image matrix. Before the 
examination, all patients received orally 10 mg oxazepam (Seresta", Wyeth) and 
0.25 mg atropin (Centrafarm) by intramuscular injection. Moreover, all patients 
received intravenously 20 mg of butylscopolaminebromide (Buscopan", Boehnnger) 
as antiperistaltic medication directly before contrast medium injection. laDSA was 
performed with a 5F pigtail catheter (Cook, the Netherlands) placed in the 
abdominal aorta at the level of the coeliac trunc by the transfemoral route. Twenty-
five ml of meglummeamidotrizoaat 306 mg l/ml (Angiografin", Schering, the 
Netherlands) was diluted in ratio 1 to 1 with saline to which 37 5 IE heparin was 
added. Abdominal angiography in posteroantenor projection was obtained by 
injecting 50 ml diluted contrast media, with a flow-rate of 20 ml/s, an inject delay 
of 3.5 s and 3 frames per second. 
Magnetic Resonance Imaging and Magnetic Resonance Angiography Technique 
MRI and MRA examinations were performed with a 1.5 Tesla Magnetom 63 
SP whole-body imaging system (Siemens Medical Systems, Erlangen, Germany). 
All patients received intravenously 20 mg of butylscopolamin (Buscopan") as 
antiperistaltic medication directly before and another 20 mg trough a continues drip 
infusion during the investigation. The abdomen was mildly compressed with a belt, 
and patients were allowed to breath normally during the examination. After scout 
images were obtained, the position of presaturation slices were placed superiorly 
to the image volume and over the anterior abdominal wall in order to suppress the 
signal from inflowing protons and respiratory and bowel motion artifacts. ECG 
triggered high resolution T1 weighted MR Images in coronal plane through the 
abdominal aorta and in axial angulated plane parallel to the common iliac arteries 
were acquired. The repetition time (TR) varied, depending the RR-interval, from 
620 to 850 ms. Eleven slices were obtained using the following sequence 
parameters: echo time (TE) 25 ms, flip angle (σ) 90°, matrix size 315 χ 512, field 
of view (FOV) 400 mm, contiguous slice thickness 4 mm, and 4 acquisitions. G2D-
TOF MRA images were obtained in coronal plane with presaturation pulse placed 
interiorly to the image volume and over the left side of the abdomen in order to 
suppress the signal from inflowing protons of the inferior cava vene and the left 
renal vein The following sequence parameters were used: 11 slices, TR 34 ms, TE 
8 ms, matrix size 256 χ 256, FOV 400 mm, contiguous slice thickness 4 mm, and 
1 acquisition MIP reconstructions were made. 
Evaluation 
The period between MR and DSA examinations was less than 3 weeks in all 
patients. Two observers (JOB and FMJH) evaluated independently the MR and the 
DSA examinations, respectively, from hard copy films, without prior knowledge of 
each others results The evaluated abdominal aorta and the common iliac arteries 
of each patient were divided into 5 arterial segments, i.e. the left and right wall of 
the abdominal aorta, the aortic bifurcation, and the left and right common iliac 
artery, leading to a total of 55 evaluated segments in the 11 patients. Stenosis 
was graded according to the most severely narrowed part of the evaluated 
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segment compared with the luminal diameter of the normal appearing arterial 
segment in the vicinity of the arteriosclerotic plaque. The percentage of vessel 
diameter reduction was defined as: 
M1 - M2 
100% χ — -
M1 
where M1 is the luminal diameter at the normal appearing level of the arterial 
segment; M2 is the luminal diameter of the arterial segment at the site of the most 
severe narrowing. In case of arteriosclerosis at both walls of the abdominal aorta, 
the percentage diameter narrowing was calculated for each side solely. The 
stenosis were grouped at intervals of 5% (e.g. 5, 10, 15 etc). The percentage 
diameter narrowing was subsequently divided into four categories: first, second, 
third and fourth degree arteriosclerosis with respectively 1 % to 2 5 % , 2 6 % to 
5 0 % , 51 % to 7 5 % , 7 6 % to 100% stenosis. In this study, the latter category was 
not observed. 
Results 
No complications occurred with the MRI and MRA examinations. One patient 
had a self-limiting catheter-induced hematoma after iaDSA examination at the 
punction side in the groin. 
All arterial segments 
Five out of all 11 patients were without arteriosclerosis, whereas the 
remaining 6 patients revealed arteriosclerosis in at least one evaluated arterial 
segment (Figures 12.1 and 12.2). In 18 out of 55 examined arterial segments, 
arteriosclerosis was detected by means of iaDSA showing narrowing varying from 
5% to 7 0 % of the luminal diameter (Tables 12.2 and 12.3). With gT1 MRI, 16 out 
of these 18 segments, and by g2D-TOF MRA, 7 out of 18 segments, were also 
classified as stenotic. Two and three out of 18 arteriosclerotic segments were 
classified incorrectly as normal by means of MRI and MRA, respectively. With the 
MRI technique, 3 segments with normal findings in iaDSA, and with MRA 
technique, 7 normal and 8 arteriosclerotic arterial segments in iaDSA could not be 
evaluated. The main reason was the loss of signal through which mostly the iliac 
arteries could not be depicted. The sensitivity for distinguishing normal and 
stenotic segments in the correct category with iaDSA as gold standard were higher 
by means of MRI than MRA examinations, i.e. 6 7 % and 3 3 % respectively. The 
specificity of correct evaluation of segments compared with iaDSA was 8 6 % for 
MRI and 7 8 % for MRA. Overall, the accuracy of gT1 MRI and g2D-TOF MRA 
evaluating arteriosclerosis in the abdominal aorta and the common iliac arteries 
compared to iaDSA in patients with arteriosclerosis and mHH was 8 0 % and 6 4 % , 
respectively. Three incorrectly evaluated segments by MRI were correctly evaluated 
by MRA. The sensitivity, specificity, and accuracy of combined MRI and MRA 
examinations was 7 2 % , 9 2 % and 8 5 % , respectively. 
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a b 
Figure 12 .1 . This 20 year old male patient was known with cerebral vascular 
disease leading to right sided hemiparesis and aphasia. He never smoked tobacco 
and had normal blood pressure measurements (125 mmHg and 85 mmHg, systolic 
and diastolic, respectively). The blood levels of glucose, cholesterol, triglycerides, 
creatinine, and liver enzymes (aspartate amino-transaminase and alanine amino-
transaminase) were within normal ranges. His post-load plasma homocysteine level 
was 76yt/mol/L (normal control value is below 55/ymol/L). The investigated arterial 
segments by means of laDSA (Figure 12.1a) and gT1 MRI (Figure 12.1b) 
examinations proved to be without arteriosclerosis. 
136 
Chapter 12 
Figure 12.2. A 45 year old female patient who was known with cerebral vascular 
disease and intermittent claudication which first revealed several months before the 
intraarterial digital subtraction angiography (¡aDSA; Figure 12.2a) and magnetic 
resonance imaging (MRI; Figure 12.2b) and magnetic resonance angiography (MRA; 
Figure 12.2c) were performed. She was known with 20 pack years of smoking and 
normal blood pressure measurements (130 mmHg and 85 mmHg, systolic and 
diastolic, respectively). The blood levels of protein C, antithrombin 3, glucose, 
cholesterol, triglycerides, creatinine, and liver enzymes (aspartate amino-
transaminase and alanine amino-transaminase) were within normal ranges. Her 
post-load plasma homocysteine level was 127 //mol/L (normal control value is 
below 52 /лпоІ/L). laDSA (Figure 12.2a) and gT1 MRI (Figure 12.2b) revealed 3 0 % 
stenosis at both sides of the abdominal aorta, 6 0 % stenosis at the aortic 
bifurcation and the right common iliac artery, and 7 0 % and 6 0 % stenosis, 
respectively, at the left common iiiac arterial segment. 
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Table 12 2. Findings of 55 artenal segments in 11 vascular patients with mild 
hyperhomocysteinemia evaluated with intraarterial digital subtraction angiography 
(laDSA) and high resolution gated T1-weighted magnetic resonance imaging (MRI). 
Percentages are degree of vessel stenosis. With laDSA, all vessel were évaluable; 
with MRI, 3 arterial segments were not évaluable (NE). 
Degree of stenosis 
diagnosed with MRI 
Degree of stenosis diagnosed with laDSA 
0% 1%-25% 26%-50% 51%-75% 76%-100% 
NE 
0% 
1-25% 
26%-50% 
51%-75% 
76%-100% 
3 
32 
1 
1 
-
-
-
2 
6 
3 
-
-
-
-
1 
3 
-
-
Total 37 11 
Table 12.3. Findings of 55 arterial segments in 11 vascular patients with mild 
hyperhomocysteinemia evaluated with intraarterial digital subtraction angiography 
(laDSA) and gated 2D-time of flight magnetic resonance angiography (MRA). 
Percentages are degree of vessel stenosis. With laDSA, all vessel were évaluable; 
with MRA, 15 arterial segments were not évaluable (NE). 
Degree of stenosis 
diagnosed with MRA 
Degree of stenosis diagnosed with laDSA 
0% 1%-25% 26%-50% 51%-75% 76%-100% 
NE 
0% 
1-25% 
26%-50% 
51%-75% 
76%-100% 
7 
29 
1 
-
-
-
4 
3 
3 
1 
-
-
Total 37 11 
The abdominal aorta 
In 13 out of the 22 abdominal aortic segments, all three image modalities 
showed normal configuration of the arterial wall without arteriosclerosis, and 9 
studied segments proved to be abnormal. Equivocal findings of the degree of 
arteriosclerotic lesions were determined with the MRI and MRA versus laDSA in 7 
and 5 segments, respectively. Consequently, MRI and MRA were classifying 
incorrectly in 2 and 4 segments. Slight arteriosclerosis by means of laDSA was 
underestimated and classified as normal in two segments with MRI and in three 
segments with MRA In one segment with first degree vascular changes, MRA 
examination was overestimated showing second degree arteriosclerosis. 
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Aortic bifurcation 
In 7 out of 11 segments the three image modalities revealed no 
arteriosclerosis at the site of the aortic bifurcation. In the 4 other patients, the 
aortic bifurcation proved to have vascular damages by means of the golden 
standard laDSA. One arteriosclerotic aortic bifurcation was correctly identified with 
all examinations. MRI overestimated the arteriosclerosis in two arterial segments 
and underestimated the abnormality in one segment. No abnormal aortic bifurcation 
was classified as normal with the MRI technique. With MRA, the aortic bifurcation 
in two patients could not be evaluated on the basis of signal loss, and in one 
patient the degree of arteriosclerosis was overestimated as slight arteriosclerotic 
vascular changes in stead of normal vascular arterial wall. 
Common iliac arteries 
Three out of the 22 segments with MRI and 13 segments with MRA could 
not be evaluated due to different angulation than the image plane, and due to spin 
saturation, respectively. laDSA and MRI showed equal findings in 12 normal 
segments and in 4 stenotic segments. MRI overestimated in three segments, i.e. 
one normal vascular wall was classified as second degree arteriosclerosis, and two 
first degree arteriosclerotic changes were classified as second degree arteriosclero-
sis Nine normal ihacal segments were correctly assessed with MRA examination. 
Discussion 
Mild hyperhomocysteinemia is established as a condition which leads to 
generalized arteriosclerosis with or without vascular symptoms [5,18]. In this 
study, indeed 6 out of all 11 patients (55%) revealed arteriosclerosis established 
by means of laDSA in at least one of the 5 evaluated arterial segments in each 
patient. In only one patient the demonstrated vascular damage was leading to 
clinical symptoms and was confirmed by an abnormal ankle-brachial blood pressure 
index. The other five patients were without clinical symptoms despite their 
percentage of vessel diameter narrowing upto 30%. 
The gT1 MRI technique determined 12 out of 18 stenotic segments, and 32 
out of 37 normal segments correctly. The 6 incorrectly evaluated stenotic 
segments were overestimated in three and underestimated also in three. All 
incorrectly classified arterial segments showed a discrepancy of only one degree, 
except one normal iliac segment which showed second degree arteriosclerosis by 
means of gT1 MRI. The mean (± SD) percentage of discongruence between MRI 
and DSA measurements proved to be 10% ( ± 5%) of vessel diameter. The sensiti-
vity of correctly cathegonzing by gT1 MRI versus laDSA was 67%, the specificity 
was 86%, and the accuracy was 80%. Therefore, we conclude that high resolution 
gT1 MRI of the abdominal aorta, aortic bifurcation, and the common iliac arteries 
in patients with arteriosclerosis and mild hyperhomocysteinemia appears to be an 
acceptable imaging method in terms of accuracy compared with laDSA, and may 
be an alternative method to the invasive laDSA technique 
By means of MRA examination, only 6 out of 18 stenotic segments and 29 
out of 37 normal segments were classified correctly One stenotic segment by 
means of laDSA was overestimated with MRA and 3 slightly stenotic segments 
were classified as normal. We were unable to classify 15 arterial segments with 
MRA mainly based on signal loss at the level of the bifurcation or more distally 
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The reduced visualization of flowing blood in the more distal imaged volume with 
MRA, is related to the progressive spin saturation leading to signal loss. The high 
proportion of not évaluable examinations with the g2D-T0F MRA technique is the 
main reason for the accuracy as low as 64% of MRA compared with laDSA in this 
study. MRA was classifying correctly compared to laDSA in contrast to a 
misdiagnose by MRI, in only two out of the 55 segments. Therefore, MRA does not 
seems to provide significant additional information to gT1 MRI. Further studies may 
disclose improvement of newer MRA techniques in their determination of arterio-
sclerosis in abdominal and pelvic arteries. 
To generate signal with gT1 MRI, protons must remain for at least УаТЕ time 
interval to be exposed Blood flow, remaining shorter than Уз ТЕ time during the 
exposure time, produces signal void. The reduced signal from flowing blood 
compared with the signal from arterial walls and vessel wall damages provides 
excellent contrast for detection of arteriosclerosis. However, blood flow velocity 
is highest in the center of an artery and slower at the vessel wall and turbulance 
distal to the arteriosclerotic lesion may lead to overestimation of the degree of 
arteriosclerosis with gT1 MRI [19], occunng in 5 out of 55 segments in this study. 
GT1 MRI was underestimated in 3 out of 55 segments, all three on the base of 
only 5% stenosis difference assessed by laDSA and MRI. 
Maximum enhancement with g2D-T0F MRA occurs when the velocity of 
blood is such high that the initially exitated blood volume is completely replaced by 
"fresh" inflowing blood spins in the imaged volume. A disadvantage of g2D-TOF 
MRA method appears when the imaged volume is too large to be fully replaced and 
this is the reason that 15 arterial segments, 2 aortic bifurcations and 13 iliac 
arterial segments, were not évaluable and 2 segments were overestimated with the 
g2D-TOF MRA technique in this study. A thinner slice tickness could increase the 
signal intensity, but consequently the examination time would increase 
unacceptably and the signal to noise ratio will decrease. 
Conventional angiography is nowadays a well accepted technique, but 
remains nevertheless not completely without risk Renal dysfunction, embolism and 
puncture site trauma, such as hematoma, bleeding, pseudoaneurysm, dissection, 
arteriovenous fistula, thrombosis, and infection are the mam complications 
Furthermore, laDSA can provide only two-dimensional images [20]. 
MR images are performed without vessel invasion which is attractive 
especially in arteriosclerotic patients. One of the further merits of MRI technique, 
in contrast to laDSA, is that it provides also information of surrounding tissues. 
Although the number of patients is limited, these initial results show, that 
high resolution gated T1-weighted MRI is of such image quality that it is a 
acceptable alternative to conventional angiography to determine generalized though 
mild arteriosclerotic arterial damages such as in patients with mild hyperhomocys-
teinemia In the follow up of the clinical effect of homocysteine-lowenng treatment 
in such patients this non-invasive technique is preferable. Gated two dimensional 
time of flight MRA does not provide additional information to gT1 MRI. 
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IS HOMOCYSTEINE-LOWERING TREATMENT 
BENEFICIAL IN ARTERIOSCLEROSIS DUE TO 
MILD HYPERHOMOCYSTEINEMIA? 
Preliminary results of a prospective trial. 
D.G. Franken, G.H.J. Boers, J.O. Barentsz, 
W. van Asten, and J.H.J. Ruijs. 
Submitted. 
Abstract 
Supplementation of combined vitamin B6 and folic acid can normalize 
elevated homocysteine blood levels, a risk factor for arteriosclerosis and 
thrombosis. Clinically beneficial effect of this treatment by means of slowing down 
the progress of arteriosclerosis has not been established until now. A 2 year 
running double-blind placebo-controlled prospective trial in vascular patients with 
mild hyperhomocysteinemia started, to assess the effect of this treatment. 
Evaluation of arteriosclerosis is performed with Magnetic Resonance Imaging of the 
abdominal aorta and proximal segments of the common iliac arteries, segmental 
blood pressure measurements of the lower extremities and duplex scanning of the 
carotid and vertebral arteries. 
In this preliminary report on the outcome in a small group of the first 14 
included vascular hyperhomocysteinemic patients, it is shown that 8 had also 
arteriosclerotic signs at segments where their clinical symptoms did not originate 
from. Four out of 8 vitamin-treated and one of the 6 placebo-treated patients 
showed regression, and 3 placebo-treated patients showed progression of arterio-
sclerosis, in contrast to one in the vitamin-treated group. In the remaining 5 
patients, 3 vitamin and 2 placebo-treated, the arteriosclerosis was overall 
unchanged. 
We conclude from this preliminary trial that in vascular patients with mild 
hyperhomocysteinemia, arteriosclerosis is found to be very often generalized. 
Although these results are small in number, they do not contradict a possible 
potency of combined vitamin B6 and folic acid to prevent progression of 
arteriosclerotic changes in vascular patients with mild hyperhomocysteinemia. 
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Introduction 
With a frequency which varies from 9% to 4 7 % of patients with premature 
arteriosclerosis leading to occlusive cerebral, peripheral, or coronary artery disease, 
mild hyperhomocysteinemia (mHH) has been detected retrospectively in numerous 
studies1. The association between premature arteriosclerosis and mHH has also 
been found in large epidemiological prospective studies2'4. 
Until now, two enzyme deficiencies have been detected in vascular patients 
which may lead to mildly elevated blood homocysteine levels, i.e. cystathionine 
synthase5,6andthermolabile5,10-methylenetetrahydrofolatereductasedeficiency7" 
n
. The former enzyme requires pyridoxal 5'-phosphate, the biologic active form of 
vitamin B6, as cofactor. The latter enzyme catalyzes 5,10-methylenetetrahydrofo-
late into 5-methyltetrahydrofolate, which is the main form of folate in blood. 
Vitamin B6 supplementation solely, in a dose of 250 mg daily, lowers in 76%, and 
even normalizes in 56% of vascular patients the elevated post-load homocysteine 
concentrations12. Combined supplemention of vitamin B6 and folic acid normalizes 
the pathological homocysteine blood levels in the vast majority of hyperhomocys-
teinemic patients who poorly or not at all respond to sole vitamin B6 treatment12,13. 
This combined homocysteine-lowering treatment even improves some markers of 
endothelial dysfunction in vascular patients with mHH14. Reportedly, the incidence 
of vascular accidents is significantly reduced after initiating homocysteine-lowering 
treatment in severe hyperhomocysteinemia, revealing the clinically beneficial effect 
of such intervention16. However, it is not clarified whether homocysteine-lowering 
treatment has also such positive effect in vascular patients with mHH in terms of 
a regression or stabilization of arteriosclerosis. Hence, we have started a 2 year 
running double-blind placebo-controlled prospective study with combined vitamin 
B6 and folic acid treatment in vascular patients with mHH. Evaluation of the 
arteriosclerotic lesions was performed with Magnetic Resonance Imaging (MRI) of 
the abdominal aorta and proximal segments of the common iliac arteries, segmental 
blood pressure (SBM) and duplex measurements (DU) of the carotid arteries. The 
results of outcome after 2 years of inter-vention in the first 14 treated patients are 
presented here preliminarily. 
Materials and methods 
Patients 
Patients were selected consecutively among those suffering from arterial 
vascular disease which had become symptomatic before the age of 55 years who 
showed after methionine loading elevated homocysteine concentration. 
Conventional risk factors such as diabetes, hypercholesterolemia and hypertension 
unless of renovascular origin were excluded, however, cigarette smoking (range 
from 0 to 26 pack years of smoking, one pack year is defined as smoking one pack 
of cigarettes daily for one year) was not. Of the first 14 of such patients, seven 
patients had suffered from stroke due to cerebral vascular disease (CVD), two from 
coronary heart disease (CHD), one from intermittent claudication due to peripheral 
vascular disease (PVD), one from anterior spinal arterial syndrome (SAS), two from 
combined CVD and CHD, and one from combined CVD and PVD. The clinical 
diagnosis in patients with stroke was confirmed by computer tomography, and in 
patients with PVD by SBM. All patients with CHD had undergone a bypass 
operation or percutaneous transluminal coronary angioplasty. The patient with SAS 
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presented with loss of sensibility and strength below the level of thoracal VIM at 
the right, and thoracal IX at the left side, and with paresis of the urine bladder. In 
this patient, the diagnosis SAS was based on clinical presentation The vascular 
disease in the patients became symptomatic between their 20 t h and 50 t h year of 
age (37 ± 6 years; mean ± SD). The age of the 14 patients at the start of the 
study was 39 ± 7 years (mean age ± SD). Not any of these patients were known 
to have a cardiac pace maker, metallic surgical clips or was pregnant in an early 
stage as these factors are a contraindication for MRI examination 
Trial design 
All patients were known with post-load elevated homocysteine levels, which 
decreased within the range of normal controls after combined vitamin Be and folic 
acid treatment, 250 mg and 5 mg daily, respectively Although we have had 
reported previously that this combined treatment will normalize the post-load 
homocysteine levels in almost all hyperhomocysteinemic vascular patients1 3, all the 
studied patients had to prove such normalization after combined homocysteine-
lowermg treatment during 6 weeks after a repeated methionine loading test, for 
reasons of scrutiny, before entering this prospective study Informed consent was 
obtained from each patient. The patients were randomized in a double-blind way 
into either a vitamin (i.e. vitamin Be, 250 mg daily, and folic acid, 5 mg daily) or 
a placebo-treated group. At study entry, one and two years after the s t a r f o f the 
study, all patients underwent a methionine loading test, SBM, DU, standardized 
questionnaire, physical examination, and electrocardiography in supine position. 
Standardized questionnaire was focused upon complaints of arterial ischaemia, and 
physical examination was carried out, with special attention to arterial pulsations 
in neck and extremities MRI was performed at study entry and after two years 
The research protocol for this study had been approved by the Hospital's 
Ethical Committee 
Methionine loading test 
MHH was established by means of increased total homocysteine blood 
concentrations above mean control level plus 2 standard deviations after a 
standardized methionine loading, as described earlier16 Venously collected plasma 
samples in the fasting state and 6 hours after methionine loading (0.1 g L-
methionine/kg body weight) were centrifuged instantly and total homocysteine 
concentrations (free plus protein bound) were measured by high-performance liquid 
chromatography1 7 Because the mean post-load homocysteine levels between 
control men, pre-, and postmenopausal women differs, the studied patients were 
categorized a c c o r d i n g l y 5 1 6 1 8 1 9 . Moreover, fasting vitamin B6 (normal range: 28 -
107 nmol/L), vitamin B,2 (160 - 750 pmol/L), folic acid (5 5 - 40 0 nmol/L), 
creatinine, and liver enzymes (aspartate amino-transaminase and alanine amino-
transaminase) levels were measured by means of standard procedures. 
Segmental blood pressure measurement (SBM) 
Pressure measurements were performed by means of 4 pair of cuffs 
strapped around the lower extremities, ι e at high thigh, above the knee, below the 
knee, and at ankle levels2 0. Pressure measurements were determined at all levels, 
with a pocket Doppler apparatus (Omex, USA) The highest systolic brachial artery 
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pressure was used as a reference for the systemic blood pressure. Measurements 
were performed at rest and during reactive hyperaemia induced by a 5 minutes 
arterial occlusion, by means of thigh cuff compression with pressures above the 
systolic arterial pressure with the patient in supine position. When the leg-brachial 
arterial pressure index was beneath 0.90 at rest, or beneath 0.85 after 5 minutes 
occlusion, the SBM was considered abnormal. If after one or two years one of 
these indices had passed these values or had changed by more than 0.2, this was 
considered as a significant alteration in arterial occlusive disease. 
Duplex scanning measurements (DU) 
Blood flow velocity measurements of extracranial part of the internal, 
external, and the common carotid arteries, and vertebral arteries at both sides was 
performed by means of duplex sonographic scanning. The velocity of the internal 
carotid arteries was performed at 3 levels. Thus, measurements at 6 levels are 
determined at each side of the patient The patient was in supine position with the 
neck flexed contralateral to the examined side. A Toshiba SSA-270 A system was 
used, equipped with 7 5-Mhz linear probe which was positioned parallel to each 
arterial segment for color Doppler imaging. The blood velocity during the early 
systolic peak and during the diastolic phase were measured The grade of stenosis 
was scored according Strandness2 '. In short: stenosis up to 4 9 % was defined 
when peak systolic velocity did not raise above 1.25 m/s. Velocities above this 
blood f low level indicates stenosis of 50% or more Furthermore, stenosis of 50% 
to 75% was defined when peak systolic velocity ratio (i.e. peak systolic velocity 
divided by peak systolic velocity proximal of this level) was ¿ 2 and < 3 , and 
stenosis of 76% to 99% was determined when peak systolic velocity ratio raised 
above 3. Occluded arterial segments showed no blood flow. 
Magnetic Resonance Imaging (MRI) 
MRI of the abdominal aorta and proximal segments of the common iliac 
arteries was performed with 1.5 Tesla Magnetom 63 SP whole-body imaging 
system (Siemens, Germany), according to a protocol reported previously22. Briefly, 
all patients received intravenously 20 mg of butylscopolamin (Buscopan") as 
antiperistaltic medication directly before and another 20 mg via a continuous 
infusion during the investigation. High resolution T1-weighted MRI in coronal 
(frontal) and sagittal (lateral) direction of the abdominal aorta and axial angulated 
orientated images parallel to the common iliac arteries were obtained during ECG 
gating. The percentage diameter narrowing was measured and grouped at intervals 
of 5% (e.g 5, 10, 15 etc). To determine the accuracy of MRI, we previously have 
performed a digital subtraction angiography as golden standard in 11 out of 14 
patients at the start of the study22. The accuracy of high resolution MRI versus 
laDSA was 80%. From that study, it is to conclude that this MRI technique is an 
acceptable technique for determination of arteriosclerosis in hyperhomocysteinemic 
vascular patients. The percentage of vessel diameter reduction was defined as: 
M1 - M2 
100% χ 
M1 
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where M1 ¡s the luminal diameter at the normal appearing level of the arterial 
segment; M2 is the luminal diameter of the arterial segment at the site of the most 
severe narrowing. 
Statistics 
If arteriosclerosis determined by the various examination techniques used in 
this trial led to the establishment of progression and regression within one patient, 
the overall conclusion was defined as progression. The effect of treatment in the 
studied vascular patients with mHH were analyzed by a chi-square independence 
test. To determine significant difference in vitamin Be, folic acid, vitamin B12, 
fasting and post-load homocysteine blood concentrations of the vitamin-treated and 
placebo-treated group of patients a analyses of variance (ANOVA test) has been 
used. 
Results 
Asymptomatic arteriosclerosis 
At the start of the study, 8 out of 14 patients (57%) showed arteriosclerotic 
changes in arterial segments from which no clinical symptoms originated (Table 
13 .1 ; patient number 1, 2, 4, 5, 8, 10, 1 1 , and 14). Four out of these 8 patients 
have had CVD, one patient has had CHD, one has had SAS, and 2 patients have 
had combined CVD and CHD. Arteriosclerotic damages were determined bylneans 
of SBM in 7 out of these 8 patients, and by MRI in 5 patients. 
Biochemical effect of treatment 
In all included patients the levels of creatinine and liver enzymes remained 
within normal ranges throughout the study period. Nine out of the 14 patients with 
post-load hyperhomocysteinemia were also known with elevated fasting 
homocysteine levels in plasma. At baseline, the mean fasting and post-load 
homocysteine blood levels were 26 ± 22 //mol/L (mean ± SD) and 83 ± 26 
//mol/L, respectively, in the group of patients randomized for vitamin treatment, not 
significantly different from those in patients randomized for placebo treatment, i.e. 
27 ± 13 //mol/L and 79 ± 26 //mol/L, respectively (Table 13.2). In all 14 patients 
the mean fasting and post-load homocysteine blood levels could be normalized 
after probational vitamin treatment for 6 weeks, showing then a mean of 10 ± 3 
//mol/L (mean ± SD) and 39 ± 7 //mol/L, respectively, with no significant 
difference of the homocysteine concentrations between the vitamin and placebo-
treated group. The mean reduction of fasting and post-load homocysteine 
concentrations after this combination of vitamin supplementation was 7 4 % and 
68%, respectively. Also the blood levels of vitamin B6, vitamin B12, and folic acid 
were at baseline and after probational treatment not significantly different between 
the 2 groups. 
Vitamin B6, folic acid, vitamin B12, fasting and post-load homocysteine blood 
concentrations after one and two years of treatment were not significantly 
different from the levels at baseline in the placebo-treated patients. During this 
period of follow-up not any of the vitamin-treated patients became 
hyperhomocysteinemic again, and all of the placebo-treated patients continued to 
have pathologically elevated homocysteine blood levels. 
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Table 1 3 . 1 . Evaluation of arteriosclerosis at baseline and after two years of vitamin 
(patient number 1 to 8) or placebo (patient number 9 to 14) supplementation was 
performed with segmental blood pressure measurements (SBM) of the lower 
extremities, duplex scanning (DU) of the carotid and vertebral arteries, and 
Magnetic Resonance Imaging (MRI) of the abdominal aorta and proximal segments 
of the common iliac arteries. Patient number 8 received the first year placebo and 
the second year vitamin supplementation. With SBM and OU, the abnormal side, 
and with MRI, the percentage of occlusion in the segment in which the vascular 
damage had changed after two years are given in this table, η = normal; R = right 
side abnormal; L = left side abnormal, t = SBM improved by more than 0.20. 1 
= SBM deteriorated by more than 0.20. 
Patient number 
1.CVD 
2.SAS 
3.PVD 
4.CVD 
5.CVD&CHD 
6.CHD 
7.CVD 
8.CHD 
9.CVD&CHD 
10.CVD&PVD 
11.CVD 
12.CVD 
13.CVD 
14.CVD 
SBM 
DU 
MRI 
SBM 
DU 
MRI 
SBM 
DU 
MRI 
SBM 
DU 
MRI 
SBM 
DU 
MRI 
SBM 
DU 
MRI 
SBM 
DU 
MRI 
SBM 
DU 
MRI 
SBM 
DU 
MRI 
SBM 
DU 
MRI 
SBM 
DU 
MRI 
SBM 
DU 
MRI 
SBM 
DU 
MRI 
SBM 
DU 
MRI 
Baseline 
R & L 
η 
2 0 % 
L 
η 
η 
R & L 
η 
3 0 % 
R & L 
η 
5 % 
L 
η 
3 0 % 
η 
η 
η 
η 
η 
η 
η 
η 
2 0 % 
R & L 
η 
5% 
R & L 
η 
6 0 % 
R & L 
R 50 - 7 5 % 
η 
R & L 
η 
η 
η 
η 
η 
η 
η 
η 
After 2 years 
η 
η 
1 0 % 
η 
η 
η 
R & Lt 
η 
3 0 % 
η 
η 
5% 
η 
R & L 
3 0 % 
η 
η 
η 
η 
η 
η 
η 
η 
2 0 % 
R i & L 
η 
2 5 % 
RI & Li 
η 
1 0 0 % 
η 
R 1 0 0 % 
η 
L at rest 
η 
η 
η 
η 
η 
η 
η 
η 
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Table 13.2. Mean ± SD values are shown for the continuous variables, in all 
patients (n = 14), thus included the patient with one year placebo, and one year 
vitamin therapy, for the vitamin-treated (n = 8) and placebo-treated (n = 6) patients. 
Probational therapy consisted of 250 mg vitamin Be and 5 mg folic acid daily for 
6 weeks, which continued in the 8 vitamin-treated patients for 2 years, and was 
withheld from in the placebo-treated group of patients. Statistically significance 
was calculated with ANOVA in the vitamin-treated group versus the placebo-
treated group of patients * < 0.05; # < 0 . 0 1 . 
vitamin-treated 
patients (n = 8) 
all patients 
(n = 14) 
placebo-treated 
patients (n = 6) 
fasting homocysteine //mol/L 
baseline level 26 
after probational therapy 11 
after one year* 11 
after two years# 12 
post-load homocysteine //mol/L 
baseline level 83 
after probational therapy 40 
after one year* 41 
after two years* 44 
± 
± 
± 
± 
+ 
± 
± 
± 
22 
2 
4 
3 
26 
9 
8 
14 
26 
10 
± 17 
± 3 
80 ± 24 
39 ± 7 
27 ± 13 
10 ± 3 
24 ± 12 
25 ± 10 
79 ± 26 
40 ± 6 
71 ± 28 
73 ± 23 
vitamin B6 nmol/L 
baseline level 52 ± 7 
after probational therapy 505 ± 223 
after one year* 2271 ± 2 1 9 2 
after two years 1885 ± 2144 
54 ± 19 
871 ± 1343 
60 ± 27 
1380 ± 2020 
64 ± 28 
51 ± 15 
folic acid nmol/L 
baseline level 9.9 ± 2.5 
after probational therapy 72.1 ± 36.7 
after one year* 182.0 ± 178.4 
after two years 206.7 ± 232.1 
vitamin B12 pmol/L 
baseline level 256 
after probational therapy 231 
after one year 200 
after two years 361 
145 
33 
64 
416 
9.8 ± 2.7 
77.1 ± 32.5 
300 ±210 
221 ± 35 
255 ± 220 
273 ±312 
9.5 ± 3.2 
77.5 ± 29.6 
8.7 ± 3.8 
7.1 ± 3.4 
372 ± 280 
215 ± 9 
332 ± 330 
164 ± 45 
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Clinical effect of treatment 
One patient had erroneously received the first year placebo and the second 
year vitamin supplementation, which was confirmed by normal respectively 
elevated levels of these vitamins in blood, and elevated respectively normal fasting 
and afterload homocysteine concentrations. In that patient, who had suffered from 
coronary heart disease with no vascular changes at the studied segments after 
both the first and the second year, neither progression or regression was concluded 
(Table 13 .1 , patient number 8). Eight patients, included the above mentioned, 
appeared retrospectively to be treated with vitamin, and 6 patients with placebo 
supplementation. All randomized patients completed this prospective study for 2 
years. Although cigarette smoking was discouraged, 3 patients continued their 
smoking habit after the vascular disease revealed. At the start of the study, there 
was no difference in the mean pack years of smoking between the vitamin and 
placebo-treated patients, i.e. 12 and 13, respectively. 
Four out of 8 vitamin-treated patients showed regression of the 
arteriosclerosis as assessed in all 4 with SBM (Table 13 .1 ; patient number 1, 2, 3, 
and 4). In these four patients, the blood pressure of the lower extremities in two 
legs in rest and five legs after occlusion increased significantly after 2 years. 
Additionally, with MRI in one of these four patients, the initial 20% stenosis at the 
abdominal aorta showed a decrease to 10% after two years. In the other 3 of 
these 4 patients, MRI and DU findings were not changed. In one other vitamin-
treated patient (Table 13 .1 ; patient number 5) the aberrant SBM at rest of the left 
lower extremity improved significantly, whereas DU showed accelerated blood f low 
velocity in both external carotid arteries not at baseline, but after two years. This 
was defined as progression of arteriosclerosis. In the resulting other 3 vitamin-
treated patients the arteriosclerosis remained unchanged (Table 13 .1 ; patient 
number 6, 7 and 8). 
In 2 out of 6 placebo-treated patients (Table 13 .1 , patient number 9 and 10) 
the arteriosclerosis deteriorated as assessed with MRI and SBM. With SBM, the 
blood velocity in the right leg in patient number 9, and in both legs in patient 
number 10 deteriorated. The arteriosclerosis assessed with the MRI technique in 
patient number 9, who had only slight vascular damages at the left side of the 
aortic wall of 5%, was also progressive, resulting in artenoslerotic changes at the 
left aortic wall to 25% (Figure 13.1a and 13.1b). In patient number 10, who 
showed on the baseline MRI large arteriosclerotic plaques upto 60% in the 
abdominal aorta and left common iliac artery (Figure 13.2a and 13.2b), the 
vascular damage was that much deteriorated that the abdominal aorta was 
occluded completely after two years of placebo treatment (Figure 13.1b). The 
placebo-treated patient number 11 with CVD on the basis of right common carotid 
artery stenosis of 50% to 75%, showed deterioration after two years to complete 
occlusion of this arterial segment with retrograde blood flow in the right external 
carotid artery In that same patient, the SBM revealed regression of the arterioscle-
rosis at both lower extremities. The arteriosclerosis in this specific patient was 
defined as progressive. In the placebo-treated patient number 12 the arteriosclero-
sis improved by means of SBM in rest at the right side, and after occlusion in both 
legs. In the resulting 2 placebo-treated patient (Table 13 1 ; patient number 13 and 
14) no vascular changes were determined. 
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Figure 13.1a and 13.1 b. A 40 year old patient showed no arteriosclerotic damages 
on the baseline MRI (Figure 13.1a). After two years of placebo-treatment (Figure 
13.1 b), an arteriosclerotic plaque was visual at the left side of the abdominal aorta. 
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Figure 13.2a and 13.2b. A female 46 year old patient showed severe 
arteriosclerotic damages on the baseline MRI (Figure 13.2a) with arteriosclerotic 
plaques to 6 0 % in the abdominal aorta and left common iliac artery. After two 
years of placebo-treatment (Figure 13.2b), the vascular damages were such 
deteriorated that the abdominal aorta was occluded completely. 
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Discussion 
Mild hyperhomocysteinemia is an established risk factor for premature 
arteriosclerosis In this study, more than half of hyperhomocysteinemic vascular 
patients revealed vascular changes at segments from which no clinical symptoms 
originated Therefore, arteriosclerosis in these relatively young patients is likely to 
be generalized23. 
Blood homocysteine, vitamin B6 and folic acid concentrations were measured 
as an indication of the compliance of the patients in taking the prescribed vitamin 
treatment The homocysteine, vitamin B6 and folic acid levels after one and two 
years were about equal as the baseline levels in the placebo-treated patients, 
showing that they did not use vitamin supplementation prescribed by another 
doctor or bought in a drug store. 
Vitamin Be, 250 mg daily, as a sole therapy normalizes the exaggerated rise 
after methionine loading of homocysteine only in about 56%1 2 , but does not affect 
fasting hyperhomocysteinemia2* Nowadays, it is shown that a lower dose of 
vitamin B6 of 100 mg daily has the same effect26. Folic acid treatment solely in a 
dose as low as 0 65 mg daily, can reduce elevated fasting homocysteine levels 
with about 40% 2 6 A dose of 5 mg daily may not lead to a substantially higher 
decrease2527. However, at the time of the start of this study, folic acid was only 
available in tablets of 5 mg Therefore, we have supplemented the studied patients 
with 250 mg vitamin B6 and 5 mg daily folic acid daily According to reports in 
literature, this combined supplementation will normalize elevated fasting and post-
load homocysteine levels in more than 90% of patients13 The mean reductions 
obtained in the present study by this combination of supplementation of fasting 
and post-load homocysteine, 58% and 5 1 % , respectively, were comparable with 
earlier findings by van den Berg et al.13, who administered the same dose of this 
combination, and by Dudman et al 27, after supplementation of only 100 mg of 
vitamin B6 and 5 mg of folic acid daily 
The extensive experience with biochemical effects of such vitamin treatment 
in mild hyperhomocysteinemia contrasts very much with lack of knowledge of 
clinical significance of such treatment in terms of preventing the arteriosclerotic 
progress. Prehminairy data of the present double-blind, placebo-controlled 
intervention study should be enterpreted with caution because of the still small 
number of included patients. Three out of 6 placebo-treated patients showed 
progression of arteriosclerosis, whereas the arteriosclerosis in 2 other placebo-
treated patients remained unchanged and showed regression only in one In case 
of combined vitamin B6 and folic acid supplementation had no effect at all, the 
same percentage of number of patients with progression of arteriosclerosis as 
observed in the placebo-treated patients, would have been expected in the vitamin-
treated group of patients, i.e 4 out of the 8 patients. However, progression in the 
vitamin-treated group of patients was established in not more than one out of eight 
vitamin-treated patients (12.5%) Although the number of patients in this study is 
quite small, significance of the difference between these effects could be 
calculated (p< 0 05, chi-square) These findings suggest that combined vitamin 
B6 and folic acid treatment might be capable to prevent progression of 
arteriosclerotic disease in most vascular patients with mHH 
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General discussion and future perspectives 
Mild hyperhomocysteinemia has been established in vascular patients in 
numerous studies with a frequency varying from 9% to 47%, as reviewed 
extensively by Ueland et al.1 and Kang et al.2. From pooled data, it can be 
estimated that one in four to five patients with symptomatic arteriosclerosis will 
show mild hyperhomocysteinemia34. This prevalence corresponds well wi th our 
percentages of mild hyperhomocysteinemia among patients with coronary, 
cerebrovascular, and peripheral vascular disease, as described in Chapters 8 and 
9 of this thesis5 6 Comparably mild elevations of homocysteine blood levels can be 
measured in about 5% to 8% of healthy subjects1 2. So, mild hyperhomocys-
teinemia is a common risk factor for cardiovascular disease 
The findings from the investigations described in this thesis are discussed 
in the light of recently reported relevant studies and are put into future 
perspectives. The following questions will be dealt wi th: 
- are fasting or post-load homocysteine levels or both required to diagnose mild 
hyperhomocysteinemia? 
- to what extent is mild hyperhomocysteinemia genetically based7 
- by what mechanism(s) is mild hyperhomocysteinemia causing vascular disease7 
- how to treat mild hyperhomocysteinemia7 
- will homocysteine-lowering intervention be clinically efficacious7 
Are fasting or post-load homocysteine levels or both required to 
diagnose mild hyperhomocysteinemia? 
Quantitative meta-analysis of 27 studies published before 1995 relating 
homocysteine to arteriosclerotic vascular disease, showed a combined odds ratio 
as an estimate of the relative risk of elevated fasting homocysteine blood levels for 
coronary artery disease of 1.8 (95% CI 1.6 - 2 0), for cerebrovascular disease of 
2.3 (95% CI 1 8 - 2 9), and for peripheral vascular disease of 6 5 (95% CI 2 9 -
15 8)12 The odds ratios of all included elevated homocysteine levels, either fasting 
or basal or post-load, did not differ from these of the fasting elevated levels, 
suggesting an equally strong relative risk of fasting and post-load 
hyperhomocysteinemia. Furthermore, from a large multi-centre study including 750 
vascular patients and 800 controls, it could also be calculated that the odds ratio 
for vascular disease of increased homocysteine blood levels in the fasting state is 
about equal to the odds ratio of increased post-load levels, i.e 2.2 versus 2 1 1 3 . 
By combining fasting and post-load hyperhomocysteinemia the relative risk of 
vascular disease increased to 313. 
From studies in which methionine loading was used to define mild 
hyperhomocysteinemia, it can be calculated in what frequency post-load 
hyperhomocysteinemia was accompanied by elevated fasting levels Such 
concomitance was found varying from 37% to 59% 7 1 1 . This finding is in 
concordance with the frequency of 46% of the combination of fasting and post-
load hyperhomocysteinemia as found in our study described in Chapter 96. 
Therefore, if only the fasting homocysteine level is determined in the individual 
vascular patient, then a considerable number of patients with exclusively post-load 
hyperhomocysteinemia will be missed. Therefore, in our opinion, it is not justifiable 
to abolish the standardized methionine loading test as a determinant of mild 
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hyperhomocysteinemia in individual vascular patients. The performance of a 
methionine loading test in epidemiological studies in large groups of patients may 
be too laborious, and the determination of fasting or even non-fasting "basal" level 
can be an alternative. 
Possible simplifications of the methionine loading test should be explored. 
Shortening the methionine loading test by determining the plasma homocysteine 
concentration 2 or 4 hours after methionine intake might be an option 1 4 . Another 
possibility to simplify the screening could also be to skip sampling of fasting blood 
for homocysteine determination and to draw blood 6 hours after the patient has 
taken methionine at home. The patient may use a light breakfast, because 3 
studies showed that such meal will give no or only a minor change in the 
homocysteine blood levels15"17. Skipping sampling of fasting blood, this screening 
would fail to detect no more than about 6 vascular patients with fasting 
hyperhomocysteinemia among 100 with post-load normohomocysteinemia (own 
observation, η = 269). This is in line with the conclusion by Bostom et a l . 1 0 who 
found increased fasting blood homocysteine levels in 17 out of 227 (7.5%) 
subjects with normal plasma homocysteine concentration 4 hours after oral 
methionine load. Fasting homocysteine level was elevated in only 2 out of 60 
(3.3%) post-load normohomocysteinemic family members of post-load 
hyperhomocysteinemic vascular patients as described in Chapter 4 ' 8 , which low 
percentage could, however, been biased because only family members of post-load 
hyperhomocysteinemic patients were included in that study, regardless their fasting 
homocysteine concentration. 
Individuals with pathologically high homocysteine blood levels in the fasting 
state and normal post-load levels may represent a subgroup different from those 
with both fasting and post-load hyperhomocysteinemia, or different from that with 
post-load hyperhomo-cysteinemia and fasting normohomocysteinemia. Such a 
diversity which can only be disclosed by a methionine loading test, may be due to 
heterogeneity in enzymatic defects underlying hyperhomocysteinemia. In case 
future studies will confirm such diversity, it may also be warranted in these 
subgroups to prescribe specific homocysteine-lowering regimen. 
To what extent is mild hyperhomocysteinemia genetically based? 
The conclusion from data as presented in Chapters 4, 5 and 6 of this 
thesis1 8"2 0 is in line with previous reports2 1"2 5 that mild hyperhomocysteinemia is at 
least partially genetically based. Low blood vitamin Be, vitamin B,2 and folic acid 
concentrations, genetically or environmentally determined, can also lead to 
elevated plasma homocysteine concentration1 , 2 6 - 2 7. Non-genetic causes, such as 
liver and renal diseases can also increase blood homocysteine levels1. In a study 
which is presented in Chapter 4 among family members of 21 post-load 
hyperhomocysteinemic vascular patients, after excluding vitamins deficiencies and 
liver and renal diseases in the index patients, it is shown that the chance to find 
pathologically high homocysteine levels is much higher in the family members than 
might be expected in the normal populat ion 1 8 . Post-load mild 
hyperhomocysteinemia was established in at least one other family member in 71 % 
of the families, indicating a strong genetic base of the mild hyperhomocysteinemia. 
Thermolability of MTHFR, associated with decreased enzyme activity2 0 and based 
upon homozygosity for 677 C-*T mutation in the gene for this enzyme on 
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chromosome 1 , could be established in 28% of vascular patients with mild 
hyperhomocysteinemia, as presented in Chapter 520. Cystathionine ß-synthase 
deficiency has been shown to be present in none or only a very small minority of 
vascular patients with mild hyperhomocysteinemia20·29,30. Therefore, other genetic 
defects must account for the majority of mild hyperhomocysteinemia as detected 
among vascular patients. Deficiency of activity of homocysteine remethylation 
enzymes, i.e. methionine synthase and betaine-homocysteine methyltransferase, 
and inborn errors in folic acid and vitamin B12 metabolism, especially in the 
synthesis of their substrates and cofactors relevant for methionine-homocysteine 
metabolism, are to be focused upon as potential genetical origins of 
hyperhomocysteinemia. 
By what mechanism(s) is mild hyperhomocysteinemia causing vascular 
disease? 
Although the sulphydryl containing amino acid homocysteine is generally 
held to be an atherogenic and thrombotic agent, there is no consensus about the 
pathophysiological mechanism, as has been discussed in Chapter 2. Some 
hypotheses based on results from in vitro studies are promising, but the extremely 
high homocysteine levels at which these investigations have been performed, are 
not reflecting the physiological state in mild or even severe hyperhomocysteinemia 
in man. Apart from this, not one hypothesis is unifying clearly the atherogenic and 
thrombophilic tendency of hyperhomocysteinemia. The well known cases of 
classical homocystinuria with severely elevated blood homocysteine levels, despite 
homocysteine-lowering treatment, who remain free of arteriosclerotic or 
thromboembolic events during several decades of follow-up are in this respect very 
enigmatic31. Possible synergistic interactions of elevated blood homocysteine 
concentration with other risk factors for vascular disease are very interesting. Such 
synergism, leading to expression of vascular disease, occurred in those family 
members with concomitant protein С deficiency and mild hyperhomocysteinemia 
in a family with both conditions inherited, as described by us in Chapter 6 1 9 . In line 
with this observation is the recently reported synergism between severe 
hyperhomocysteinemia and factor V Leiden mutation leading to a resistance against 
activated protein C3 2. In this study, only those homocystinuric patients suffered 
from arterial and venous thrombosis or pulmonary embolismin case factor V Leiden 
mutation was also present. 
How to treat mild hyperhomocysteinemia? 
After reviewing available studies until now on homocysteine-lowering 
treatment as described in Chapter 7 3 3 , the use of folic acid, 0.65 mg daily, seems 
to be capable to decrease elevated fasting blood levels of homocysteine with about 
4 0 % , and the combined use of 100 mg vitamin B6 and 5 mg folic acid daily can 
lower the post-load homocysteine levels with about 5 0 % . Normalization of 
elevated post-load homocysteine levels in blood is obtained by daily 250 mg 
vitamin B6 solely in about half of the vascular patients as described in Chapter 8 s . 
Combined vitamin B6, 250 mg daily, and folic acid, 5 mg daily, surpasses this 
effect because it leads to a normalization of the fasting and the post-load increased 
homocysteine levels in almost all vascular hyperhomocysteinemic patients, as 
reported in Chapters 9 and 11 6 - 7 . Future dose-response studies should clarify the 
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lowest required dosage. Clinical adverse effects of these two vitamins in the 
dosages as presently used, are not reported3438. Therefore, dose-response studies 
do not have the highest precedence. 
Summarizing, fasting and post-load hyperhomocysteinemia as present in 
vascular patients can be treated safely and easily with folic acid and vitamin Be at 
the aforementioned dosages. In rare non-responsive hyperhomocysteinemic 
patients, there is need for other options for therapy. One option could be the 
prescription of betaine, which has been discussed in Chapter 733. This substance, 
however, is a non-registered drug and can not be prescribed in most countries. In 
the study described in Chapter 11 3 9 , the use of vitamin B, therapy as alternative 
homocysteine-lowering intervention is explored. The active form of thiamine, 
thiamine pyrophosphate, is a cofactor of the supposed rate-limiting oxidative 
decarboxylation in the transamination pathway of methionine. A dose up to 75 mg 
of vitamin B, daily showed no significant reduction of fasting homocysteine 
concentration in homocystinuric patients who had still high homocysteine blood 
levels despite conventional therapy. This finding does not make a beneficial effect 
of such treatment in vascular patients with mild hyperhomocysteinemia likely. 
Will homocysteine-lowering intervention be clinically efficacious? 
Screening for mild hyperhomocysteinemia in vascular patients and 
prescribing homocysteine-lowering treatment at a large scale, will only be justified 
if a clinically beneficial effect of homocysteine-lowering treatment has been 
established. In Chapter 11 7 we describe that the combined use of vitamin Be and 
folic acid as homocysteine-lowering treatment during one year is capable to 
significantly decrease elevated von Willebrand factor and thrombomodulin, both 
markers of endothelial dysfunction, which are elevated in hyperhomocysteinemic 
vascular patients. This result is suggestive of a redression of endothelial damage 
by such intervention. However, this study was not placebo controlled, so the 
presence of elevated endothelial markers on the base of the vascular event itself 
can not be ruled out. For the future, randomized clinical trials, to prove a beneficial 
effect of homocysteine-lowering treatment, should be given the highest priority. 
Studies to explore the reduction of number of recurrent clinical events in treated 
hyperhomocysteinemic vascular patients will require a large number of included 
patients and a long follow-up period. Therefore, the development of methods to 
measure minimal changes of arteriosclerotic lesions should be continued and the 
accuracy of these techniques should be thoroughly evaluated. In this regard, as 
described in Chapter 12, the accuracy of Magnetic Resonance Imaging (MRI) and 
Magnetic Resonance Angiography (MRA) techniques were compared with intra-
arterial digital subtraction angiography (iaDSA) procedures in 11 mildly 
hyperhomocysteinemic patients with an established vascular event at young age. 
It could be concluded that MRI in such patients appears to be an acceptable 
imaging technique compared with iaDSA, and may be an alternative method to the 
invasive iaDSA technique. MRA, however, does not seem to provide significant 
additional information to MRI. Preliminary results of our placebo-controlled double-
blind prospective intervention study with the use of vitamin Be and folic acid as 
homocysteine-lowering agent in 14 hyperhomocysteinemic vascular patients are 
presented in Chapter 13. It is concluded that such intervention may have a potency 
to prevent progression of arteriosclerosis. The outcome of ongoing studies is 
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mandatory to prove such clinically effect definitively. 
Assuming that homocysteine-lowering treatment is effective in reducing the 
progression of arteriosclerosis in vascular hyperhomocysteinemic patients, then it 
will be likely that such intervention prevents arteriosclerosis in the general 
population. If so, it can be calculated for the general population in the United 
States of America, that if folic acid intake is increased by fortification of flour and 
cereal products by using 350 μς folic acid per 100 g of such food daily, 9 % 
coronary heart deaths in men and 5% in women could potentially be pre vented' 2 · 4 0 . 
In 1993 in the Netherlands, 12,691 men and 9,427 women have died from acute 
myocardial infarction4 1. So, under the proviso that the estimate for the USA is valid 
in the Netherlands as well, about 1,600 patients could be saved from coronary 
death yearly. Speculating that the same percentage of death prevention is 
applicable in cerebrovascular and peripheral arterial disease, about 1000 more 
deaths could be prevented yearly. 
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Summary 
In general health care vascular disease is a major disorder with a high 
prevalence, resulting in considerable morbidity and medical costs. During the last 
two decades, it became overwhelmingly clear that mild hyperhomocystememia has 
to be recognized as one of the risk factors for arteriosclerotic and thrombotic 
diseases. 
The aims of the studies presented in this thesis were to investigate whether 
mild hyperhomocystememia in vascular patients is genetically determined, i.e 
which genetic defects are the basis for this risk factor for cardiovascular disease, 
and what is their prevalence (Part 1). Furthermore, it was explored if elevated 
blood homocysteine concentrations can be lowered or even normalized by the use 
of B-vitamms in vascular patients with mild hyperhomocystememia (Part 2), and 
whether this treatment may result in a clinically beneficial outcome (Part 3). 
After a general introduction and the presentation of the objectives of this 
thesis (Chapter 1) an update on hyperhomocystememia is presented (Chapter 2), 
and laboratory assays of homocysteine in plasma have been described (Chapter 3). 
All 3 investigated methods for measuring the concentration of homocysteine in 
blood, i.e. one by means of a conventional amino acid analyzer and t w o by using 
high-performance liquid chromatography (HPLC), are appropriate. HPLC sodium 
borohydnde/monobromobimane technique may be preferable because this method 
is fully automated and has a large sample capacity. 
In part 1 in Chapter 4, the prevalence of mild hyperhomocystememia in 
families of which one family member was known with vascular disease and mild 
hyperhomocystememia was studied. We measured fasting and post-load 
homocysteine levels among 96 family members of 21 post-load hyperhomocys-
tememic vascular index patients. In 7 1 % of the 21 screened families, post-load 
elevated homocysteine level could be established in at least one other family 
member. Fasting and post-load mild hyperhomocystememia in these family 
members was observed in 21 % and 3 2 % , respectively. It was concluded that both 
fasting and post-load mHH seems to be inherited in the majority of 
hyperhomocysteinemic vascular patients. 
In Chapter 5, the method of determination and prevalence of thermolabile 
mutant variant of methylenetetrahydrofolate reductase (MTHFR) among vascular 
patients with mild hyperhomocystememia has been reported. In 2 8 % of such 
patients their mild hyperhomocystememia was caused by thermolabile mutant 
variant of MTHFR, which is determined by a decrease of enzyme activity and 
increased inactivation after incubation at 46 °C. 
The occurrence of two inherited risk factors for vascular disease, ι e. mild 
hyperhomocystememia and protein С deficiency type 1, within one family has been 
described in Chapter 6. Only those family members exhibiting the two risk factors 
combined revealed symptomatic vascular disease. From this family a synergistic 
interaction between these atherogenic and thrombogenic risk factors is suggested. 
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The biochemical effect of homocysteine-lowering treatment is explored in 
Part 2, Chapters 7 to 9. 
Firstly, a review of the literature on homocysteine-lowering regimen until 
1996 is reported in Chapter 7. Elevated fasting homocysteine concentration in 
blood can be reduced with 4 0 % to 50% by folic acid supplementation, in a dose 
of 0.65 mg to 5 mg daily, respectively. A higher dosage of folic acid up to 10 mg 
daily has no further effect on the decline of elevated fasting homocysteine 
concentration. Vitamin B6 supplementation has no effect on fasting homocysteine 
levels. For the reduction of post-load hyperhomocysteinemia, the use of solely 
vitamin B6, in a dose of 100 mg to 250 mg, showed a reduction of 40%. 
Combined treatment of vitamin B6, 100 mg daily, and folic acid, 5 mg daily, 
surpasses this effect and can lead to 50% reduction. Adding orally daily 0.4 mg 
vitamin B,2 may avoid deterioration of unrecognized vitamin B12 deficiency 
(perniciosa) after starting folic acid treatment. 
From data presented in Chapter 8, the prevalence of post-load mild 
hyperhomocysteinemia in vascular patients, i.e. cerebral, peripheral or coronary 
artery occlusive disease, and the effect of vitamin Be as homocysteine-lowering 
treatment are described and the figures were in concordance with data from 
literature so far. In the period of January 1980 until December 1990, 421 patients 
under 55 years of age with documented premature peripheral or cerebral occlusive 
arterial disease had been screened for mild hyperhomocysteinemia by oral 
methionine loading tests at the University Hospital Nijmegen. Thirty-three percent 
of these patients with peripheral, and 20% of these patients with cerebral 
occlusive arterial disease were identified with mild hyperhomocysteinemia. Post-
load hyperhomocysteinemic patients were treated with vitamin B6, 250 mg daily 
for 6 weeks, which resulted in a normalization of the post-load 
hyperhomocysteinemia in 56% of the treated patients. 
In Chapter 9, 309 patients with peripheral, cerebral, or coronary artery 
occlusive disease, diagnosed at the University Hospital of the Free University of 
Amsterdam, were included to establish the prevalence of mild 
hyperhomocysteinemia, fasting as well as in the post-load state. Mild post-load 
hyperhomocysteinemia was detected overall in 2 3 % of the patients, of whom 
about 50% also had fasting hyperhomocysteinemia. Increased fasting and/or post-
load homocysteine concentrations could be normalized in more than 90% of the 
hyperhomocysteinemic patients by combined vitamin B6 and folic acid 
supplementation, 250 mg and 5 mg daily, respectively. It could be concluded from 
Chapter 8 and 9 that mild hyperhomocysteinemia is a frequently encountered risk 
factor for arteriosclerosis, which can easily and inexpensively be treated by vitamin 
B6 and folic acid. 
As presented in Chapter 10, vitamin B, supplementation to stimulate 
transamination of methionine has been administered to nine homozygotes for 
homocystinuria, with persistence of their elevated homocysteine levels in spite of 
conventional homocysteine-lowering treatment. In case such supplementation 
would normalize elevated homocysteine concentration, it might also be an effective 
treatment in those cases in whom the mild hyperhomocysteinemia is not 
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responding to treatment of vitamin B6, folic acid or both. However, vitamin B, does 
not lower the homocysteine concentration in 8 out of the 9 studied homozygotes 
for homocystinuna, and therefore, is likely not an alternative treatment in patients 
with mild hyperhomocysteinemia. 
In Part 3 of this thesis, Chapters 11 to 13, the clinical effect of 
homocysteine-Ιο wering treatment is described. 
The amelioration of two markers of endothelial function, i.e von Willebrand 
factor and thrombomodulin, achieved by one year of combined vitamin B6 and folic 
acid therapy in patients with peripheral arterial occlusive disease in the presence 
of mild hyperhomocysteinemia is described in Chapter 1 1 . Tissue-type plasminogen 
activator, another endothelium-denved protein, was normal at baseline and 
remained unchanged after one year of treatment. 
In Chapter 12, the abdominal aorta and proximal segments of the common 
iliac arteries assessed by gated T1 -weighted Magnetic Resonance Imaging (MRI), 
and gated 2D-time of flight Magnetic Resonance Angiography (MRA) were 
compared with the same arterial segments assessed by intra-artenal Digital 
Subtraction Angiography (laDSA) in 11 patients with proven arterial occlusive 
disease and mild hyperhomocysteinemia. Six patients showed arteriosclerosis in 
one or more arterial segments by means of laDSA. Eighty percent of the segments 
with MRI, and 6 4 % of the segments with MRA were classified correctly. The 
sensitivity, specificity and accuracy of MRI could be calculated as 6 7 % , 8 6 % , and 
8 0 % , respectively. MRA could not achieve these results. It can be concluded that 
signs of generalized arteriosclerosis are frequently present in hyper-
homocysteinemic patients, and MRI in such patients is an acceptable non-invasive 
technique to use as a diagnosticum for detection of even small arteriosclerotic 
lesions. 
In a two-year running, placebo-controlled, double-blind prospective 
intervention study with combined vitamin B6 and folic acid treatment in 14 vascular 
patients with mild hyperhomocysteinemia, the clinical effect of such homocysteine-
lowering treatment was studied and presented in Chapter 13. As one of the non­
invasive methods to measure progression or regression of arteriosclerotic changes 
of vessel walls after 2 years of intervention, the MRI technique as described in 
Chapter 12 was used. Three out of 6 placebo-treated patients and 1 out of 8 
vitamin-treated patients showed progression of arteriosclerosis after two years of 
daily placebo or combined vitamin B6 and folic acid treatment, respectively. 
Moreover, one out of 6 placebo-treated, and four out of 8 vitamin-treated patients 
showed regression of arteriosclerosis. Although the number of studied patients is 
small, statistical significance of the effect on arteriosclerosis by the homocysteine-
lowering regimen compared to placebo-treatment was found. Thus, combined 
vitamin B6 and folic acid treatment might even be capable to redress arteriosclerotic 
vessel wall changes in hyperhomocysteinemic patients. 
In Chapter 14, it is discussed how the objectives of this thesis have been 
met by the presented results and future perspectives are indicated. 
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Samenvatting 
Vaataandoeningen komen in de algemene gezondheidszorg vaak voor, 
resulterend in een redelijk hoge overlijdingskans van de patiënten hoge medische 
kosten voor de gemeenschap. De afgelopen twee decennia is het duidelijk 
geworden dat een milde verhoging van het homocysteïne-gehalte in het bloed, een 
zogenaamd "milde hyperhomocysteïnemie", één van de risicofactoren voor 
vaatverkalking (artériosclérose) en thrombose (bloedstolsels) is. 
Het doel van de studies, beschreven in dit proefschrift, was te onderzoeken 
of milde hyperhomocysteïnemie voornamelijk erfelijk bepaald is of door 
omgevingsfactoren veroorzaakt wordt. Welke erfelijke defecten zijn de oorzaak voor 
deze risicofactor voor hart- en vaatziekten en hoe vaak komen deze voor (Deel 1, 
hoofdstukken 4 tot 6)? Bovendien is onderzocht of een verhoogd homocysteïne-
gehalte in het bloed verlaagd of zelfs tot binnen normale waarden gebracht kan 
worden door het gebruik van vitamine B6, eventueel in combinatie met foliumzuur 
( = vitamine Bn) bij patiënten met vaatverkalking en milde hyperhomocysteïnemie 
(Deel 2, hoofdstukken 7 tot 10), en tenslotte, of deze vitamine B-therapie een 
klinisch gunstig effect heeft (Deel 3, hoofdstukken 11 tot 13). Anders gezegd, kan 
vitamine В als homocysteïne-verlagende therapie de toename van vaatverkalking 
doen afnemen? 
Na een korte algemene introductie (Hoofdstuk 1) en een overzicht van wat 
er bekend is op het gebied van hyperhomocysteïnemie (Hoofdstuk 2), zijn 
laboratoriumtechnieken om het homocysteïne-gehalte in het bloed te meten 
beschreven (Hoofdstuk 3). De 3 onderzochte methoden blijken alle geschikt te zijn. 
De voorkeur gaat echter uit naar één van de beschreven technieken, aangezien 
deze volledig geautomatiseerd is en veel bloedmonsters per dag kan verwerken. 
In Hoofdstuk 4 is de frequentie van vóórkomen van milde hyperhomocys-
teïnemie bestudeerd bij families van wie één familielid met vaatverkalking en milde 
hyperhomocysteïnemie bekend is. We hebben de homocysteine- concentratie zowel 
nuchter als na methionine belasting (een test die de methionine-homocysteine 
stofwisseling belast) bepaald bij 96 familieleden van 21 patiënten met 
artériosclérose en milde hyperhomocysteïnemie. Bij 7 1 % van de 21 onderzochte 
families kon bij minstens één ander familielid een verhoogd homocysteïne-gehalte 
in het bloed vastgesteld worden. Bij deze familieleden werd milde 
hyperhomocysteïnemie bij 2 1 % in nuchtere toestand en bij 32% na methionine 
belasting geconstateerd. We concludeerden dat milde hyperhomocysteïnemie 
erfelijk is bij de meeste patiënten met vaatverkalking. 
In Hoofdstuk 5 wordt de methode beschreven, waarmee een tekort in 
activiteit van de thermolabiele variant van methyleentetrahydrofolaat reductase kan 
worden vastgesteld. Dit is een enzym in het homocysteine metabolisme, dat bij een 
verlaagde activiteit tot een verhoogde homocysteïne-concentratie in bloed kan 
leiden. Bij 28% van hyperhomocysteïnemische patiënten met artériosclérose bleek 
de milde hyperhomocysteïnemie inderdaad te berusten op een verlaagde activiteit 
van dit enzym. 
Het vóórkomen van twee erfelijke risicofactoren voor hart- en vaatziekten, 
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namelijk milde hyperhomocysteïnemie en proteine ( = eiwit) С tekort type 1, binnen 
één familie is in Hoofdstuk 6 beschreven. Alleen bij die familieleden bij wie de twee 
risicofactoren gecombineerd voorkwamen, openbaarden zich hart- en vaatziekten. 
Op basis hiervan is een onderling versterkende werking van deze risicofactoren 
gesuggereerd. 
Het homocysteïne-verlagende effect van vitamine behandeling is beschreven 
in Deel 2, Hoofdstuk 7 tot 9. 
Allereerst wordt in Hoofdstuk 7 een overzicht gepresenteerd van beschikbare 
gegevens over homocysteine verlagende therapieën. Een verhoogd nuchter 
homocysteïne-gehalte kan met 4 0 % tot 50% verlaagd worden door toediening van 
respectievelijk 0,65 mg of 5 mg foliumzuur in tabletvorm. Een hogere dosering van 
foliumzuur tot 10 mg dagelijks heeft geen verder homocysteïne-verlagend effect. 
Het verhoogde homocysteïne-gehalte na methionine belasting kan bij gebruik van 
100 mg tot 250 mg vitamine B6 4 0 % dalen. Combinatie therapie van 100 mg 
vitamine B6 en 5 mg foliumzuur geeft zelfs een halvering van het homocysteïne-
gehalte na methionine belasting. 
Het onderzoek beschreven in Hoofdstuk 8 laat zien hoe vaak milde 
hyperhomocysteïnemie na methionine belasting voorkomt bij patiënten met een 
herseninfarct, hartinfarct of "etalageziekte" (dit is vaatverkalking in de slagaders 
naar of in de benen, in het proefschrift "perifere artériosclérose" genoemd) en welk 
effect vitamine B6 als homocysteïne-verlagende therapie heeft op de verhoogde 
homocysteïne-spiegels. De cijfers komen overeen met de in de literatuur 
gepresenteerde cijfers. In de periode van januari 1980 tot december 1990 zijn 421 
patiënten, jonger dan 55 jaar, met een klinisch vastgelegd herseninfarct of 
"etalageziekte", onderzocht op milde hyperhomocysteïnemie door middel van de 
methionine belasting test in het Academisch Ziekenhuis Nijmegen. Bij 33% van de 
patiënten met "etalageziekte" en 20% van de patiënten met herseninfarct werd 
milde hyperhomocysteïnemie gevonden. Deze patiënten met een verhoogd 
homocysteine- gehalte zijn vervolgens behandeld met vitamine B6, in een dosering 
van 250 mg per dag gedurende 6 weken. Het verhoogde homocysteïne-gehalte na 
methionine belasting kon genormaliseerd worden bij 56% van de behandelde pati-
ënten. 
In Hoofdstuk 9 zijn 309 patiënten met "etalageziekte", hersen- of hartinfarct 
onderzocht in het Vrije Universiteit Ziekenhuis te Amsterdam op het voorkomen van 
milde hyperhomocysteïnemie, zowel nuchter als na methionine belasting. Bij 2 3 % 
van de patiënten werd milde hyperhomocysteïnemie na methionine belasting 
vastgesteld, waarvan ongeveer de helft ook een nuchter verhoogd homocysteïne-
gehalte liet zien. Het verhoogde (nuchtere en/of na methionine belasting) 
homocysteïne-gehalte in bloed kon bij meer dan 90% van de 
hyperhomocysteïnemische patiënten genormaliseerd worden door gecombineerde 
therapie met 250 mg vitamine B6 en 5 mg foliumzuur. Op basis van de gegevens 
beschreven in Hoofdstuk 8 en 9 kon geconcludeerd worden dat milde 
hyperhomocysteïnemie een veel voorkomende risicofactor voor vaatverkalkingen 
is, welke eenvoudig, veilig en goedkoop te behandelen is. 
Aan negen homozygoten voor homocystinurie (patiënten met een ernstig 
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verhoogde homocysteïne-concentratie in bloed) is vitamine B, toegediend om de 
afbraak van methionine via de zogeheten "transamineringsroute" te stimuleren 
(Hoofdstuk 10). Deze patiënten hadden, ondanks hun homocysteïne-verlagende 
therapie, nog steeds een verhoogde homocysteïne-concentratie in het bloed. Indien 
ten gevolge van een behandeling met vitamine B, de homocysteïne-concentratie 
zou normaliseren bij deze groep van patiënten, dan zou vitamine B, mogelijk ook 
effectief kunnen zijn bij die patiënten met milde hyperhomocysteïnemie die geen 
normalisering van het homocysteïne-gehalte in het bloed ondanks gebruik van 
vitamine B6 en foliumzuur laten zien. Echter, vitamine B, verlaagde de 
homocysteine- concentratie bij acht van negen patiënten niet, en heeft dus geen 
betekenis als alternatieve behandeling bij pat iënten met milde 
hyperhomocysteïnemie. 
In Deel 3 van dit proefschrift. Hoofdstuk 11 tot 13, zijn enkele aspecten van 
het klinisch effect van homocysteïne-verlagende therapie beschreven. 
Het effect op de vaatwandfunctie van behandeling met vitamine B6 en 
foliumzuurtherapie gedurende één jaar bij patiënten met perifere artériosclérose en 
mild hyperhomocysteïnemie, werd getest aan de hand van de bepaling van een 
tweetal indicatoren van de vaatwandfunctie, namelijk "von Willebrand factor" en 
"thrombomoduline" (Hoofdstuk 11). Deze waren vóór de start van de behandeling 
bij deze patiënten gestoord. Hiermee kon een verbetering van de vaatwandfunctie 
worden vastgesteld. Een andere indicator van de vaatwandfunctie, namelijk 
"weefsel-type plasminogeen activator", was vóór en na behandeling normaal. 
De lichaamsslagader ( = aorta) in de buik en ter hoogte van het begin van de 
slagaders naar de benen toe, zijn onderzocht met behulp van drie soorten opname 
technieken namelijk met twee soorten Magnetische Resonantie technieken 
(namelijk met Magnetic Resonance Imaging = MRI en met Magnetic Resonance 
Angiography = MRA) en met slagaderlijk vaatonderzoek door middel van inspuiten 
van contrastvloeistof (Digital Subtraction Angiography = DSA) bij 11 patiënten 
met klinisch bewezen artériosclérose en milde hyperhomocysteïnemie (Hoofdstuk 
12). Zes patiënten lieten vaatverkalking in één of meer slagaderlijke segmenten zien 
onderzocht door middel van DSA. Tachtig en 64% van de slagaderlijke segmenten 
werden respectievelijk met de MRI- en MRA-technieken in vergelijking met DSA 
correct beoordeeld. De gevoeligheid, de specificiteit en de nauwkeurigheid van de 
MRI-techniek waren respectievelijk 67%, 86% en 80%. Met MRA werden meestal 
slechtere resultaten verkregen. Geconcludeerd werd dat vaatverkalkingen diffuus 
verspreid aanwezig zijn bij patiënten met milde hyperhomocysteïnemie en dat de 
MRI-techniek een acceptabele methode is ter vaststelling van zelfs geringe 
artériosclérose. Door deze studie kon MRI in de opgezette prospectieve studie als 
één van de methoden geïntroduceerd worden om progressie of regressie van de 
vaatverkalkingen in de vaatwand van hyperhomocysteïnemische patiënten te 
detecteren. 
In een twee-jaar-durend onderzoek, waarbij de helft van de patiënten 
homocysteïne-verlagende therapie en de andere helft tabletten kreeg zonder B-
vitaminen (placebo's) en waarbij zowel de patiënt als de arts niet wist welke 
behandeling de patiënt gebruikte (dubbel-blind), is het klinisch effect van gecom-
bineerde vitamine B6 en foliumzuurbehandeling beschreven (Hoofdstuk 13). Drie 
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van de zes placebo-behandelde patiënten en slechts één van de acht vitamine-
behandelde patiënten lieten verergering van de vaatverkalkingen zien na twee jaar 
dagelijks gebruik van respectievelijk placebo of gecombineerde vitamine B6 en 
foliumzuurtherapie. Bovendien liet één van de zes placebo-behandelde en vier van 
de acht vitamine behandelde patiënten een teruggang van de vaatverkalkingen zien. 
Hoewel het aantal bestudeerde patiënten klein is, kon een significant gunstig effect 
van de homocysteïne-verlagende therapie vastgesteld worden. 
In Hoofdstuk 14 wordt besproken in hoeverre aan de in de inleiding van dit 
proefschrift omschreven doelstellingen is voldaan. De resultaten van de 
onderzoeken in dit proefschrift worden vergeleken met die van andere 
onderzoekers. Ook worden suggesties gedaan voor toekomstig onderzoek. 
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Nu het proefschrift afgerond ¡s, ben ik me er meer dan ooit van bewust dat 
ik deze klus nooit alleen had kunnen klaren. Vanaf het begin van mijn onderzoek 
heb ik gezegd dat het onderwerp hyperhomocysteïnemie net een trein is die (toen) 
nog langzaam reed, maar al snel zijn vaart zou gaan verhogen. Heden ten dage 
blijkt het onderwerp "hyperhomocysteïnemie" een hogesnelheidstrein geworden te 
zijn, hetgeen alleen mogelijk is geworden doordat er zich zoveel wetenschappers 
met dit onderwerp bezighouden. Iedereen die direct of indirect betrokken is 
geweest bij de totstandkoming van dit proefschrift wil ik van harte danken. Een 
aantal van hen wil ik met name noemen. Zoals het hoort, staat dit dankwoord 
achterin het proefschrift, maar troost U, op de stellingen na wordt dit "hoofdstuk" 
het best gelezen. 
Allereerst wil ik dr. G.H.J. Boers bedanken. Beste Frits, jij bent degene die 
alweer 11 jaar geleden milde hyperhomocysteïnemie mondiale bekendheid gaf met 
jouw artikel in N Eng J of Med. Je weet dat ik je enorm waardeer en veel van je 
geleerd heb in de afgelopen jaren, behalve het gevoel voor "-ly". Jouw kritische 
beschouwingen hebben de manuscripten leesbaard gemaakt. Door jouw vertrouwen 
in mij heb ik de vrijheid gekregen de onderzoeken in mijn tempo uit te voeren. 
Veel dank ben ik ook verschuldigd aan dr. H.J. Blom. Beste Henk, met de 
subsidie die verkregen werd als uitvloeisel van jouw promotie onderzoek, moest er 
een arts aangesteld worden om het onderzoek uit te voeren zoals beschreven ¡n 
hoofdstuk 10. Je vindt het toch niet erg dat het een paar hoofdstukken meer 
geworden zijn? Bij jou kon ik altijd terecht tijdens de "ups and downs" die 
onvermijdelijk horen bij wetenschappelijk onderzoek en het dagelijks leven. 
Prof .dr.ir. J.M.F. Trijbels, dank voor de tijd die U, met een overvolle agenda, 
altijd voor mij maakte. Uw voortdurende steun, heldere visie op de studies en Uw 
persoonlijkheid veraangenaamden het doen van dit onderzoek. 
Prof.dr. J.H. J. Ruijs. Het verrichten van wetenschappelijk onderzoek is vaak 
een kwestie van een lange adem. U heeft mij mijn gang laten gaan, waarvoor ik U 
hartelijk dank. 
M. te Poele - Pothoff. Beste Maria, waar ben je als onderzoeker als er geen 
betrouwbare meetmethode is? Jouw nauwgezetheid en jarenlange ervaring op het 
gebied van de homocysteine bepalingen vormden de basis waarop het onderzoek 
steunde. Hartelijk dank voor de plezierige samenwerking en ik ben dan ook heel blij 
dat jij mijn paranimf wil zijn. 
A. Garretsen - van Loon, I. Konijnenberg - Kramer en S. Vloet. Beste Anne-
Marie, Inge en Stephanie, jullie hebben samen circa 6.000 patiënten gezien, 9.000 
methionine belastingtesten uitgevoerd, 17.900 bloedmonsters afgedraaid en circa 
60 kilogram methionine is door jullie handen gegaan. Een ieder die dit leest weet 
dat jullie dus onmisbaar waren voor het onderzoek. 
M. van den Berg, beste Michiel, samenwerken met jou is een bijzonderheid. 
Ondanks de raakvlakken van onze onderzoeken beschouwden we elkaar nooit als 
concurrenten. Door onze efficiënte samenwerking verdubbelde het onderzoeks-
materiaal en resteerde er ook tijd om over niet-homocysteïne zaken te filosoferen, 
al dan niet met enige borrelgarnituur. 
A.M.T. Engbersen, beste Astrid, jij hebt je nauwgezet bezig gehouden met 
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de "thermolabielen" onder ons. (Of elke contrôle persoon daar zo blij mee was ...?). 
Dankzij jou kwam hoofdstuk 5 tot stand, waarvoor ik je hartelijk dank. 
O.H. Berger - Hartog en R.E.M. Berger. Beste Olette en Rob, altijd waren 
Geert en ik welkom bij jullie als ik weer eens te lang in het ziekenhuis bezig was, 
het eten had laten aanbranden of gewoon voor de gezelligheid. Deze vriendschap 
en voorziening van de inwendige mens is jullie steentje dat bijgedragen heeft aan 
dit boekwerk en maakt jou, Olette, een waardige paranimf. 
G.G. Franssen, lieve Geert, de afgelopen jaren heb je de concurrentie voor 
aandacht moeten aangaan met de computer. Al die jaren heb je geduldig en met 
rustgevende invloed mij gesteund, waarvoor ik je oneindig dankbaar ben. Nu het 
boek eindelijk daar is, zal ik je niet meer uit je slaap halen om 5 uur 's ochtends 
met het gepiep van de computer. The winner gets it all, de computer heeft het 
begeven ... 
Gaarne wil ik tevens Addy de Graaf - Hess, Dinny Oppenraaij - Emmerzaal, 
Henriette van Lith - Zanders, Erik Stevens, José Haenen, Adriënne van Maarseveen, 
Nathalie van der Put en Jolanda van Nieuwkerk - Remmits hartelijk danken voor 
hun inzet. 
Het proefschrift is een verlengstuk van een lange opleiding en leerperiode. 
De basis hiervoor werd gelegd door mijn ouders, die door hun methode van 
opvoeding mij een solide en stabiele ondergrond hebben meegegeven. Ik profiteer 
hier nog dagelijks van en ben jullie veel dank verschuldigd. 
Laurens en Conja, jullie wil ik gaarne bedanken voor de interesse die jullie 
altijd tonen voor dit onderzoek in het bijzonder en voor mij in het algemeen. 
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CurriaJuTi Vrtae 
Curriculum vitae 
De schrijfster van dit proefschrift werd geboren op 1 april 1965 te Son c a . In 
1983 behaalde zij het VWO-diploma aan het van der Putt-lyceum te Eindhoven. 
Aansluitend werd aangevangen met de studie geneeskunde aan de Katholieke 
Universiteit te Nijmegen, alwaar zij haar arts-diploma in september 1991 ontving. 
Sedert juni 1991 verrichtte zij op het laboratorium kindergeneeskunde en neurologie 
(hoofd: prof. dr. ir. J.M.F. Trijbels), de afdeling endocriene ziekten (hoofd: prof. dr. 
P.W.C. Kloppenborg) en de afdeling radiologie (hoofd: prof. dr. J.H.J. Ruijs) van 
het Academisch Ziekenhuis Nijmegen als arts-onderzoeker het wetenschappelijk 
onderzoek waarvan de resultaten zijn beschreven in dit proefschrift. In juni 1993 
is zij begonnen met haar opleiding tot radiologe in het Academisch Ziekenhuis 
Nijmegen (opleider: prof. dr. J.H.J. Ruijs). 
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Stellingen 
I Milde hyperhomocysteinemie is een veel voorkomende risicofactor voor 
artériosclérose in patiënten met claudicalo intermittens of herseninfarct vóór 
hun vijftigste levensjaar 
Dit proefschrift. 
2. Milde hyperhomocysteinemie leidt tot gegeneraliseerde artériosclérose 
Dit proefschrift. 
3 Milde hyperhomocysteinemie na een gestandaardiseerde methionine 
belastingtest gaat in circa 50% niet gepaard met een verhoogd 
homocysteine gehalte in nuchter bloed. 
Dit proefschrift. 
4 Milde hyperhomocysteinemie, zowel nuchter als na een methionine 
belastingtest, komt in respectievelijk 21 % en 32% voor bij familieleden van 
hyperhomocysteinemische patiënten met artériosclérose 
Dit proefschrift. 
5 Homozygotie voor thermolabiel 5,10-methyleentetrahydrofolaat reductase 
deficiëntie is een veel voorkomende genetische oorzaak van milde 
hyperhomocysteinemie. 
Dit proefschrift. 
6 De combinatie van behandeling met vitamine B6 en foliumzuur kan in vrijwel 
alle hyperhomocysteinemische patiënten met artériosclérose het verhoogde 
homocysteine-gehalte in het bloed normaliseren. 
Dit proefschrift. 
7 Vitamine Be en foliumzuur therapie bij hyperhomocysteinemische patiënten 
met artériosclérose lijkt progressie van deze vaatverkalkingen tegen te 
kunnen gaan. 
Dit proefschrift. 
8 Een mens is pas oud als hij/zij zegt de leeftijd te hebben die hij/zij dit jaar nog 
moet bereiken. 
9. De vervanging van de postzegel door een stempel is een uiting van 
cultuurverarming 
10 Het gras groeit niet harden door er aan te trekken. 
I I Een appel die niet ver van de boom valt, heeft geen groei mogelijkheden 
12 Mensen die van lange nagels en lang haar houden, zijn necrofielen. 
13 Als een inspreekapparaat een antwoordapparaat of telefonische 
beantwoorder zou zijn, zou er niet zo vaak teruggebeld hoeven worden 
14 Gepromoveerde deskundigen dienen de bevoegdheid te kunnen verkrijgen bij 
een promotie als promotor te mogen optreden. 



